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xi Abstract 
Clostridium  difficile  is  a  major  cause  of  nosocomial  intestinal  infection.  The 
pathogen  possesses  two  potent  toxins,  Toxin  A  and  Toxin  B,  both  of  which  are  responsible 
for  diarrhea,  intestinal  inflammation  and  tissue  damage.  Antibiotics  are  effective  against 
the  disease;  however,  around  20  %  of  patients  on  treatment  relapse  after  the  termination  of 
antibiotic  therapy.  The  binding  of  Toxin  A  to  a  receptor  on  human  intestinal  epithelial  cells 
initiates  disease.  This  is  considered  the  starting  point  from  which  the  toxin  elicits  its  effect. 
One  feature  of  the  carboxy-terminal  domain  of  Toxin  A  is  the  presence  of  repeating  units 
of  amino  acids.  These  repeats  form  a  series  of  binding  domains  that  create  a  multivalent 
lectin  able  to  recognise  trisaccharides  and  disaccharides  on  glycolipid  and  glycoprotein 
receptor  molecules.  Antibody  response  against  the  toxin  can  protect  against  C.  difficile 
disease  and  efforts  to  generate  vaccines  have  focused  upon  the  carboxy-terminal,  receptor 
binding  domain.  The  aims  of  this  project  were  to  use  phage  display  to  isolate  recombinant 
antibodies  against  part  of  the  receptor-binding  domain  of  Toxin  A  and  to  assess  if  the 
antibodies  were  capable  of  blocking  this  aspect  of  toxin  function.  Potentially,  antibodies 
with  this  activity  might  protect  against  the  action  of  Toxin  A. 
To  assess  the  feasibility  of  these  goals,  Fab  fragments  were  generated  from  a 
polyclonal  antiserum  against  Toxin  A  and  tested  for  protection  against  in  vitro  challenge 
with  native  toxin.  This  established  that  monovalent  antibody  fragments  of  appropriate 
specificity  can  neutralize  the  action  of  Toxin  A.  Recombinant,  ýOvý  proteins  against  the 
receptor  binding  domain  of  Toxin  A  were  then  sought  using  phage  display. 
The  carboxy-terminal  region  of  Toxin  A  was  expressed  as  a  recombinant  protein 
(rTA),  purified,  and  shown  to  behave  as  would  be  expected  of  the  receptor-binding 
domain.  rTA  was  then  used  to  isolate  scFv  antibodies  from  a  phage  display  library  using 
conventional  bio-panning  methods.  Progressive  enrichment  of  rTA-specific  scFvs  through 
3  rounds  of  selection  was  observed.  Those  scFvs  that  showed  strongest  reaction  with  rTA 
x1i in  ELISA  were  sequenced,  expressed  as  soluble  antibodies  and  purified.  A  panel  of  diverse 
scFvs  was  established  that  appeared  to  bind  to  non-overlapping  epitopes  on  rTA. 
To  assay  for  protective  activity,  scFvs  were  mixed  with  native  Toxin  A,  added  to 
cells  in  culture,  and  the  response  monitored  over  a2  hour  period.  The  scFvs  were  able  to 
consistently  delay  the  cytopathic  activity  of  Toxin  A  but  were  unable  to  match  the 
neutralizing  activity  of  a  polyclonal  serum  or  its  Fab  derivatives.  The  epitopes  recognised 
by  the  scFvs  were  localized  using  a  sub-cloning  strategy.  Defined  parts  of  the  rTA  reading 
frame  were  recovered  by  PCR  and  fusions  created  with  maltose  binding  protein.  scFvs 
were  tested  for  recognition  of  the  maltose  binding  fusion  proteins.  In  one  instance,  a  scFv 
reacted  with  multiple  fusion  proteins  suggesting  recognition  of  a  repeated  peptide  motif.  A 
maltose  binding  protein  fusion  carrying 
/ 
candidate  sequence  was  successfully  recognised 
by  this  scFv. 
Overall,  phage  display  enabled  assembly  of  a  panel  of  scFv  antibodies  against 
epitopes  in  the  carboxy-terminal  domain  of  Toxin  A.  The  inability  of  these  antibodies  to 
block  the  activity  of  Toxin  A  may  be  due  to  the  multivalent  interaction  between  the  toxin 
and  its  receptor.  Alternatively,  the  rTA  used  in  scFv  isolated  may  lack  functions  that  are 
crucial  for  receptor  interaction  and  hence  potential  targets  for  antibody-mediated 
inhibition. 
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1  General  Introduction 
Clostridium  difficile,  a  Gram-positive  micro-aerophilic  (Weiner  et  al.,  1999),  rod 
shaped,  spore-forming  bacterium,  is  a  major  causative  of  nosocomial  intestinal  infections 
(Samore,  1993).  This  pathogen  is  responsible  of  about  one  fifth  of  the  cases  of  antibiotic- 
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associated  diarrhea,  three  quarters  of  antibiotic-associated  colitis,  and  more  importantly 
almost  all  the  cases  of  life  threatening  pseudomembranous  colitis  (Bartlett,  1994;  Kelly  et 
al.,  1994b).  These  are  estimated  to  be  3  million  cases  of  pseudomembranous  colitis  in  the 
United  States  alone  (Bartlett,  1992;  Mylonakis  et  al.,  2001)  regardless  of  the  seropositivity 
of  the  majority  of  adults  in  the  USA  (Weiner  et  al.,  1999).  Symptoms  can  range  from  mild 
disease  characterized  by  mild  diarrhea,  low  grade  fever  and  leukocytosis  to  a  very  serious 
disease  characterized  by  fulminant  course  of  colitis  (toxic  megacolon)  with  a  high 
mortality  rate  (Wilcox,  2003).  Frequent  symptoms  reported  include  fever,  abdominal  pain, 
and  cramping  (Vora  et  al.,  2006).  In  England  and  Wales  reports  of  infection  with  C. 
difficile  increased  about  six  times  in  the  three  years  starting  from  1990  (Settle  &  Wilcox, 
1996)  and  have  risen  steadily  therafter.  C  difficile-associated  disease  (CDAD)  is  estimated 
to  cause  problems  to  1%  of  hospitalized  patients  especially  the  immunocompromised  and 
the  elderly  (Kelly  et  al.,  1994b)  and  causes  considerable  morbidity,  increased  financial 
implications  on  hospitals,  and  longer  hospital  stays  (Riley,  1996;  Silva,  1989;  Wilcox  et 
al.,  1996).  In  some  instances  ward  closure  or  even  hospital  closure  (Cartmill  et  al.,  1994) 
are  nessessary  to  control  infection.  C  difficile  is  a  very  persistent  nosocomial  pathogen; 
transmission  in  hospital  wards  and  nursing  homes  is  assisted  by  the  heat-resistance  and 
resilience  of  the  spores.  With  the  increased  use  of  broad-spectrum  antibiotics  such  as 
clindamycin,  cephalosporins,  and  amoxicillin  during  the  last  three  decades,  MAD  has 
become  a  leading  clinical  problem  (Bartlett,  1981).  Unlike  many  other  bacteria,  C.  difficile 
infection  requires  antibiotic  exposure  in  order  to  elicit  its  effect.  Virtually  all  antibiotics, 
including  vancomycin  (Hecht  &  Olinger,  1989)  and  some  other  agents  like  cancer 
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chernotherapeutics  can  induce  MAD  (Anand  &  Glatt,  1993).  Even  so,  the  use  of 
antibiotics  for  the  treatment  of  MAD  remains  one  of  the  few  options  for  treatment  of  the 
disease. 
1.1  Pathogenicity 
Many  strains  of  C  difficile  are  able  to  produce  two  potent  toxins,  Toxin  A  and 
Toxin  B.  Both  are  responsible  of  the  virulence  that  is  associated  with  the  tissue  damage. 
Toxin  A  is  the  primary  mediator  of  intestinal  tissue  damage  (Lyerly  et  al.,  1982;  Lyerly  et 
al.,  1985).  Toxin  A  is  an  enterotoxin  with  glucosyltransferases  activity  and  causes  tissue 
damage  (Faust  et  al.,  1998).  The  binding  of  Toxin  A  to  a  trisaccharide  receptor  on  the 
human  intestinal  epithelial  cells  initiates  disease  (Wren  et  al.,  1991).  Indeed,  only  Toxin  A 
has  been  shown  to  recognize  a  binding  domain  on  epithelial  cell  surface  carbohydrates 
(Krivan  et  al.,  1986)  and  it  is  considered  that  this  marks  the  starting  point  from  which  both 
toxins  can  elicit  their  effects  on  the  epithelial  cells  on  a  later  stage.  There  are  a  limited 
number  of  reports  indicating  that  Toxin  B  alone  can  initiate  an  effect  on  the  gastrointestinal 
cells  (Riegler  et  al.,  1995;  Savidge  et  al.,  2003).  Unlike  some  enzymes  like  exoenzyme  C3, 
Toxin  A  does  not  require  assistance  to  permeabilize  cells  (Bartlett,  1994)  which  gives  it  the 
flexibility  to  invade  damaged  or  intact  tissues.  Reports  suggest  that  Toxin  B  has  little  effect 
when  administered  orally  to  animals  without  Toxin  A,  and  its  lethality  only  became 
evident  after  Toxin  A  had  exerted  an  effect  on  the  intestine  (von  Eichel-Streiber  et  al., 
1987). 
When  cells  are  exposed  to  Toxin  A  they  tend  to  retract  and  round  up.  This  is  a 
direct  effect  of  the  loss  of  filamentous  F-actin  and  the  accumulation  of  G-actin  (Dillon  et 
al.,  1995;  Pothoulakis  &  Lamont,  2001).  This  opens  tight  junctions,  disturbing  the  barrier 
function  of  the  epithelium,  and  leading  to  the  watery  diarrhea  which  is  typical  for  C. 
difficile  antibiotic-associated  disease  (Poxton  et  al.,  2001).  The  fluid  exudates  in  the 
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response,  a  feature  that  is  not  be  seen  in  other  enterotoxins  (Tucker  et  al.,  1990).  In 
contrast  to  some  other  bacterial  toxins  like  cholera  toxin  and  E.  coli  enterotoxins  which 
trigger  intestinal  secretion  without  causing  intestinal  inflammation,  when  Toxin  A  was 
injected  to  the  colonic  loops  in  experimental  animals,  it  induced  secretion  of  fluid,  and 
triggered  epithelial  cell  destruction  and  neutrophil  infiltration  (Pothoulakis  &  Lamont, 
2001). 
Toxin  A  has  potent  biological  activities  that  are  described  later.  However,  its 
receptor-binding  activity  may  activate  biological  responses  such  as  signal  transduction 
cascades,  cytokines  release,  and  lymphocyte  proliferation  by  clustering  molecules  at  the 
surface  of  host  cells  (Castagliuolo  et  al.,  2004).  These  effects  are  likely  due  to  the  lectin- 
like  structure  of  the  C-terminal  region  of  C.  difficile  Toxin  A  which  can  stimulate  IL-2  and 
gamma  interferon  (IFN-7)  production  in  vitro.  The  integrity  of  the  C-tenninal  domain  of 
Toxin  A  is  required  for  these  effects;  short  recombinant  peptides  carrying  C-terminal  were 
not  found  to  induce  any  inflammatory  responses  (He  et  al.,  2000). 
Amongst  the  important  effects  of  Toxin  A  on  the  epithelium  is  the  disruption  of  the 
tight  junctions,  fluid  accumulation  and  induction  of  neutrophil  infiltration.  The  disruption 
of  the  tight  junction  Js  reported  to  arise  from  effects  on  cell  surface  projections  and 
rearrangement  of  micro-villi,  as  studied  by  electron  microscopy  (Chang  et  al.,  1979; 
Fiorentini  et  al.,  1990).  It  was  reported  that  in  cell  culture,  the  disruption  of  cell  integrity 
takes  place  before  the  cell  shrinkage  (Hecht  et  al.,  1988).  Some  observations  reported  a 
retraction  phenotype  that  is  characterized  by  marginalization  of  the  nucleus,  an  effect 
associated  with  the  disruption  of  the  cytoskeleton. 
Neutrophil  infiltration  and  accumulation  is  an  important  step  in  the  development  of 
pseudomembranous  colitis.  Neutrophil  infiltration  is  thought  to  occur  after  the  loss  of 
epithelial  integrity.  It  was  reported  that  direct  neutrophil-Toxin  A  interaction  is  essential 
for  neutrophil  infiltration  (Kelly  et  al.,  1994a). 
4 Chapter  1,  General  introcluction 
There  is  evidence  that  sensory  neurons  are  regulated  by  Toxin  A.  This  is  supported  by 
studies  of  substance  P,  an  immunoreactive  peptide  that  is  linked  to  sensory  neurons  in  the 
epithelium  (Mantyh  et  al.,  1996).  Substance  P  is  thought  to  activate  neutrophils  via  the 
activation  of  macrophages  and  the  release  of  TNF-a.  Substance  P  was  also  shown  to 
mediate  mast  cell  activation  and  degranulation.  Hence,  it  may  be  also  be  involved  in  the 
pathogenesis  of  C  difficile-induced  colonic  inflammation. 
Another  potentially  important  effect  is  the  triggering  of  apoptosis  when  intestinal 
cells,  mast  cells,  and  endothelial  cells  are  exposed  to  Toxin  A  (Alcantara  et  al.,  2001;  Brito 
et  al.,  2002;  Mahida  et  al.,  1996).  This  may  have  a  significant  role  in  the  pathogenesis  of 
pseudomembranous  colitis  induced  by  C  difficile.  It  was  postulated  that  apoptosis  could  be 
induced  by  two  different  pathways.  In  the  first  pathway,  apoptosis  is  initiated  as  a  result  of 
the  transmission  of  a  death  signal  after  binding  of  TNF-a  or  Fas  receptor  to  cell  surface 
ultimately  leading  to  activation  of  intracellular  cysteine  protease  caspase  8  (Ashkenazi  & 
Dixit,  1998).  The  second  pathway  is  the  activation  of  caspase  9  (Green  &  Amarante- 
Mendes,  1998)  as  a  result  of  cellular  stress  and  mitochondrial  changes.  The  activation  of 
caspase  8  or  9  leads  to  the  activation  of  caspases  3,6  and  7  that  have  crucial  consequences 
on  a  group  of  important  proteins  and  DNA  fragmentation  in  the  cell.  It  was  reported  that 
both  pathways  are  induced  by  Toxin  A  (Carneiro  et  al.,  2006). 
In  cell  culture,  the  detachment  of  epithelial  cells  from  the  basement  membrane  in 
response  to  Toxin  A  may  also  lead  to  apoptosis  (Brito  et  al.,  2002;  Fiorentini  et  al.,  1998). 
Although  apoptosis  is  an  important  natural  process  that  corrects  cell  numbers  by 
management  of  growth  and  death,  it  can  be  triggered  by  extracellular  factors  leading 
damage  and  disfunction  of  tissues.  This  damage  is  seen  in  the  form  of  cell  shrinkage, 
damage  nucleic  acid  and  paradoxically,  impaired  inflammation  activity  (Kroemer  et  al., 
1995). 
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One  feature  of  C.  difficile  infection  is  the  strong  inflammatory  response  seen  in  the 
intestine.  Linevsky  and  colleagues  found  that  production  of  IL-8,  IL-1p  and  TNF-a  by 
macrophages  can  be  activated  as  a  result  of  Toxin  A  and  B  (Linevsky  et  al.,  1997).  These 
factors  up-regulate  the  expression  of  neutrophil  and  endothelial  cells  adhesion  receptors, 
guide  neutrophils  to  the  vascular  endothelium,  promote  diapedesis  and  tissue  infiltration 
(Strieter  et  al.,  1994).  This  provides  a  link  between  macrophage  activation  and  neutrophil 
infiltration  in  the  pathogenesis  of  Clostridium  difficile  (Linevsky  et  al.,  1997).  When 
cytokine  synthesis  was  inhibited  by  drugs,  the  damaging  effect  of  Toxin  A  in  the  intestine 
was  minimized  (Triadafilopoulos  et  al.,  1989).  This  finding  shows  the  role  of  cytokines  as 
important  proinflammatory  mediators  in  the  pathophysiology  caused  by  virulence  factors 
from  the  bacteria.  Monokines  like  l1L-1P  and  IL-6  can  also  be  released  from  monocytes  in 
the  presence  of  Toxins  A  and  B  (Flegel  et  al.,  1991).  Another  group  (Kelly  et  al.,  1994a) 
showed  that  Toxin  A  can  stimulate  sensory  neurons  and  trigger  degranulation  of  mast  cells 
causing  release  of  inflammatory  mediators  that  eventually  lead  to  infiltration  of  neutrophils 
into  the  affected  region.  Castagliuolo  and  his  colleagues  reported  that  Toxin  A  induces  the 
production  of  the  neutrophil  chemoattractant  macrophage-inflammatory  protein-2  (MIP-2) 
from  the  intestinal  epithelial  cells  in  the  rat.  The  importance  of  MIP-2  is  that  it  is  a  potent 
neutrophil  chemoattractant  and  leads  to  neutrophil  activation  and  attraction  which  is  a 
unique  phenomenon  of  Toxin  A  (Castagliuolo  et  al.,  1998a).  It  was  also  reported  that 
Toxin  A  can  act  directly  as  a  chernotactic  factor  for  neutrophils  (Pothoulakis  et  al.,  1993) 
and  peripheral  blood  monocytes.  Although  these  cells  are  unlikely  to  be  exposed  directly  to 
significant  amounts  of  the  toxin  in  the  peripheral  circulation,  the  situation  may  be  different 
in  areas  of  colonic  damage  (Linevsky  et  al.,  1997).  Interestingly,  Toxin  B  lacks  this 
activity  (Pothoulakis  et  al.,  1988).  Inflammation  may  also  be  exacerbated  by  down 
regulation  of  other  activities.  For  example  one  study  has  reported  that  Toxin  A  leads  to 
activation  of  adenosine  deaminase,  an  enzyme  that  can  down-regulate  immune  responses 
by  acting  as  an  anti-inflammatory  agent  (Cavalcante  et  al.,  2006). 
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These  findings  show  how  the  pathogenesis  of  C.  difficile  enterocolitis  is  influenced 
by  inflammatory  mediators  like  IIL-8  and  the  response  of  infiltrating  monocytes  and 
neutrophils.  These  responses  probably  underlie  the  massive  vascular  blockage,  infiltration 
of  the  lamina  propria  with  neutrophils  and  formation  of  pseudomembrane  in  the  colon 
(Pothoulakis,  1996). 
Surprisingly,  in  the  last  few  years,  it  has  been  repeatedly  reported  that 
pseudomembranous  colitis  and  nosocornial  MAD  can  be  caused  by  C.  difficile  Toxin  A- 
negative,  Toxin  B-positive  stains  (A/B')  (Johnson  et  al.,  2001;  Kato  et  al.,  1998;  Limaye 
et  al.,  2000).  These  strains  were  distinguished  by  a  small  to  large  deletions  in  tcdA  (Sambol 
et  al.,  2000).  It  seems  that  the  deletion  did  not  impair  the  toxin  function  as  expected,  but 
produced  other  forms  or  variants  of  the  toxin  with  equivalent  potential  for  disease 
initiation.  Pathogenicity  of  A"/B'  strains  was  very  similar  to  A/B'  when  measured  by  fluid 
secretion  in  rabbit  intestinal  loops  (Borriello  et  al.,  1992).  These  variants  were  found  to  be 
very  comparable  in  potency  to  C  sordellff  lethal  toxin  (Soehn  et  al.,  1998). 
The  occurance  of  these  strains  appears  widespread  but  variable.  One  study  has 
reported  that  39  clinical  isolates  out  of  50  contained  small  deletions  of  1.7  or  1.8  kb  and 
were  considered  as  Toxin  A-/B'  strains.  Out  of  those  39  A/B+  isolates,  85  %  were 
clindamycin  resistant.  This  properly  may  boost  the  risk  of  C  difficile  disease  (van  den 
Berg  et  al.,  2004).  Another  study  by  Sambol  (Sambol  et  al.,  2000)  reported  only  7  cases  of 
Toxin  K  strains  amongst  5000  screened,  suggesting  that  their  frequency  can  be  very  low. 
These  conflicting  findings  suggest  that  there  is  a  very  considerable  difference  in  the 
occurrence  of  Toxin  A-/B'  in  different  parts  of  the  world.  These  contradictory  findings 
raise  some  important  questions  ;  in  the  absence  of  Toxin  A,  does  Toxin  B  play  a  more 
active  role  than  was  thought  and  does  Toxin  A-  represent  a  selection  event  within  the  host 
(Voth  &  Ballard,  2005).  These  issues  have  not  yet  been  resolved  because  most Chapter  1,  General  introduction 
experimental  work  carried  out  on  the  association  of  C.  difficile  with  colitis  has  used  of 
Toxin  A  or  Toxin  A  producing  C.  difficile. 
1.2  Toxin  structure 
Toxins  A  and  B  are  to  some  extent  related  to  each  other  with  nearly  50  %  amino 
acid  similarity  in  their  sequences.  The  highest  similarity  is  found  in  the  N-terminal  (70  %) 
and  in  the  C-terminal  regions  of  the  toxins  (von  Eichel-Streiber  et  al.,  1990).  This  finding 
helps  to  explain  the  common  mechanism  of  action  adopted  by  both  toxins  and  the  degree 
of  similarity  of  substrate  for  both  toxins.  Both  toxins  are  related  to  virulence  factors  from 
C  sordelli  and  C.  novyi,  based  on  the  similarity  of  their  sequences  (von  Eichel-Streiber  et 
al.,  1996). 
Cloning  and  sequencing  of  the  C.  difficile  toxins  showed  that  the  Toxin  A  gene  is 
8.1  kb  in  length  and  encodes  a  2710  amino  acid  polypeptide  of  308  kDa  (Dove  et  al.,  1990; 
von  Eichel-Streiber  et  al.,  1992a).  For  many  other  smaller  toxins  that  act  on  intracellular 
targets,  it  has  been  possible  to  identify  three  main  regions:  the  receptor-binding  domain, 
the  transfer  domain  and  the  enzymatic  domain.  Toxin  A  is  an  extraordinarily  large 
molecule  and  this  property  has  presented  a  challenge  to  the  analysis  of  its  structure  and 
toxicity  (Faust  et  al.,  1998).  Progress  to  unravel  the  mechanism  of  toxicity  for  this  toxin 
has  been  relatively  slow. 
One  of  the  first  clues  to  toxin  action  came  from  analysis  of  the  C-terminal  part  of 
the  toxin,  where  so-called  CROPS  (combined  repetitive  oligopeptides)  were  identified 
(Florin  &  Thelestarn,  1983)  These  consist  of  31  short  repeats  (SRs)  and  7  long  repeats 
fT  D 
kLms)  of  peptide  sequence.  The  repeat  sequences  appear  to  be  unique  among  extra-cellular 
bacterial  proteins  (Ho  et  al.,  2005).  However,  four  repeat  motifs  show  homology  to 
features  in  the  C-terminal  region  of  Toxin  B.  Each  repeat  consists  of  a  P-hairpin  and  a  loop 
structure  as  shown  by  structural  analysis.  These  features  are  thought  to  play  a  role  in  the 
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receptor-binding  activity  of  the  toxin.  The  sequence  conservation  in  the  SRs  and  LRs  are 
thought  to  play  a  role  in  formation  of  kinks  in  structure,  speculated  to  interfere  with 
receptor  recognition  and  cell  entry.  It  was  found  that  between  5  and  15  repeats  are  able  to 
form  stable  secondary  structures  without  interference  with  other  structures.  The  repetition 
of  these  features  may  augment  the  binding  affinity  of  the  C-terminal  domain  with  its 
receptor  (von  Eichel-Streiber  et  al.,  1992b;  Weis  &  Drickamer,  1996).  It  has  also  been 
suggested  that  due  to  the  repetitive  manner  of  the  carbohydrate  binding  sites  of  Toxin  A, 
toxin  binds  to  the  receptor  in  a  multivalent  pattern.  The  binding  sites  present  on  the  toxin 
were  not  thought  to  bind  to  carbohydrate  receptor  molecules  simultaneously  because  they 
are  orientated  in  different  directions  on  the  C-terminal  domain  (Greco  et  al.,  2006). 
The  central  region  of  each  toxin  is hydrophobic  and  this  region  is  thought  to  play  a 
role  in  translocation  of  the  N-terminal  domain  across  the  host  membrane  and  into  the 
cytosol  (Dove  et  al.,  1990;  von  Eichel-Streiber  et  al.,  1992a).  The  third  part  of  the  toxin  is 
the  N-tenninal  region  that  carries  biological  activity  with  a  hypothetical  nucleotide  binding 
site  (Barroso  et  al.,  1994;  von  Eichel-Streiber  et  al.,  1996)  that  was  analysed  by  Faust  and 
colleages  (Faust  et  al.,  1998).  The  following  sections  describe  these  features  in  more  detail. 
1.3  Toxin  mode  of  action 
1.3.1  Receptor  and  receptor  binding 
The  repeating  units  of  amino  acids  present  in  the  C-terminal  domain  of  Toxin  A 
represent  sites  that  act  as  multivalent  lectin,  recognizing  the  trisaccharide  Galal-3Galpl- 
4GIcNAc  and  the  disaccharide  Galpl-4GIcNac.  These  features  are  found  on  the  I,  X,  and 
Y  blood  group  antigens  (Tucker  et  al.,  1990;  Tucker  &  Wilkins,  1991).  It  has  been 
suggested  that  Toxin  A  binds  to  these  receptors  in  the  intestine  of  animals  but  not  humans 
where  a-galactosyltransferase  activity  that  is  essential  for  the  assembly  of  Galul-3GalOl- 
4GIcNAc  does  not  exist.  This  implicates  the  involvement  of  other  receptors  which  are  not 
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yet  identified  (Krivan  et  al.,  1986;  Pothoulakis  &  Lamont,  2001).  It  has  been  postulated 
that  the  receptor  for  Toxin  A  on  mammalian  cells  may  be  a  glycoprotein.  On  rabbit 
erythrocytes  the  receptor  is  a  glycolipid  (Pothoulakis  &  Lamont,  2001).  A  receptor  for 
Toxin  B  has  not  yet  been  identified  (Stubbe  et  al.,  2000). 
One  study  (Castagliuolo  et  al.,  1998b)  has  pointed  out  the  importance  of  the 
neurokinin-1  receptor  in  activation  of  sensory  neurons  and  immune  cells  of  the  intestinal 
lamina  propria  after  the  injection  of  Toxin  A  into  animal  intestine.  This  study  demonstrated 
that  mice  genetically  deficient  in  the  neutokinin-1  receptor  were  protected  from  the  severe 
consequences  of  inflammation  and  secretion  observed  after  Toxin  A  introduction  into  the 
intestine. 
It  was  thought  that  all  or  some  of  the  receptor-binding  domain  of  Toxin  A  interacts 
with  the  receptor  on  target  cells.  If  the  structural  analysis  reported  recently  (Greco  et  al., 
2006)  accurately  reflects  the  organization  of  the  C-terminal  domain  of  Toxin  A,  it  is 
difficult  to  imagine  how  all  potential  receptor-binding  sites  could  be  occupied 
simultaneously  unless  major  reorganization  of  the  domain  takes  place.  This  is  because  the 
receptor-binding  pockets  identified  by  Greco  and  colleages  face  in  different  directions.  It  is 
thought  that  cross-linking  of  receptors  by  Toxin  A  drives  clustering,  leading  to  endocytosis 
(von  Eichel-Streiber  et  al.,  1996).  This  simple  model  is  not  consistent,  however  with  the 
finding  (Florin  &  Thelestam,  1983)  that  recombinant  protein  containing  50  %  of  the 
receptor-binding  domain  of  Toxin  A  failed  to  bind  to  the  cellular  target  receptor  and  to 
initiate  endocytosis.  An  alternative  model  would  be  that  one  toxin  molecule  binds  to  one 
cellular  receptor  despite  the  repetitive  nature  of  the  toxin  binding  domain.  This  is 
supported  by  another  study  (Lyerly  et  al.,  1986)  showing  that  blocking  two  epitopes  in  the 
109  kDa  receptor-binding  domain  with  monoclonal  antibody  was  enough  to  render  the 
toxin  completely  inactive. 
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Conditions  that  affect  the  receptor  binding  of  Toxin  A  have  been  studied  by  different 
groups.  To  understand  the  behavior  of  binding,  it  has  been  reported  that  a  recombinant 
fragment  of  the  binding  domain  of  Toxin  A  containing  11  repetitive  sequences  was  able  to 
bind  to  the  receptor  of  F9  cells  (Sauerborn  et  al.,  1997)  in  high  concentration  of  the 
recombinant  protein  which  was  also  able  to  inhibit  the  cytotoxicity. 
Genth  and  colleages  (Genth  et  al.,  2000)  reported  similar  findings.  However,  they 
also  noted  that  inclusion  of  central,  amino  acids  from  the  hydrophobic  domain  in  a 
recombinant  form  of  the  binding  domain  enhanced  inhibition  of  Toxin  A  action.  The 
recombinant  protein  was  also  able  to  undergo  internalization  after  binding  to  the  surface  of 
target  cells  in  vitro.  This  shows  that  the  hydrophobic  domain  has  an  importance  in 
influencing  the  binding  activity.  The  central  domain  alone,  or  parts  of  the  C-terminal 
domain  lacked  these  properties  (Frisch  et  al.,  2003). 
The  importance  of  metals  in  binding  activity  of  Toxin  A  to  the  receptor  has  been 
investigated  by  some  groups  (Cho,  2001;  Dodd  &  Drickamer,  2001)  as  carbohydrate 
receptors  often  incorporate  metal  ions  for  binding.  One  study  (Demarest  et  al.,  2005) 
pointed  out  that  Toxin  A-receptor  interaction  is  Ca2'  dependent.  The  role  of  intracellular 
Ca2'  in  cytotoxicity  is  still  controversial  (Demarest  et  al.,  2005;  Fiorentini  et  al.,  1993)  as 
some  investigators  report  that  exposure  to  C.  difficile  can  increase  the  cellular  Ca2+ 
concentrations  (Castagliuolo  et  al.,  2004). 
1.3.2  Toxin  A  entry  to  the  cell 
Internalization  of  Toxin  A  into  the  host  cell  is  an  important  step  for  the  toxin  to 
exert  full  activity  which  ends  with  changes  to  cell  morphology  and  tissue  damage.  Figure 
1.1  summarises  the  mode  of  action  of  Toxin  A. 
Toxin  A  gains  entry  to  the  cell  by  endocytosis  into  vesicles  which  then  undergo 
acidification.  The  low  pH  of  the  endosome  is  thought  to  play  an  important  role  in  changing 
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the  structure  of  the  toxin.  It  is  thought  that  the  toxin  unfolds,  exposing  the  hydrophobic 
central  domain  of  the  protein  QaDan  et  al.,  2000).  The  role  of  the  C-terminal  binding 
domain  and  the  hydrophobic  central  domain  of  Toxin  A  after  endocytosis  is  not  well 
understood.  One  study  (Pfeifer  et  al.,  2003)  reported  that  the  N-terminal  domain  of  Toxin 
B  is  the  only  part  of  the  toxin  which  gains  access  to  the  cytosol  and  binds  to  its  target.  The 
finding  may  help  understanding  the  importance  of  the  C-terminal  and  the  hydrophobic 
domains  of  Toxin  A. 
1.3.3  Toxin  function 
Toxin  A  is  an  intracellular  toxin  with  an  action  that  is  characterized  by  the 
enzymatic  glucosylation  of  the  low  molecular  mass  GTP-binding  proteins  Rho,  Rac,  and 
Cdc42  (Aktories  &  Just,  1995;  Just  et  al.,  1995).  To  do  so,  the  toxin  uses  UDP-glucose  as 
substrate.  Glucosylation  takes  place  at  threonine  37  and  threonine  35  in  the  target  proteins 
in  that  order.  This  leads  to  the  deactivation  of  the  small  GTPases  (Chardin  et  al.,  1989; 
Paterson  et  al.,  1990).  As  a  result,  signal  transduction  pathways  controlled  by  the  GTPases 
are  inhibited  (Just  et  al.,  1995;  Prepens  et  al.,  1996)  causing  destruction  of  the 
cytoskeleton,  transcription  of  some  stress-activated  protein  kinases,  and  a  drop  in  synthesis 
of  phosphatidylinositol  4,5  bisphosphate  which  could  lead  to  the  loss  of  cell  polarity 
(Mackay  &  Hall,  1998).  In  the  absence  of  the  acceptor  protein,  Toxin  A  hydrolyzes  UDP- 
glucose  to  UDP  and  glucose  (Ciesla  &  Bobak,  1998).  This  is  analogous  to  the  ADP- 
ribosyltransferase  activity  of  toxins  like  cholera  toxin  in  that  the  absence  of  acceptor 
protein,  hydrolysis  of  NAD  to  nicotinamide  and  ADP-ribose  takes  place. 
Immediately  after  Toxin  A  has  gained  access  to  the  cytosol  of  epithelial  cells,  it 
initiates  glucosylation  of  Rho,  Rac,  and  Cdc42,  the  actin  cytoskeleton  collapses  and 
inflammation  is  initiated.  It  was  reported  that  the  induction  of  chemokine  expression  is 
provoked  by  the  transcription  factor  NF-KB.  The  activation  of  NF-KB  in  the  early  stage  of 
C.  difficile  pathogenesis  is  accompanied  by  release  of  reactive  oxygen  species  and 
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activation  of  mitogen-activated  kinases.  It  is  thought  that  this  pathway  is  responsible  for 
the  neutrophil  infiltration  (Pothoulakis  &  Lamont,  2001).  It  has  also  been  reported  that 
cellular  infiltration  may  occur  before  the  Rho  glucosylation,  suggesting  an  independent 
route  of  action  that  requires  further  studies  (Pothoulakis  &  Lamont,  2001). 
The  small  GTPases  Rho,  Rac  and  Cdc42  which  share  similar  mechanisms  of 
regulation,  are  found  in  eukaryotic  cells  and  regulate  the  actin  cytoskeleton  (Hall,  1990). 
Rho  and  other  small  GTPases  hydrolyze  GTP  to  GDP  which  result  conversion  from  the 
"on"  to  the  "off'  state.  This  state  of  fluctuation  is  controlled  by  guanine  exchange  factors 
that  are  needed  for  regulation  of  activity.  When  Rho  is  activated  as  part  of  its  role  in  the 
cytoplasm,  it  hydrolyzes  bound  GTP  to  GDP.  GDP  dissociation  inhibitors  then  keep  the 
Rho  blocked  from  interaction  with  guanine  exchange  factors  (Zhou  et  al.,  1998).  When  the 
GDP  bound form  of  Rho  is  dissociated,  Rho  is  able  to  interact  with  guanine  exchange 
factors,  leading  to  binding  of  GTP,  activation,  and  initiation  of  regulatory  cascade. 
Hydrolysis  of  GTP  to  GDP  returns  Rho  to  the  off  state.  Furthermore,  through  activation  of 
Rho-kinase  or  other  signal  proteins,  Rho  participates  in  regulation  of  stress  fiber  formation 
(Fujisawa  et  al.,  1998).  The  later  events  take  place  after  an  extracellular  signal.  When  the 
interaction  of  Rho  with  the  signal  proteins  is  blocked,  the  actin  cytoskeleton  is  disrupted. 
Although  small  GTPases  like  Rac  and  Cdc42  share  a  common  mechanism  with 
Rho,  Rac  and  Cdc42  activity  is  directed  more  towards  the  formation  of  flamellipodia  and 
filopodia  which  are  important  for  movement  of  cells  (Nobes  &  Hall,  1995). 
13 Chapter  1,  General  introduction 
Toxin  A 
v 
Binding  to  surface 
re"Ptors 
v 
Intcmalization 
Adle 
Glucosylation  of 
Rho,  Racý  C&  42 
I 
Actin  disorganization 
I 
Increased  tight 
junction  permeability 
11 
Epithelial  ccll  rounding 
**  Mitochomkial  Activation 
0 
49, 
NF-Ka  activa6on 
--------  --  j,  Release  of  cytokines 
Stimulation  orsewory 
incurons  and  entcric  incrycs 
SP.  CGRP.  NT 
Stimulation  of  Mut 
Celts  and  Frucrophoses 
Endothdial.  cell  activation 
I  Ncutrophil  adhesion 
and  transmigradon 
I 
Colitis  and  Diarrhea 
Figure  1.1:  Summary  of  the  proposed  mode  of  action  of  Toxin  A 
(Pothoulakis  &  Lamont,  2001). 
14 Chapter  1,  General  introduction 
1.4  Humoral  and  cellular  immune  response  against  Clostridium 
difficile  Toxin  A 
To  date,  no  comprehensive  studies  have  been  done  with  a  significant  number  of 
cases  to  establish  the  importance  of  immunoglobulin  responses  during  and  after  infection 
with  C  difficile.  Some  reports  have  investigated  different  aspects  of  the  immune  response 
in  normal  individuals  and  patients  to  correlate  with  infection,  age,  and  sex.  One  study 
suggested  that  sex  may  have  a  significant  role  in  disease  prevalence  as  women  are  more 
prone  to  MAD  (Aronsson  et  al.,  1985).  Age  was  also  found  to  be  an  important  factor  of 
C  difficile  has  been  found  capable  of  colonizing  the  intestinal  tracts  of  90  %  of  healthy 
newborns  and  children  under  one  year.  Although  toxin  appears  to  be  produced,  newborns 
are  resistant  to  the  disease.  In  nonnal  adults,  two-thirds  of  nonnal  subjects  develop  anti- 
Toxin  A  antibodies  but  the  incidence  of  MAD  is  much  higher  than  in  newborns.  The  role 
of  different  immunoglobulin  classes  and  their  levels  were  reported  to  be  of  significance  in 
immune  response  against  Toxin  A.  One  study  has  linked  the  development  of  anti-Toxin  A 
IgG  in  the  serum  of  colonized  patients  on  antibiotic  therapy  and  the  asymptomatic  carriage 
of  C.  difficile.  These  patients  were  found  to  be  48  times  more  resistant  to  diarrhea  than 
those  who  failed  to  develop  IgG  against  Toxin  A  in  serum  (Kyne  et  al.,  2000).  This  finding 
highlights  the  importance  of  the  humoral  response  in  protection.  The  elevation  of  IgG  anti- 
Toxin  A  antibody  in  serum  was  also  accompanied  by  the  elevation  of  IgG  in  the  stool.  This 
suggests  a  filtration  mechanism  from  the  serum  to  the  lumen  of  the  intestine  (Warny  et  al., 
1994).  Serum  levels  of  IgM  and  IgG  antibodies  were  monitored  in  patients  who  did  not 
relapse  and  it  was  found  that  both  immunoglobulins  were  markedly  elevated.  In  contrast, 
patients  who  relapsed  after  the  first  occurrence  of  the  disease  developed  much  less  serum 
IgM  and  IgG  (Kyne  et  al.,  2001).  Warny  and  colleages  (Warny  et  al.,  1999)  reported  that 
patients  who  developed  recurrent  MAD  had  lower  IgA  and  IgG  anti-Toxin  A  antibodies 
levels  in  the  stool  than  those  who  recovered  from  infection.  These  findings  clearly  suggest Chapter  1,  General  introduction 
that  elevated  immunoglobulins  are  a  good  marker  of  the  immune  response  against  the 
disease  and  may  also  be  critical  protective  factors  in  recurrence  of  CDAD. 
It  has  also  been  reported  (Wamy  et  al.,  1994)  that  anti-Toxin  A  antibody  level  is 
an  important  factor  in  the  length  of  CDAD.  In  patients  with  low  levels  of  antibody,  the 
duration  of  disease  and  the  chances  of  relapse  were  both  higher  than  in  patients  with  high 
levels  of  anti-Toxin  A  antibodies. 
Toxins  A  and  B  were  found  to  have  an  influence  on  the  cellular  immune  system  in 
vitro.  The  T-cell  response  against  Toxin  A  was  studied  in  parallel  with  the  monocyte 
response  and  it  was  found  that  monocyte-independent  T-cell  proliferation  was  not  affected 
while  monocyte-dependent  T-cell  proliferation  was  inhibited  by  the  toxin.  This  suggested 
.  that  Toxin  A  interacts  with  monocyte  receptors  and  leads  to  cytopathic  effects  which  are 
not  seen  with  T-cells  (Daubener  et  al.,  1988) 
1.5  Methods  for  control 
1.5.1  Antibiotics 
The  two  most  effective  antibiotics  for  treatment  of  MAD  are  metronidazole  and 
vancomycin  for  mild  or  severe  cases  respectively.  Most  patients  respond  to  these  two 
antibiotics,  but  20  %  of  patients  relapse  after  the  termination  of  antibiotic  treatment 
(Fekety,  1997).  Further  treatment  of  MAD  with  antibiotics  can  be  successful  in  70  %  of 
patients  but  some  may  suffer  many  rounds  of  relapses  (Buggy  et  al.,  1987;  Jobe  et  al., 
1995).  Other  antibiotics  like  bacitracin,  fusidic  acid,  rifampicin  and  teicoplanin  are  also 
reported  as  first  line  antibiotics  in  the  treatment  of  CDAD.  However,  high  relative  toxicity, 
the  cost  of  these  antibiotics  and  the  high  rate  of  carriage  of  the  pathogen  in  stool  after 
treatment,  leaves  metronidazole  and  vancomycin  as  first  and  second  line  antibiotics  of 
choice  for  CDAD  (McFarland  et  al.,  2005;  Young  et  al.,  1985).  Many  strategies  have  been 
employed  to  control  the  disease,  like  the  normalization  of  microbial  flora  and  the  use  of Chapter  1,  General  introduction 
combination  of  antibiotics,  but  success  tends  to  be  limited  (Buggy  et  al.,  1987;  Gorbach  et 
al.,  1987).  Although  it  has  been  found  that  some  strains  of  C  difficile  carry  genes  for 
antibiotic  resistance  (Roberts  et  al.,  1994),  relapse  is  more  often  due  to  reinfection  or 
failure  to  complete  antibiotic  treatment  (Fekety,  1997). 
Rounds  of  antibiotic  treatment  in  recurrent  cases  can  be  extended  to  months  or,  in 
some  cases,  years  as  the  percentage  of  recurrence  increases  at  each  round  of  relapse 
(Fekety  et  al.,  1997;  McFarland  et  al.,  1999).  Some  studies  have  reported  that  relapse  was 
often  due  to  the  discontinuation  of  antibiotic  therapy  (Kato  et  al.,  1996;  Tang-Feldman  et 
al.,  2003;  Wilcox  et  al.,  1998).  The  authors  discovered  that  50  %  of  recurrent  infections 
were  due  to  relapse  with  the  original  strain  that  caused  the  first  infection.  Neýv  strains  of  C 
difficile  were  blamed  for  the  other  50  %  of  recurrence.  Discontinuation  of  antibiotics  may 
take  into  account  factors  like  age,  health  and  the  severity  of  the  disease.  Moreover,  the 
decision  to  cease  antibiotic  treatment  may  be  made  because  the  fecal  culture  has  gone  from 
positive  to  negative.  Relapse  may  arise  when  spores  germinate  in  the  susceptible  intestine. 
Metronidazole  was  found  to  be  very  effective  in  the  majority  of  CDAD;  however,  it  might 
not  be  a  favorable  choice  for  treating  recurrence  because  it  has  been  found  that 
metronidazole  can  be  associated  with  occurrence  of  multiple  resistant  strains.  In  addition, 
metronidazole  has  a  relatively  high  toxicity  (Beloosesky  et  al.,  2000;  Pelaez  et  al.,  2002). 
Vancomycin  appears  to  be  an  effective  and  relatively  safe  therapy  for  recurrence  with  very 
few  side  effects  (Jarvis,  1998). 
The  use  of  broad  spectrum  antibiotics  inhibits  the  non-nal  flora  in  the  gut  causing 
overgrowth  of  resident  or  incoming  C  difficile  which  consequently  produces  the  toxins 
responsible  for  CDAD  (Nord  &  Edlund,  1990).  The  irresponsible  use  of  broad  spectrum 
antibiotics  is  accelerating  the  emergence  of  multiple  resistant  bacteria.  Of  particular 
concern  is  the  appearance  of  bacterial  pathogens  that  are  resistant  to  vancomycin  (1997; 
Watanabe  et  al.,  1997).  Moreover,  metronidazole,  vancomycin  or  other  choices  of Chapter  1,  General  introduction 
antibiotics  do  not  allow  recovery  of  intestinal  normal  flora  which  can  inhibit  enteric 
pathogens  like  C  difficile.  The  sole  use  of  antibiotics  for  control  of  C.  difficile  infection 
also  fails  to  limit  the  exposure  to  pathogens  in  hospital  environments.  Hand  washing  and 
the  isolation  of  infected  patients  in  parallel  with  antibiotic  therapy  are  important  issues 
(Schroeder,  2005;  Valiquette  et  al.,  2004). 
In  mild  cases  of  CDAD,  discontinuation  of  the  offending  antibiotic  or  shifting  to  a 
less  potent  antibiotic  is  usually  enough  to  reduce  symptoms.  Electrolyte  replacements  are 
usually  administered  in  severe  forms  of  diarrhea  (McFarland  et  al.,  2000). 
It  was  also  reported  that  probiotics  may  be  of  value  in  recurrent  cases  of  MAD  by 
competing  with  the  pathogen  for  colonization  and  inducing  the  other  normal  organisms  to 
establish  in  the  colon.  Micro-organisms  like  Saccharomyces  boulardii  and  Lactobacillus 
species  were  introduced  to  the  intestine.  The  outcome  of  this  strategy  was  a  significant 
decrease  of  recurrence.  However,  these  results  were  achieved  only  when  probiotics  were 
combined  with  vancomycin  or  metronidazole  (Surawicz  et  al.,  2000). 
Other  treatment  strategies  like  bowel  irrigation,  or  use  of  ion  exchange  resins  were 
reported  in  some  studies.  In  spite  of  some  promising  results,  these  studies  were  either 
performed  on  a  small  scale  lacking  placebo  controls  or  antibiotics  were  still  required  to 
achieve  success  (Mogg  et  al.,  1982;  Persky  &  Brandt,  2000). 
1.5.2  Immunotherapy 
Alternative  strategies  to  antibiotic  treatments  are  required  to  reduce  the  increasing 
incidence  of  C.  difflicile  infection.  Active  vaccination  against  Toxins  A  and  B  has  been 
used  successfully  to  protect  animals  against  C  difficile  disease.  However,  vaccines 
appropriate  for  use  in  human  patients  are  still  under  development.  One  study  has  assessed 
the  safety  and  immunogenicity  of  Toxoids  A  and  B  vaccines  in  humans  (Kotloff  et  al., 
2001).  This  study  has  found  that  the  two  toxoids  were  tolerated  without  serious  side Chapter  1,  General  introduction 
effects.  Minimal  local  or  systemic  reactions  were  observed.  Antibody  responses  to  the 
different  doses  of  the  toxins  were  strong  in  more  than  90  %  (serum  IgG)  and  50  %  (fecal 
IgA)  of  subjects  respectively.  However,  the  importance  of  IgG  and  IgA  against  Toxins  A 
and  B  in  human  infection  remains  incompletely  defined.  Stubbe  and  his  group  have 
demonstrated  that  dimeric  IgA  is  more  effective  against  Toxin  A  than  either  monomeric 
IgA  or  IgG  immunoglobulins  that  share  the  same  variable  domain.  The  authors  proposed 
that  the  neutralization  efficacy  of  dimeric  IgA  and  its  extended  duration  of  protection  are 
due  to  the  degree  of  polymerization  (avidity)  and  not  to  the  peristaltic  movement  of 
dimeric  IgA  as  tested  in  the  absence  of  mucus  (Stubbe  et  al.,  2000).  Salcedo  et  al.  have 
reported  the  use  of  human  Igs  pooled  from  healthy  individuals  for  therapy  against  C. 
difflicile.  The  immunoglobulin  therapy  was  administered  intravenously  to  patients  suffering 
from  severe  pseudomembranous  colitis  that  was  unresponsive  to  antibiotic  treatments. 
Despite  the  success  in  controlling  the  disease,  diarrhea  recurred  four  weeks  after  infusion 
of  immunoglobulins.  This  study  suggested  that  passive  immunotherapy  using 
immunoglobulins  from  normal  donors  accompanied  by  antibiotic  therapy  can  speed  up 
recovery  and  may  prevent  recurrence  (Salcedo  et  al.,  1997).  Kyne  and  co-workers,  also 
reported  a  successful  trial  in  which  chronic  recurrent  C.  difficile  colitis  was  treated  with 
pooled  immunoglobulins  (Kyne  et  al.,  2001).  Immunotherapy  has  been  suggested  as  a 
routine  treatment  for  recurrent  CDAD  where  antibiotics  including  vancomycin  have  failed 
(Murphy  et  al.,  2006).  However,  the  lack  of  a  supply  of  immunoglobulin  against  the  toxin 
for  therapeutic  use  and  the  cost  of  the  treatment  imposes  a  limitation  to  the  wider  use  in 
CDAD  (Wilcox,  2004). 
Studies  on  animals  have  shown  that  the  protective  effect  is  correlated  to  in  vitro 
neutralization  of  the  toxins  and  not  to  the  quantitative  level  of  antibodies  as  measured  by 
ELISA.  Moreover,  active  immunization  with  Toxoids  A  and  B  may  not  be  an  ideal 
prophylactic  or  therapeutic  treatment  for  hospitalized  patients  and  individuals  at  high  risk 
because  the  immune  response  requires  time  to  develop  (Corrado  et  al.,  1990).  The  risk  of 
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adverse  immune  interactions  and  inflammation  are  relevant  considerations.  Under  these 
circumstances,  passive  immunization  might  be  a  more  suitable  therapeutic  choice. 
Animal  studies  have  evaluated  these  ideas.  Few  have  devised  effective 
immunotherapy  for  MAD  after  the  onset  of  the  disease  (Kink  &  Williams,  1998).  Instead, 
considerable  effort  has  been  invested  in  the  study  of  active  immunization  (Corthier  et  al., 
1991;  Kim  et  al.,  1987;  Libby  et  al.,  1982;  Lyerly  et  al.,  1991).  In  one  study,  hamsters 
were  immunized  with  toxoids  inactivated  with  formaldehyde.  These  were  made  from 
Toxins  A  or/and  Toxin  B.  Although  immunization  stimulated  high  antibody  titers, 
vaccination  against  Toxin  A  or  Toxin  B  individually  failed  to  produce  antibodies  that  were 
protective  against  the  lethal  consequences  of  infection.  However,  the  study  was  able  to 
demonstrate  the  role  of  both  toxins  in  the  pathology  of  antibiotic-associated  cecitis  (AAC) 
(Libby  et  al.,  1982).  A  more  recent  study  by  Aboudola  et  al.  (Aboudola  et  al.,  2003)  has 
confirmed  this  finding  and  despite  the  high  level  of  antibody  titers,  these  antibodies  failed 
to  neutralize  the  toxin  when  tested  by  cytotoxicity  assay  in  vitro.  Other  groups  have 
reported  different  outcomes.  Fernie  et  al.  (Fernie  et  al.,  1983)  showed  that  80  %  protection 
could  be  achieved  when  Toxoid  A  and  B  were  used  together  to  vaccinate  hamsters. 
Interestingly,  Toxin  B  iminunization  gave  more  protection  than  Toxin  A  alone.  Kim  et  al. 
(Kim  et  al.,  1987)  suggested  that  more  studies  are  required  to  resolve  these  discrepancies. 
This  group  also  suggested  that  Toxin  B  might  have  less  importance  than  Toxin  A  in  the 
pathogenesis  of  ileocecitis  because  immunization  against  Toxin  A  was  required  in  order  to 
protect  hamsters  against  antibiotic-associated  intestinal  disease  caused  by  Clostridium 
difficile  (Kim  et  al.,  1987).  This  was  supported  by  later  studies  which  showed  that  the 
introduction  of  a  high  concentration  of  Toxin  B  alone  to  the  intestinal  loop  did  not  show 
damaging  effects.  This  conflicts  with  earlier  studies  suggesting  equal  roles  for  Toxins  A 
and  B  in  the  disease  in  hamsters  (Lyerly  et  al.,  1985).  When  both  Toxins  A  and  B  were 
introduced  together  to  the  intestinal  tract  in  low,  non-lethal  doses,  animals  developed  the 
disease  and  died.  Immunization  of  the  animals  against  Toxin  B  failed  to  protect  from 
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effects  of  Toxin  A  and  death  (Kim  et  al.,  1987).  This  suggests  a  synergistic  effect  in  which 
Toxin  B  appears  to  be  dependent  upon  Toxin  A,  but  more  aggressive  in  its  action. 
Kink  and  Williams  (Kink  &  Williams,  1998)  have  studied  the  impact  of  antibodies 
against  Toxins  A  and  B  upon  disease  in  hamsters.  Antibodies  were  raised  in  chickens 
against  epitopes  of  Toxin  A  and  Toxin  B  located  in  the  carboxy-termini  of  each  protein. 
Anti-Toxin  A  provided  efficient  protection  against  disease  when  delivered  before  infection 
with  C.  difficile,  but  protection  against  diarrhea,  weight  loss  and  death  was  only  partial  if 
applied  after  infection.  This  is  consistent  with  a  previous  report  (Kim  et  al.,  1987).  When 
antibodies  against  Toxin  A  and  B  were  combined,  protection  against  infection  was  solid 
and  exceeded  that  of  vancomycin  treatment.  Significantly,  it  protected  against  on-going  C. 
difficile  disease. 
One  study  (Lyerly  et  al.,  1991)  has  evaluated  passive  immunization  of  hamsters 
using  bovine  antibodies  against  C  difficile  toxoids.  Regardless  of  the  failure  of  antibodies 
to  treat  the  MAD  after  the  onset  of  the  disease,  the  authors  were  able  to  show  protection 
against  disease,  raising  the  prospect  of  a  novel,  high  volume  source  for  persons  at  high  risk 
of  C  difficile  infection.  Bovine  colostrum  has  particularly  high  concentrations  of  IgG 
whereas  in  human  colostrum,  IgA  is  the  main  class.  Kelly  et  al.  prepared  bovine 
immunoglobulin  concentrate  against  C  difficile  from  the  colostral  milk  of  Holstein  cows 
by  immunizing  them  with  the  toxoids  of  the  pathogen.  The  outcome  was  a  specific  IgG 
directed  against  C  difficile  Toxin  A  and  B  which  was  able  to  neutralize  the  action  of  both 
toxins  actions  when  tested  in  vitro  and  in  animal  models.  The  authors  proposed  the  use  of 
bovine  immunoglobulin  concentrate  as  an  oral  treatment  for  MAD  and  colitis.  it  was 
expected  that  loss  of  antitoxin  activity  due  to  the  acidic  gastric  secretions  might  take  place. 
Therefore,  the  anti-toxin  was  combined  with  an  anti-acid  and  administered  to  human 
volunteers.  This  showed  the  IgG  survived  passage  through  the  full  length  of  the  intestine 
(Kelly  et  al.,  1996;  Kelly  et  al.,  1997;  Warny  et  al.,  1999).  Aside  from  its  safety,  antitoxin 
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has  the  advantage  of  not  interacting  with  the  normal  flora  in  the  colon.  This  should  assist 
re-establishment  and  normalization  of  the  normal  flora  which  may  also  help  protect  against 
subsequent  relapses. 
The  use  of  murine  monoclonal  antibodies  against  Toxin  A  in  passive  protection  has 
been  examined  by  Corthier  et  al.  The  study  investigated  if  MAbs  that  neutralize  the  toxic 
activity  of  Toxin  A  can  protect  mice  by  passive  transfer.  Three  monoclonal  antibodies 
were  selected  according  to  their  ability  to  recognize  the  repeating  units  of  the  C-  tenninus 
of  Toxin  A.  Each  of  the  selected  MAbs  protected  against  C  difficile  disease  when  injected 
intravenously  to  the  mice  (Corthier  et  al.,  1991).  In  human  vaccination  with  MAbs, 
however,  a  second  MAb  against  Toxin  B  might  be  required  as  Toxin  A  and  Toxin  B  do  not 
share  neutralizing  epitopes.  A  further  issue  of  potential  importance  is  the  existence  of  C 
difficile  strans  of  different  toxinotypes  of  Toxin  A,  as  discussed  below  (Giannasca  & 
Wamy,  2004). 
One  distinctive  study  (Sauerborn  et  al.,  1997)  proposed  the  use  of  recombinant 
fragments  from  the  repetitive  receptor-binding  domain  of  Toxin  A  as  passive  or/and  active 
vaccine  depending  on  the  route  of  introduction.  The  recombinant  fragment  recognized  the 
toxin  receptor  on  epithelial  cells  and  thereby  blocked  the  action  of  Toxin  A.  The 
recombinant  fragment  can  also  act  as  an  immunogen  triggering  an  immune  response.  The 
efficacy  of  the  recombinant  fragment  to  protect  against  Toxin  A  was  evaluated  and  it  was 
able  to  protect  against  the  toxicity  of  Toxin  A  in  vitro  and  in  vivo. 
1.6  Toxinotypes  and  strains  of  importance 
Most  of  the  work  done  on  Toxin  A  and  Toxin  B  has  been  based  on  one  strain,  VPI 
10463,  which  may  represent  around  20  %  of  clinical  isolates.  However,  there  are  22 
different  serogroups  of  C  difficile  that  can  be  further  classified  based  on  restriction  length 
polymorphisms  (RFLPs)  in  the  toxin  genes.  To  establish  this  diversity,  parts  of  the  toxin Chapter  1,  General  introduction 
genes  were  amplified  and  digested  with  selected  restriction  enzymes.  Although  the 
heterogeneity  of  Toxin  A,  as  observed  by  RFLP  analysis,  is  much  less  than  Toxin  B, 
deletions  were  observed  in  Toxin  A.  It  was  also  noticed  that  genetic  variants  of  Toxin  A 
were  seen  in  clinical  isolates  which  may  include  hybrids  that  resulted  from  genetic 
exchange  between  different  Clostridia  strains. 
Different  serogroups  were  then  subdivided  into  10  toxinotypes  based  on  subtle 
difference  variations  in  the  genes  of  the  pathogenicity  locus.  Each  toxinotype  was 
designated  with  Roman  numbers  I  to  X  where  strain  VPI  10463  was  considered  as 
toxinotype  0  (Table  1.1  and  1.2).  No  striking  pathological  differences  were  seen  between 
variant  strains  and  the  classical  C.  difficile  (Table  1.2).  It  has  been  speculated  that 
molecular  typing  might  be  a  useful  tool  not  only  in  establishing  toxinotypes  and  variants 
among  the  C.  difficile  toxins,  but  also  in  diagnosis  and  prediction  of  the  degree  of 
virulence  of  clinical  isolates  (Rupnik  et  al.,  1998). 
Amongst  the  C  difficile  strains  that  have  been  identified,  some  are  more  important 
than  others  because  of  their  epidemic  or  virulence  properties.  For  example,  027  strain 
isolated  in  Canada  has  been  associated  with  a  number  of  very  important  outbreaks  and 
seems  to  create  greater  severity  of  illness  than  the  classical  C  difflicile  strains.  It  has  been 
reported  that  some  of  the  027  isolates  produced  20  times  the  level  of  Toxin  A  and  B  than 
other  C.  difficile  strains,  a  property  that  has  obvious  implications  for  patient  health  and  the 
costs  of  treatment  (Eggertson,  2005). Chapter  1,  General  introduction 
Table  1.1:  RFLP  characteristics  used  for  typing  of  toxin  genes 
Hincll  and  HindIll  and  EcoRl  NsA 
Toxino- 
Accl 
restriction 
Rsal 
restriction  restriction  restriction  Standard 
No.  of 
type  pattern  for  pattern  for  pattern  for  pattern  for 
strain 
strains 
f  nd  Bl  B3  A3  PL2  ou 
fragment'  fragment  f  ragment  f  ragment 
0  1  1  1  1  VPl  172 
10463 
1  1  1  4d  EX  623  2 
1  1  3d  1  AC  008  1 
4  4  2  2  44027  6 
IV  2  2  _  2  3i  55767  4 
v  3  3  8  4i  SE  881  1 
vi  3  3  5d  4i  51377  4 
Vil  3  3  6d  4i  57267  1 
Vill  5  1  7d  3i  1470  25 
Ix  5  4  2  4i  51680  2 
x  15  4  NA  4i  r  8864 
'  Restriction  patterns  were  analysed  and  a  number  given  to  each  profile.  NA,  not  amplified;  d,  deletion;  1, 
insertion. 
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Table  1-2:  C.  difficile  strains  with  variant  toxin  genes 
Strain 
I 
Toxino- 
type 
PFGE 
type 
Serogroup  tcdB  tcdA  Date  of 
Isolation 
(day.  mo.  yr 
Patient 
birth 
date  (yr) 
Diagnosis 
38544  T-  -FT=  c  +,  1.7.1991  1944  PMC 
EX 
623 
8  c  + 
1 
+  19.11.1990  Unknown  AAD 
AC 
008 
9  A14  +  +  7.4.1994  Unknown  AAD 
SE 
844 
111  2  Al  +  +  10.4.1995  1966  AAD 
SE 
847 
111  2  Al  + 
1 
+  10.4.1995  1959  AAD 
EX 
482 
111  2  Al  +  +  2.1.1990  1920  AAD 
45129  111  2  Al  +  +  7.9.1992  1939  AAD 
35004  111  2  Al  +  +  16.11.1989  1932  PMC 
44027  111  NY  Al  +  +  15.6.1992  1939  PMC 
55538  IV  5a  Al  +  +  12.5.1995  1991  AAD 
55767  IV  5b  Al  +  +  12.6.1995  1944  AAD 
_40067 
IV  5b  Al  +  +  14.10.1991  1990  AAD 
7701  IV  6  A5  +  +  23.7.1985  Unknown  AAD 
SE 
881 
V  10  A15  +  + 
1 
30.8.1995  1951  AAD 
_48489 
VI  3  A15  +  +  9.4.1993  1931  Pmc 
51377  VI  4  A15  +  +  11.2.1994  1926  PMC 
BR 
071 
Vi  3  A15  +  +  3.7.1995  Unknown  AAD 
_39696 
VI  4  E6  +  +  19.9.1991  1980  AAD 
57267  Vil  4  E6  +  +  21.12.1995  1946  AAD 
1470  Vill  7a  IF  +  -  2.12.1981  1981  Asvmi)tomatic 
20376  Vill  7b  X  +  -  8.7.1988  1986  Asymptornatic 
_51680 
Ix  11a  A16  +  +  17.3.1994  1933  AAD 
SE 
_938 
ix  11b  A16 
I 
+ 
I 
+  5.1.1996 
I 
1931 
I 
AAD 
I 
L8864  X  12  1  Unknown  I+  I  Unknown  I  Unknown  I  Unknown 
'  Brusselsl,  Brussels2,  etc.,  represent  different  units  or  different  hospitals  in  Brussels.  b  NT,  nontypeable. 
ND,  not  done.  AAD,  antibiotic  associated  disease.  PMC,  pseudomembranous  colitis. 
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1.7  Antibodies  ani  CDR  onformation. 
In  response  to  materials  that  are  foreign  to  the  mammalian  immune  system,  B- 
lymphocytes  produce  proteins  which  can  recognize  and  bind  to  these  immunogens-  These 
proteins  are  known  as  antibodies.  When  antibodies  are  electrophoresed,  their  structure  and 
molecular  weight  confers  a  migration  pattern  that  is  similar  to  the  globulins,  hence  their 
designation  as  immunoglobulins.  Immunoglobulins  have  a  common  basic  structure  but 
they  can  interact  with  different  antigens  due  to  the  differences  in  sequence  in  regions 
I  known  as  the  variable  or  complementarity  determining  regions  (CDRs).  The  huge  range  of 
CDR  variability  allows  binding  to  a  very  wide  range  of  dissimilar  protein  antigens  and 
non-peptide  structures  like  phospholipids,  sugar  moieties  or  even  metals  (Amoroso  et  al., 
2003;  Bosslet  et  al.,  1991;  Cabrera  et  al.,  2006). 
The  natural  response  to  an  antigen  is  polyclonal  as  different  features  of  the 
immunogen  provoke  the  synthesis  of  individual,  specific  antibodies.  During  the  last 
century,  a  major  advance  in  the  development  of  antibodies  was  the  development  of 
techniques  for  production  of  monoclonal  antibodies.  Originally  developed  by  Kohler  and 
Milstein  (Kohler  &  Milstein,  1975),  monoclonal  technology  allows  the  production  of 
antibodies  against  just  one  feature  (epitope)  of  an  antigenic  compound.  Due  to  their 
specificity,  sensitivity  and  the  continuous  supply,  monoclonal  antibodies  have  become 
used  increasingly  as  tools  for  therapy  and  diagnosis  by  many  researchers.  Monoclonal 
antibody  therapy  is  being  use  to  treat  variety  of  disease  including  cancers  (Cheson,  2006; 
Furman  et  al.,  2006;  Zhong  et  al.,  2006),  pathogens  (Casadevall,  1998;  Zeitlin  et  al.,  1998) 
and  autoimmune  diseases  (Amoura  &  Piette,  2006). 
It  was  not  until  1950  that  the  structure  of  antibodies  became  clear  and  the 
contributions  of  the  heavy  and  light  chains  to  the  Fab  and  Fc  regions  of  the  molecule  were 
understood  through  X-ray  crystallography  (Deisenhofer  et  al.,  1976;  Poliak  et  al.,  1973).  It 
was  from  these  studies  that  the  idea  of  T-shaped  structure  arose  with  each  Fab  component 
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independent  in  its  orientation  with  respect  to  the  Fc  region.  This  is  of  importance  because  it 
means  that  antibody  can  recognize  epitopes  on  a  single  or  two  different  separate  antigen 
molecules  (Harris  et  al.,  1992).  Antibodies  display  a  structure  known  as  the 
immunoglobulin  fold  that  consists  of  two  antiparallel  P-sheets  packed  to  form  a  P-sheet 
'sandwich',  the  two  halves  of  the  sandwich  being  held  together  by  a  disulfide  bond. 
Functionally,  two  regions  of  importance  can  be  defined  in  the  antibody.  The  first  contains 
the  CDRs  which  are  formed  by  the  variable  domains  of  light  and  heavy  chains  (VL  and 
VH).  The  second  are  the  constant  domains.  The  antigen  binding  domain  is  formed  when  six 
CDR  loops  (H1,  H2  and  H3  from  heavy  chain,  and  L1,  L2  and  L3  from  light  chain)  are 
arranged  in  juxtaposition.  Four  of  the  loops  are  encoded  in  the  VL  and  VH  germline 
segments  and  the  other  two  are  formed  at  the  junctions  of  the  J  segment  for  light  chain  and 
V,  D  and  J  for  heavy  chain.  The  segments  fuse  during  the  process  of  genomic 
rearrangment  and  somatic  mutation  during  B-cell  maturation  (Wu  &  Kabat,  1970). 
1.8  Engineered  antibodies 
Molecular  biology  has  made  possible  the  modification  and  manipulation  of 
naturally  existing  proteins  including  antibodies.  This  has  lead  to  the  development  of 
antibody  engineering  techniques.  With  proper  primer  design,  it  is  possible  to  generate 
cDNA  from  mRNA  isolated  from  spleen,  lymph  cells  or  hybridomas  (Maynard  & 
Georgiou,  2000).  Since  these  cells  will  express  a  whole  repertoire  of  transcripts,  PCR  is 
used  to  recover  immunoglobulin-coding  cDNAs.  The  VH  and  VL  can  be  fused  and 
expressed  as  single  chain  variable  fragments  (scFv)  or  the  light  and  heavy  chains  can  be 
expressed  separately,  allowing  natural  non-covalent  association  into  a  Fab  fragment. 
Although  the  scFv  is  a  synthetic  form  of  antibody,  fusion  through  the  linker  sequence 
prevents  the  dissociation  Of  VH  and  VL  domains  (Winter  et  al.,  1994).  These  forms  of 
antibodies  are  illustrated  in  Figure  1.2. Chapter  1,  General  introduction 
In  addition  to  scFvs,  other  recombinant  forms  of  antibodies  like  chimeric  and 
humanized  antibodies  can  also  be  generated.  One  aim  of  these  manipulations  is  to  reduce 
the  response  of  human  immune  system  when  recombinant  antibodies  are  introduced  into 
patients.  The  other  aim  is  to  combine  the  characteristics  of  one  antibody  such  as  its 
specificity  or  sensitivity  with  the  characteristics  of  another  (for  example  efficiency  of 
complement  fixation)(Sandhu,  1992;  Weiner,  2006).  In  recent  years,  fusion  techniques 
have  also  been  used  to  join  the  Fc  domain  of  antibodies  with  non-immunoglobulin 
peptides.  In  this  case,  the  variable  region  of  the  Ig  molecule  is  replaced  with  a  non- 
immunoglobulin  structure  that  confers  binding  specificity  upon  the  recombinant  protein. 
These  molecules  are  known  as  'immunoligands'  (Capon  et  al.,  1989;  Landolfi,  1991; 
Traunecker  et  al.,  1989). 
1.8.1  Humanization  of  antibodies 
Laboratory  aminals  such  as  mice  have  been  very  valuable  in  modeling  human 
disease  and  in  developing  methods  for  the  manipulation  of  the  immune  response.  The 
original  development  of  monoclonal  antibody  technology  was  founded  upon  isolation  of 
B-lymphocytes  from  n-fte  and  their  manipulation  in  vitro.  However,  mouse  monoclonal 
antibodies  can  not  be  used  directly  for  human  therapy  as  the  proteins  are  quickly 
recognised  as  foreign,  provoking  a  human  anti-mouse  response.  Investigators  have  sought 
ways  to  modify  mouse  antibodies  to  overcome  this  problem. 
1.8.1.1  Chimeric  antibodies 
In  these  forms  of  recombinant  antibodies,  the  variable  genes  of  a  mouse  antibody 
replace  the  equivalent  human  sequences  to  produce  a  complete  immunoglobulin.  The 
antibody  will  possess  the  specificity  and  avidity  characteristics  of  the  mouse 
immunoglobulin  while  two  thirds  of  the  antibody  is  of  human  origin  to  reduce  the 
immunogenicity  when  introduced  into  the  human  immune  system.  These  constructs  are Chapter  1,  General  introduction 
illustrated  in  Figure  1.2.  Studies  have  shown  that  immune  adverse  responses  against 
chimeric  antibodies  occur  rarely  and  some  chimeric  antibodies  have  been  further 
developed  as  therapeutics  (Brekke  &  Sandlie,  2003;  Maynard  &  Georgiou,  2000;  van  Dijk 
&  van  de  Winkel,  2001). 
1.8.1.2  CDR-  grafted  antibodies 
The  other  route  for  creation  of  human-like  antibodies  from  murine  origins  is  the 
grafting  of  CDRs  from  the  variable  domains  of  rodent  antibodies  onto  human  variable 
domains  (Jones  et  al.,  1986).  This  is  shown  in  Figure  1.2.  After  manipulation,  around  90 
of  the  recombinant  antibody  is  human  in  sequence.  However,  this  does  not  completely 
eliminate  the  risk  of  human  anti-mouse  responses.  One  challenging  issue  in  CDR  grafting 
is  that  the  affinity  of  the  protein  might  not  be  as  high  as  the  original  mouse  antibody.  For 
this  reason,  it  is  critical  to  use  a  human  antibody  framework  with  high  sequence  homology 
to  the  original  murine  immunoglobulin  to  minimize  the  loss  of  affinity  from  sub-optimal 
conformation  in  the  CDRs  (Shearman  et  al.,  1991). 
1.8.1.3  Transgenic  Antibodies 
One  recent  innovation  for  production  of  human  antibodies  is  to  use  mice  that  have 
an  impaired  or  inactivated  immunoglobulin  response  but  carry  in  their  genome,  repertoires 
of  human  heavy  and  light  chains.  These  transgenic  mice  can  be  immunized  with  any  target 
and  the  resulting  antibody  response  can  be  captured  and  immortalized  by  creating 
hybridomas  that  produce  complete  functional  human  monoclonal  antibodies  (Fishwild  et 
al.,  1996;  Neuberger,  1996).  An  illustration  of  this  approach  has  been  described  recently 
(Tomizuka  et  al.,  2000).  Human  chromosomal  fragments  containing  the  immunoglobulin 
heavy  chain  and  k  light  chain  loci  were  introduced  to  a  mouse  after  inactivation  of  the 
endogenous  humoral  response.  Several  human  antibodies  generated  from  transgenic  mice 
are  currently  in  clinical  trials  (van  Dijk  &  van  de  Winkel,  2001).  One  further  strategy Chapter  1,  General  introduction 
described  the  Trimera'  mouse  (Reisner  &  Dagan,  1998).  The  animal's  immune  system  is 
disabled  by  exposure  to  radiation.  Then  bone  marrow  from  an  SCID  mouse  is  transplanted 
to  generate  a  partially  reconstrituted  immune  system  that  can  accept  foreign  cells  or 
tissues.  The  B  cell  from  a  human  source  is  then  engrafted  and  monoclonal  antibodies  are 
produced.  Antibodies  against  Hepatitis  B  produced  in  the  Trimera  mouse  are  currently 
under  clinical  trials  (Dagan  &  Eren,  2003). 
1.9  Recombinant  Antibodies  and  phage  display 
Since  1985,  when  phage  display  was  first  suggested  by  Smith  (Smith,  1985), 
recombinant  antibody  technology  has  witnessed  significant  developments  reflected  by  the 
production  of  highly  specific  antibodies  that  can  be  employed  in  diagnostics,  therapeutics, 
and  research.  In  comparison  with  the  traditional  methods  of  creating  polyclonal  antibodies 
or  even  monoclonal  antibodies,  phage  display  technology  is  considered  cheap,  fast,  and  is 
(Ij- 
not  labor  intensive.  Furthermore,  phage  display  technology  does  not  require  large  numbers 
A 
of  animals,  indeed  in  several  applications,  animals  can  be  completely  eliminated  from  the 
production  of  specific  antibodies  (Deng  et  al.,  2003).  Antibody  phage  display  can  be 
divided  into  several  distinct  phases.  Firstly,  libraries  of  antibody-coding  sequences  are 
generated.  These  genes  can  be  taken  from  immunized,  non-immunized  (ndve) 
lymphocytes  (Amersdorfer  et  al.,  2002)  or  even  synthetic  constructs  (Rauchenberger  et  al., 
2003).  These  coding  sequences  are  cloned  to  create  recombinant  antibodies  that  can  take 
different  forms  such  as  scFvs,  Fabs  or  Fvs  (McCafferty  et  al.,  1990).  These  are  illustrated 
in  Figure  1.2.  The  recombinant  antibodies  are  displayed  at  the  surface  of  viral  particles  that 
also  carry  the  coding  sequence  for  the  recombinant  antibody.  The  phage  display  library  is 
then  screened  for  the  ability  to  bind  to  a  target  antigen  through  the  specificity  of  the 
displayed  antibody.  By-passing  the  mammalian  immune  system  in  this  way  (Hoogenboom, 
1997;  Schier  et  al.,  1996)  means  that  antibodies  can  be  isolated  against  polypeptides  that 
may  be  poorly  immunogenic  in  vivo,  substances  like  fatty  acids  (Gargir  et  al.,  2002),  self- 
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antigens  (Rauchenberger  et  al.,  2003;  van  Kuppevelt  et  al.,  1998)  or  toxic  materials  (Deng 
et  al.,  2003).  The  specificity  of  the  isolated  antibodies  can  be  confirmed  with  immunoassay 
methods  based  upon  the  production  of  further  stocks  of  virus,  or  by  expression  and 
analysis  of  the  recombinant  antibody  as  separate,  soluble  proteins.  If  its  affinity  or 
specificity  is  sub-optimal,  maturation  or  other  modifications  are  possible,  in  vitro.  Finally, 
the  antibody  can  be  expressed  in  prokaryotic  or  eukaryotic  systems  for  more  detailed 
analysis,  or  downstream  applications.  In  the  following  sections,  individual  steps  of  this 
process  are  described  in  more  detail. 
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Figure  1.2:  The  various  formats  of  engineered  antibodies 
IgG  is  composed  of  two  identical  heavy  chains  (VH+CH1+CH2+CH3)  and  two 
identical  light  chains  (VL+VH).  Both  chains  are  organized  in  domains  containing 
about  110  amino  acids  with  each  domain  possessing  an  intra-disulf  ide  bond.  Inter- 
disulfide  bonds  link  the  light  chain  to  the  heavy  chain  and  the  two  heavy  chains. 
The  variable  domains  (VL  and  VH)  contain  the  complementary  determining  regions 
(CDRs)  which  bind  to  the  antigen.  The  Fv  fragment  VL  and  VH  domains  possess 
the  binding  activity.  The  scFv  corresponds  to  the  VH  linked  to  VL  by  a  flexible 
peptide  linker.  Dia-,  tri-  and  tetrabodies  can  be  obtained  by  using  short  linkers.  The 
figure  has  been  taken  from  the  work  of  (Maynard  &  Georgiou,  2000). 
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1.9.1  Creation  of  antibody  libraries 
In  antibody  phage  display,  libraries  of  functional  antibodies  are  displayed  at  the 
viral  surface  as  a  result  of  cloning  of  large  numbers  of  immunoglobulin  sequences  into  a 
display  vector.  Antibody  genes  can  be  recovered  from  different  species  (e.  g.  human,  pig) 
and  the  variability  of  the  sequences  within  the  library  depends  upon  the  immunological 
background  of  the  donor  and  the  starting  material.  The  terms  immune,  nave  and  synthetic 
libraries  describe  this  background. 
1.9.1.1  Immune  libraries 
This  kind  of  library  capitalises  upon  the  ability  of  the  immune  system  to  respond  to 
infection,  vaccination  or  immunization  and  to  develop  an  anti  gen-specific  repertoire 
(Clackson  et  al.,  1991).  The  source  of  the  starting  material  can  be  human  or  animal  B-cells 
from  subjects  immunized  against  the  target  antigen  (Barbas  et  al.,  1993;  Cai  &  Garen, 
1995).  Therefore,  the  diversity  of  this  kind  of  library  may  be  high,  but  it  will  be  biased  in 
favour  of  the  immunizing  antigen.  To  construct  the  library,  PCR  is  employed  to  amplify 
immunoglobulin  sequences  from  cDNA  prepared  from  lymphoid  cells  or  tissue  (WeIschof 
et  al.,  1995).  Since  the  immune  system  has  already  encountered  the  target  antigen,  the  size 
of  the  library  may  not  need  to  be  large  in  order  to  extract  antibodies  against  the  material  of 
interest.  One  obvious  advantage  of  this  library  is  that  the  antibody  repertoire  is  rich  with 
antigen  specific  antibodies  which  are  of  high  affinity  (Clackson  et  al.,  1991).  However, 
since  this  kind  of  library  is  prepared  from  a  natural  source,  it  is  likely  that  it  will  lack  the 
ability  to  produce  antibodies  against  self  antigens 
1.9.1.2  Non-immune  libraries 
This  library  is  also  known  as  a  naYve  library.  The  same  source  of  starting  material  is 
used  for  cDNA  isolation  as  the  previously  discussed  library  but  the  B-cells  do  come  not 
from  an  immunized  donor.  B-cells  may  be  pre-selected  for  expression  of  IgM  reflecting 
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their  naYve  status.  This  means  that  antibodies  against  wider  collection  of  antigens  can  be 
isolated  including  self  antigens  (Marks  et  al.,  1991)  or  toxins  (Cardoso  et  al.,  2000; 
McElhiney  et  al.,  2002).  The  B-cell  that  is  nonnally  selected  is  the  B-cell  that  expresses 
IgM  or  IgD  (Glockshuber  et  al.,  1990;  Philippa  M.  O'Brien,  2002)  on  its  surface  which 
indicates  that  this  cell  has  not  been  activated.  The  VH  and  VL  genes  can  be  amplified  from 
cDNA  using  PCR  and  randomly  combined  to  form  the  library.  When  the  affinity  of  the 
antibodies  isolated  from  this  kind  of  library  is  compared  to  those  isolated  from  immune 
libraries,  they  may  appear  to  be  of  lower  affinity.  To  overcome  this  problem,  larger 
libraries  are  created  to  increase  the  chance  of  isolating  high  affinity  antibodies  (Griffiths  et 
al.,  1993;  Marks  et  al.,  1991;  Perelson,  1989). 
1.9.1.3  Synthetic  libraries 
Synthetic  and  non-immune  libraries  are  known  as  "single  pot  libraries"  because 
antibodies  against  any  given  antigen  can  be  isolated  if  the  libraries  are  big  enough  (Nissim 
et  al.,  1994).  In  synthetic  libraries,  investigators  attempt  to  mimic  the  immune  system  by 
generating  diversity  after  the  rearrangement  of  V,  D,  and  J  segments  (Winter,  1998).  In  the 
course  of  a  natural  immune  respose,  somatic  mutations  add  more  diversity  to  the  CDRs 
(Rajewsky,  1996);  in  a  synthetic  library  these  regions  of  the  antibody  seqauences  are 
diversified  through  molecular  biology,  in  vitro. 
This  library  concept  was  first  applied  by  Hoogenboom  (Hoogenboom  &  Winter, 
1992)  and  Barbas  (Barbas  et  al.,  1992)  in  studies  where  synthetic  diversity  was  created  in 
the  CDRs  especially  CDR3  and  bordering  framework  regions.  This  process  allowed 
control  of  the  location  and  the  extent  of  diversity  (e.  g.  the  central  loop  CDR3  where  the 
most  diversity  is  found  naturally  (Barbas  et  al.,  1992).  In  another  synthetic  library 
(Griffiths  et  al.,  1994)  greater  control  was  applied  to  the  choice  of  framework  sequences. 
Some  scaffolds  may  be  better  suited  to  the  integration  of  random  sequences  in  the  CDRs. 
In  these  kinds  of  libraries,  problems  linked  to  the  expression  of  recombinant  antibodies  in 
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bacterial  systems  were  also  avoided  (Knappik  et  al.,  2000)  by  choosing  antibody  sequences 
known  to  be  successfully  expressed. 
One  innovative  advance  in  the  development  of  synthetic  libraries  was  the 
construction  of  the  Human  Combinatorial  Library  (HuCAL(D  GOLD).  In  this  library,  all 
six  CDRs  were  diversified  upon  master  frameworks  generated  from  consensus  sequences 
representing  each  of  the  Kabat  V-gene  subclasses.  This  library  has  a  high  percentage  of 
functional  antibody  genes  and  contained  more  than  1010  clones.  Further,  the  framework 
sequences  used  were  very  close  to  human  germline  sequences,  raising  the  potential  use  of 
these  antibodies  in  human  therapy  (Hoogenboom,  1997).  Antibodies  in  this  library  are  not 
displayed  in  the  classical  way  through  phage  display.  Usually,  proteins  are  genetically 
fused  to  the  phage  surface  proteins  (see  below).  Instead,  antibodies  in  the  HuCal  library 
were  bound  to  phage  by  disulfide  bond  offering  a  convenient  option  for  phage  elution 
(http:  //www.  morphgsya..  com). 
1.9.2  Formats  for  antibodies  in  phage  display 
Antibodies  can  be  of  different  forms  in  phage  display  i.  e.  scFv,  Fabs,  Fvs,  single  domain 
antibodies  (McCafferty  et  al.,  1990).  These  forms  are  illustrated  in  Figure  1.2.  Single 
domain  antibodies  have  achieved  popularity  in  commercial  ventures,  such  as  the  library 
developed  by  Domantis  (Holt  et  al.,  2003;  Stockwin  &  Holmes,  2003).  Fv  antibodies  have 
been  found  to  dissociate  into  VH  and  VL  components  at  low  proteins  concentrations  and 
under  physiological  conditions.  Recombinant  Fab  antibodies  represent  the  nearest 
equivalent  to  natural  immunoglobulins  and  have  been  very  widely  used  in  phage  display 
(Hoogenboom,  1997).  The  group  at  the  Scripps  Institute,  in  particular,  have  had  great 
success  in  creating  immune  libraries  of  Fab  antibodies  for  studies  of  infectious  diseases 
(Bowley  et  al.,  2007;  Skerra  &  Pluckthun,  1988;  Zhang  et  al.,  2006). Chapter  1,  General  introduction 
The  most  popular  format  for  recombinant  antibodies  used  in  phage  display  is  the  single 
chain  antibody,  scFv.  The  scFv  consists  of  cloned  heavy  VH  and  light  VL  chains,  the 
binding  domain,  bridged  by  a  peptide  linker  and  is  regarded  as  the  minimal  structural 
component  of  natural  antibody  required  for  antigen  binding  (Huston  et  al.,  1988;  Maynard 
&  Georgiou,  2000).  It  has  been  found  that  the  linker  does  not  obstruct  the  antigen  binding 
site  or  impair  domain  folding.  Also  it  was  found  that  these  small  structures  were  stable 
after  expression  and  were  able  to  bind  to  their  targets.  The  scFv  sequence  is  encoded  by 
one  reading  frame  (Sheets  et  al.,  1998).  After  the  cloning  Of  VH  and  VL  genes,  they  are 
used  to  build  immune,  naYve  or  synthetic  libraries.  The  fusion  of  the  antibody  sequence  to 
minor  coat  protein  of  a  virus  ensures  that  each  phage  in  the  library  will  carry  a  gene  for  an 
antibody  and  present  this  protein  on  its  surface.  Through  use  ofphagerniý  vectors,  the  viral 
particle  also  carries  the  gene  for  the  scFv.  Any  antibody  can  then  be  selected  based  on  its 
ý11  bility  to  bind  to  a  particular  antigen  (Vaughan  et  al.,  1996). 
Recombinant  antibodies  constructed  in  this  way  can  be  expressed  in  E.  coli  (Skerra 
&  Pluckthun,  1988)  although  there  are  some  reports  (Glockshuber  et  al.,  1990)  of  sub- 
optimal  secretion  of  functional  scFv.  High  levels  of  cytoplasmic  or  periplasmic  expression 
of  scFv  are  common  but  this  can  induce  aggregation  and  limits  the  purification  of  proteins 
which  might  need  further  renaturation  and  purification  steps.  Yeast,  plants,  and 
mammalian  cells  have  also  been  used  for  expression  (Davis  et  al.,  1991;  Dorai  et  al.,  1994; 
Makvandi-Nejad  et  al.,  2005;  Tavladoraki  et  al.,  1993)  have  all  been  used.  These 
eukaryotic  hosts  have  often  proved  valuable  for  high  level  antibody  expression.  For  library 
construction,  phage  display,  screening,  and  initial  characterization  of  recombginant 
antibodies,  E.  coli  remains  the  most  popular  host. 
1.10  Phage  display 
Displaying  antibody  molecules  on  the  surface  of  bacteriophage  particles 
(McCafferty  et  al.,  1990)  is  a  powerful  method  for  selecting  a  specific  antibody  from  a 
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mixed  antibody  pool  such  as  a  library.  Each  phage  particle  contains  the  genes  for  the 
displayed  antibody  and  hence  attachment  of  phage  to  a  target  molecule  through  a  specific 
antibody  interaction  recovers  the  coding  sequence  for  that  antibody  from  a  diverse  pool 
such  as  a  library.  This  technique  has  thus  been  used  to  isolate  antigen  specific  antibodies 
from  un-immunized  human  libraries  (Marks  et  al.,  1991)  and  from  immunized  mouse 
libraries  (Clackson  et  al.,  1991).  Antigen  specific  antibodies  were  also  selected  from  semi- 
synthetic  combinatorial  antibody  libraries  (Barbas  et  al.,  1992). 
The  bacteriophage  fd  is  most  frequently  involved  in  phage  display.  This  is  a 
filamentous  ssDNA  phage.  The  bacteriophage  binds  to  sex  pili  present  at  the  bacterial 
surface.  This  process  is  mediated  by  the  gIH  protein  of  the  virion  (Crissman  &  Smith, 
1984;  Glaser-Wuttke  et  al.,  1989).  Fusion  of  peptides  or  folded  proteins  to  the  N-terminus 
of  g3p  of  the  phage  (McCafferty  et  al.,  1990)  ensures  display  on  the  surface  of  phage 
which  then  makes  possible  isolation  by  successive  rounds  of  selection  and  enrichment 
(biopanning)  (Parmley  &  Smith,  1988). 
Antibodies  displayed  at  the  phage  surface  can  be  in  the  form  of  single  chain  Fv  fragments, 
Fab  fragments,  or  as  multivalent  bispecific  or  mono-specific  constructs  as  described  earlier 
(Holliger  et  al.,  1993;  Marks  et  al.,  1991;  McCafferty  et  al.,  1990).  Many  displayed 
proteins  including  antibody  fragments,  enzymes,  hormones  or  other  ligands  retain  their 
function  and  can  be  isolated  on  their  binding  specificity  or  catalytic  functions 
(Hoogenboom.  et  al.,  1993;  Kang  et  al.,  1991  a;  McCafferty  et  al.,  1991). 
For  the  construction  of  phage  libraries,  filamentous  phage,  phagemid  vectors  and 
excisable  lambda  phage  have  been  used  successfully  (Hogrefe  et  al.,  1993).  Phagemid 
vectors  are  superior  and  because  they  contain  the  filamentous  phage  origin  of  replication 
and  the  plasmid  origin  of  replication.  This  increases  the  efficiency  of  transformation  and 
the  ease  with  which  DNA  can  be  purified  and  characterized.  Many  phagemids  are  designed 
to  accept  DNA  inserts  such  as  scFv  coding  sequences  and  to  form  fusions  at  the  5' 
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terminus  of  the  gIH  reading  frame.  For  packing  of  the  phagemid  into  phage  particles, 
super-infection  with  a  helper  phage  is  required.  This  will  be  discussed  in  more  details  in 
following  paragraphs  (Hoogenboom  et  al.,  199  1). 
The  phagemid  pCANTAB-5  provides  a  useful  illustration  of  the  properties  of  these 
vecters.  SffflNod  sites  enable  protein  fusion  at  the  N-terminus  of  gHI.  The  translation 
products  are  directed  to  the  periplasm  by  the  synthetic  leader  sequence.  One  important 
development  illustrated  in  pCANTAB-5  is  the  presence  of  an  amber  codon  between  the 
insert  and  the  gIII  seqeuence.  This  allows  the  expression  of  the  fusion  protein  in  amber 
suppressing  strains  (e.  g.  E  coli  TGI)  or  the  antibody  alone  in  a  soluble  fonn  in  a  non- 
suppressing  E  coli  such  as  BB2151  (Beckmann  et  al.,  1998;  Harrison  et  al.,  1996;  Tang  et 
al.,  1995).  As  vectors  like  pCANTAB-5  do  not  carry  all  the  genes  required  for  assembly  of 
a  viral  particle,  transformed  bacteria  must  be  super-infected  with  a  helper  pahge  such  as 
M13KO7  helper  (Hoogenboorn  et  al.,  1991).  As  phage  progeny  are  extruded  from  the 
bacterial  host,  the  phagemid  is  packaged  into  the  virus  and  a  mixture  of  wild  type  and 
antibody-gIII  proteins  complete  assembly. 
One  further  development  in  pCANTAB-5  was  the  insertion  of  c-myc  and  histidine-tags. 
This  allows  detection  of  soluble  antibody  with  anti-c-myc  monoclonal  antibody.  His-tag 
can  be  used  for  purification  by  affinity  chromatography  (McCafferty  et  al.,  1994;  Munro  & 
Pelham,  1986). 
The  small  size,  stability  and  convienient  expression  of  scFv  have  encouraged 
widespread  Popularity  for  phage  display  (Glockshuber  et  al.,  1990).  Two  genetic 
arrangements  are  possible,  VH-linker-VL  or  VL-linker-VH.  The  first  orientation  is  the  most 
common.  If  the  linker  is  shortened,  VL-VH  constructs  can  be  useful  (George  et  al.,  1995), 
but  if  the  linker  length  is  reduced  too  far,  the  molecule  is  forced  to  dimerize  or 
multimerize.  Here,  the  VH  domain  of  one  scFv  is  forced  to  pair  with  VL  domain  of  a 
different  scFv  molecule.  This  finding  has  been  investigated  as  a  function  of  linker  length 
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(Desplancq  et  al.,  1994;  Whitlow  et  al.,  1994).  Since  several  sites  often  remain  functional 
in  such  oligomers,  some  avidity  effects  can  be  observed,  although  this  can  be  unpredictable 
and  dependent  on  the  primary  sequence  of  the  antibody  (Desplancq  et  al.,  1994;  Whitlow 
et  al.,  1994).  The  miniantibody  format  (Pack  et  al.,  1993;  Pack  et  al.,  1995)  may  be  a  more 
general  solution  to  this  problem.  While  these  molecules  have  minimal  oligornerization 
domains,  many  alternative  fusions  are  possible  that  lead  to  dimers  or  multimers.  This 
phenomenon  of  scFv  association  has  also  been  utilized  for  constructing  heterodimers, 
proteins  that  have  been  termed  diabodies  (Holliger  et  al.,  1993). 
The  diabody  concept  has  quite  a  long  history.  The  linkage  of  two  antibody  Fab 
fragments  through  disulphide  bonds  was  described  more  than  40  years  ago  (Nisonoff  & 
Mandy,  1962).  Bispecific  IgG  have  been  developed,  secreted  from  a  'hybrid-hybridoma'  or 
'quadroma'  when  two  antibody-producing  hybridoma  lines  are  fused  together  (Milstein  & 
Cuello,  1983).  IgG-heterodimers  are  equivalent  constructs  in  which  two  IgG  antibodies  are 
disulphide  bonded  together  using  a  lysyl-reactive  cross-linker  (Segal  et  al.,  1986).  The 
recent  form  of  diabodies  are  scFv-scFv  structures  (Figure  1.2).  The  antigen  binding  sites 
are  arranged  in  opposite  directions,  enabling  them  to  cross-link  two  cells  as  confirmed  by 
crystallography  (Perisic  et  al.,  1994).  These  molecules  were  first  introduced  for  enhanced 
killing  of  tumor  cells  in  which  one  binding  site  of  the  antibody  bound  to  a  tumor  cell 
antigen  while  the  other  binding  site  bound  cytotoxic  immune  effector  cells.  Diabodies  have 
also  been  labeled  with  chemotherapeutic  drugs  or  radioisotopes  through  binding  to  one  site 
of  the  diabody  while  the  other  site  bound  a  specific  cell  antigen  (Holliger  et  al.,  1996; 
Kikuchi  et  al.,  2005;  Maynard  &  Georgiou,  2000;  Schlenzka  et  al.,  2004).  As  these 
molecules  are  of  60  to  100  kDa,  they  have  faster  clearance  rates  when  compared  to  the 
complete  Ig  molecules  (Hudson  &  Kortt,  1999)  but  also  better  tissue  penetration.  Several 
antibodies  for  cancer  therapy  are  already  FDA  approved  (Farah  et  al.,  1998). 
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When  the  peptide  linker  length  between  VH  and  VL  is  decreased  to  two  residues  or 
less,  it  is  possible  to  force  the  molecule  to  form  triabodies  or  tetrabodies  (tandem 
diabodies)  which  increase  the  avidity  of  antibody.  One  study  has  reported  that  tandem 
antibodies  are  more  potent  than  the  diabody  for  inducing  T-cell-dependent  killing  of  tumor 
cells  which  reflects  the  potency  of  recognition  and  binding  (Kipriyanov  et  al.,  1999).  These 
multimers  may  be  monospecific  or  carry  multiple  specificities  (Hudson  &  Kortt,  1999). 
Among  the  large  and  small  antibody  molecules  that  can  be  expressed  using  phage 
display  technology,  scFv  antibody  has  the  advantage  because  of  its  distinctive 
physiological  properties.  scFv  has  a  low  retention  time  in  non-targeted  tissues,  has  rapid 
blood  clearance  and  better  tumor  penetration  (Nieroda  et  al.,  1995;  Yokota  et  al.,  1992). 
Moreover,  scFv  can  be  expressed  as  a  soluble  protein  with  correct  folding  in  the  bacterial 
periplasm  (Pugsley,  1993)  providing  a  better  chance  for  high  volume  expression 
(Kipriyanov  et  al.,  1997). 
One  study  has  reported  the  production  of  scFv  from  a  human  source  against 
pertussis  toxin.  The  patients  were  confirmed  as  seropositive.  The  starting  material  for  the 
library  was  peripheral  B  lymphocytes  from  patients  infected  with  B.  pertussis  and  showing 
an  antibody  immune  response.  This  study  successfully  produced  four  neutralizing  scFv 
antibodies  against  the  toxin.  The  author  suggested  that  such  antibodies  could  contribute  to 
the  treatment  of  pertussis  especially  in  neonates  who  have  high  mortality  and  morbidity 
due  to  increasing  antibiotic  resistance  (Williamson  &  Matthews,  1999). 
Another  study  has  reported  the  neutralization  of  BoNT/A  neurotoxin  of  C 
botulinum.  This  study  employed  oligoclonal  antibodies  consisting  of  three  scFvs  since 
individual  monoclonal  antibodies  failed  to  neutralize  the  toxin  in  vitro.  However,  when 
three  monoclonal  antibodies  were  used  together,  a  synergistic  effect  was  observed  and 
complete  neutralization  of  the  toxin  was  achieved  in  vitro.  Animals  treated  with  the  scFvs 
were  protected  when  challenged  with  high  levels  of  toxin  (Nowakowski  et  al.,  2002). 
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Deng  et.  al.  (Deng  et  al.,  2003)  have  successfully  combined  the  recombinant 
antibody  cloning  and  phage  display  technology  to  produce  scFv  against  C  difficile  Toxin 
B  for  diagnostic  purposes.  This  study  utilized  a  mouse  B-cell  hybridoma  line  producing 
monoclonal  antibodies  against  the  toxin.  RNA  was  isolated  from  the  cells  and  from  this, 
scFv  was  constructed.  The  recombinant  antibody  was  able  to  detect  Toxin  B  in  a  highly 
specific  manner.  The  author  suggested  that  this  study  will  serve  as  a  base  for  further 
investigations. 
1.10.1  Selection  of  Phage  antibody 
Selection  is  the  method  used  to  isolate  phage  clones  that  have  binding  properties 
for  a  target  from  those  which  can  not  interact  specifically.  Several  methods  can  be  used  for 
selection  but  the  most  common  involves  two  steps:  panning  and  screening.  In  panning, 
target  antigens  are  adsorbed  onto  plastic,  virus  are  added  and  those  phage  that  fail  to  bind 
are  removed  with  washing  (Clackson  et  al.,  1991;  Kang  et  al.,  1991b;  Marks  et  al.,  1992). 
Despite  its  simplicity,  there  are  some  disadvantages  of  this  method;  purified  antigens  are 
required  and  high  affinity  antibodies  are  difficult  to  rescue  because  of  the  avidity  effect.  In 
alternative  formats,  the  antigen  can  be  biotinylated,  phage  and  antigen  interact  in 
suspension  and  streptavidin-coated  magnetic  beads  are  used  for  selective  capture  of 
antigens  with  attached  virus  (Hawkins  et  al.,  1992).  Other  methods  include  bio-panning  on 
solid  supports,  columns  or  BIA-core  (e=nsoricips  to  which  antigen  has  been  attached 
(Hawkins  et  al.,  1992),  selection  on  fixed  prokaryotic  cells,  eukaryotic  or  even  tissues 
(Bradbury  et  al.,  1993;  Parsons  et  al.,  1996;  Van  Ewijk  et  al.,  1997). 
After  incubating  the  phage  libraries  on  target  antigens  and  washing,  antibodies  are 
eluted.  There  are  different  elution  methods.  Several  investigators  (Kang  et  al.,  1991a; 
Roberts  et  al.,  1992)  have  used  a  single  aliquot  or  gradients  of  acidic  buffers  to  disrupt  the 
antibody  antigen  interaction.  Others  (Griffiths  et  al.,  1993)  have  used  chaotropic  agents 
like  dithiothreitol  when  biotin  is  linked  to  the  target  antigen  by  a  disulphide  bridge  or  basic 
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solutions  such  as  triethylarnine  (Marks  et  al.,  1992).  Others  (Ward  et  al.,  1996)  used 
enzymatic  cleavage  at  an  engineered  site  located  between  the  antibody  and  gene  IIH. 
Competition  with  high  antigen  concentration  has  also  been  reported  as  an  elution  method 
(Clackson  et  al.,  199  1). 
The  most  important  factors  that  can  affect  the  efficiency  of  panning  are  washing 
frequency,  the  stringency  of  washing  and  the  concentration  of  the  immobilized  antigens. 
Low  affinity  antibodies  cannot  withstand  aggressive  washing  therefore,  it  is  very  important 
to  use  limited  number  of  washing  cycles.  On  the  other  hand,  high  affinity  antibodies  may 
be  best  isolated  after  aggressive  washing.  These  principles  also  apply  to  the  immobilized 
antigen  concentration,  where  a  high  concentration  of  coated  antigen  may  favor  isolation  of 
low  affinity  antibodies  and  low  concentration  may  help  isolate  high  affinity  antibodies. 
Two  to  five  rounds  of  selection  are  usually  adequate  for  recovery  of  phage  that 
carry  specific  antibody.  However,  the  degree  of  enrichment  of  the  antibodies  after  each 
round  of  selection  is  an  important  factor  which  decides  how  many  rounds  further  to  be 
taken.  Normally,  5  to  1000  fold  enrichment  after  each  round  of  selection  is  expected 
(Griffiths  et  al.,  1993;  Marks  et  al.,  199  1). 
1.10.2  Screening  of  phage  antibodies 
Since  the  selection  process  works  on  the  principle  of  enrichment,  it  is  predicted  that 
it  will  recover  a  mixture  of  phage  variants  with  differing  properties.  To  identify  the  clones 
of  interest,  large  numbers  of  clones  are  screened.  The  most  commonly  screening  method  is 
an  ELISA  based  assay.  This  format  of  assay  is  fast,  specific  and  it  is  suited  to  high 
throughput  (Marks  et  al.,  1991),  although  other  methods  such  as  flow-cytometry  have  been 
described  (Zaccolo  et  al.,  1997). 
The  control  of  the  number  of  antibody  fusions  displayed  at  the  phage  surface  has 
important  impact  on  screening.  Systems  that  favour  monovalent  display  allow  stringent 
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screening  for  variant  phage  antibodies  with  affinity  for  antigen  as  multiple  display  benefits 
from  avidity  effects.  Phagemid  systems  designed  with  an  amber  codon  between  the 
antibody  and  gHI  sequences  (Hoogenboom  et  al.,  1991;  Lowman  et  al.,  1991)  can  be 
convenient  for  analysis  of  isolated  antibody  fragments,  and  attached  (e.  g.  c-myc  or/and  his- 
tag)  tag  sequences  can  be  used  for  detection  or  purification  (Lah  et  al.,  1994;  Marks  et  al., 
1991). 
An  important  part  of  the  screening  process  is  DNA  sequencing  after  the 
identification  of  clones  of  interest  (Marks  et  al.,  1991).  This  allows  checks  for  defects  on 
the  genetic  level  and  precise  analysis  of  the  similarity  between  clones  that  emerge  from 
screening. 
1.10.3  Antibody  Expression 
Once  clones  with  useful  properties  have  been  identified,  they  must  be  expressed  on 
a  larger  scale  and  to  higher  yield  to  allow  further  characterization.  11igh  protein  expression 
of  antibodies  with  the  correct  folding  and  function  can  be  achieved  if  appropriate 
conditions  are  used  (Better  et  al.,  1988;  Pluckthun,  1994;  Skerra  &  Pluckthun,  1988). 
Many  approaches  have  been  taken  to  meet  these  goals.  The  first  approach  has  been  to 
express  soluble  antibodies  in  the  periplasm  of  E.  coli.  This  can  lead  to  successful 
expression  of  recombinant  antibodies  through  the  activity  of  periplasmic  disulfide-forming 
proteins  DsbA,  DsbB,  and  DsbC.  The  second  approach  is  the  production  of  soluble 
recombinant  antibodies  which  accumulate  in  the  periplasm  or  culture  medium  through  the 
use  of  specialized  vectors  with  strong  promoters  (Colcher  et  aL,  1990;  Gibbs  et  aL,  1991). 
The  third  approach  is  to  induced  the  production  of  cytoplasmic  inclusion  bodies  (George  et 
al.,  1995;  Knappik  &  Pluckthun,  1995)  The  yield  of  recombinant  antibody  can  also  depend 
to  a  significant  degree  upon  the  E.  coli  host  (Strachan  et  al.,  2002). 
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1.10.4  Affinity  maturation 
In  vivo,  immunoglobulins  undergo  affinity  maturation  to  elevate  their  affinity 
towards  antigens.  In  this  process,  antibody  sequences  are  diversified,  resulting  in  the 
creation  of  variants  of  the  original  primary  immunoglobulin  that  may  show  better 
recognition  (affinity)  of  the  target.  Improvement  arises  from  changes  to  critical  amino 
acids  in  the  CDRs.  This  process  is  known  as  affinity  maturation  (Adams  &  Schier,  1999). 
Selection  of  antibodies  from  recombinant  libraries  by  phage  display  usually 
recovers  a  mixture  of  antibodies  of  low  and  high  affinities.  If  the  affinity  of  antibodies 
selected  in  this  way  requires  improvement,  this  can  be  achieved  by  generating  a  secondary 
phage  library  in  a  process  that  imitates  the  immune  system.  There  are  different  approaches. 
One  of  the  most  popular  is  to  modify  the  V-gene  by  mutagenesis,  introducing  substitutions 
at  random  throughout  the  sequence  (Hawkins  et  al.,  1993).  Variants  generated  in  this  way 
can  be  screened  by  phage  display  using  a  low  antigen  concentrations  to  isolate  antibodies 
with  affinities  higher  than  that  of  the  original  immunoglobulin  (Hawkins  et  at.,  1992). 
Thus  the  power  of  phage  display  can  be  applied  to  libraries  of  antibodies  that  contain  many 
potential  specificities,  and  equally  to  variants  of  an  antibody  in  which  the  specificity  is  the 
same. 
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1.11  Aims 
The  first  aim  of  this  study  was  to  isolate  and  characterize  the  carboxy-terminal 
region  of  Toxin  A.  The  goals  were  to  express  the  carboxy-terminal  region  as  a  recombinant 
protein  in  E.  coli,  to  purify  the  material  and  to  characterize  the  protein  for  reaction  with 
antibodies  raised  against  the  native  toxin  and  haernagglutinating  activity  in  vitro.  After 
isolating  and  characterizing  the  recombinant  fragment,  the  purified  toxin  fragment  would 
be  used  as  substrate  for  recombinant  antibody  isolation  by  phage  display. 
The  second  aim  was  to  isolate  recombinant  antibodies.  It  was  proposed  to  the 
Tomlinson  I  and  J  scFv  libraries  against  purified  protein  and  to  monitoring  recoveries  of 
phage  through  successive  rounds  of  panning. 
The  third  aim  was  to  characterize  the  biological  properties  of  these  antibodies. 
Goals  were  to  overexpress  and  purifiy  the  selected  scFv  antibodies,  to  characterize  the 
ability  of  purified  scFv  antibodies  to  bind  to  their  target  antigen  by  ELISA  and  Western 
blotting  and  to  determine  if  the  scFv  antibodies  recognised  common  or  unique  epitopes. 
The  last  aim  was  to  seek  antibodies  with  toxin  neutralizing  activity  and  evaluate 
their  immunotherapeutic  potential.  This  would  involve  testing  if  the  recombinant 
antibodies  possessed  the  ability  to  neutralize  Toxin  A  using  an  in  vitro  cell  cuture  system. Chapter  2 
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2  Materials  and  methods 
2.1  Bacterial  strain 
The  plasmid  pET767  was  a  generous  gift  of  Dr.  N.  Fairwealter,  Imperial  College,  London. 
The  construct  carried  an  insert  of  lkb  encoding  14  of  the  peptide  repeat  motifs  present  in 
the  carboxy-terminal  domain  of  Toxin  A.  The  insert  was  cloned  into  pET28a  (Novagen), 
placing  expression  of  the  insert  under  the  control  of  the  T7  promoter.  DNA  was 
transformed  into  E  coli  DH5a  for  propagation  and  analysis. 
2.2  Confirmation  of  insert  encoding  Toxin  A  C-terminal  region 
To  confirm  the  presence  of  sequence  encoding  the  terminal  carboxy  region  of  Toxin 
A,  a  fresh  single  colony  of  E.  coli  pET767  was  inoculated  to  5  ml  of  LB  liquid  medium 
(composition  in  Appendix)  containing  50  jig/ml  kanamycin  and  incubated  overnight  in  a 
shaking  incubator  at  37'  C.  Next  day,  the  culture  was  centrifuged  at  4000  xg  at  40  C  for  10 
min.  DNA  was  extracted  using  a  miniprep  kit  (QIA  prep-miniprep,  QIAGEN,  UK.  ) 
following  the  recommended  protocol  and  DNA  then  stored  at  4'  C.  Purified  plasmid  DNA 
was  then  digested  using  the  restriction  enzymes  NcoI  and  XhoL  Fifteen  III  reaction 
mixtures  were  set  up  comprising  5  jil  of  plasmid  DNA,  1  [d  (IOU)  NcoI  (Promega,  UK),  1 
Al  (IOU)  Viol  (Promega,  UK),  8.5  Al  of  distilled  water  and  1.5  Al  of  10  x  Buffer  D  (60 
mM  Tris-HCI,  pH  7.9,1.5  M  NaCl,  60  MM  MgC12  and  10  mM  DT`F).  The  reaction 
mixtures  were  incubated  at  37'  C  for  1.5  hrs.  Each  reaction  mixture  was  run  on  a1% 
agarose  gel  at  100  volts  for  45  minutes  and  visualized  with  UV  light.  Plasmid  DNA  was 
sequenced  using  primers  annealing  to  the  T7  promoter  T7  terminater  and  sequences 
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present  in  the  pET28a  vector  sequences.  Sequencing  was  carried  out  at  the  Sir  Henry 
Wellcome  Functional  Genomics  Facility,  University  of  Galsgow. 
2.3  Growth  of  bacteria  and  expression  of  the  Toxin  A  carboxy- 
terminal  region 
E  coli  pET767  was  streaked  on  LB  agar  plates  (Appendix)  containing  50  [Lg/mI 
kanamycin  (Sigma,  UK)  and  incubated  overnight  at  37"  C.  The  following  day,  a  single 
bacterial  colony  was  inoculated  to  10  ml  LB  medium  containing  kanamycin  and  incubated 
in  a  shaking  incubator  overnight  at  37'  C.  Next  day,  a  larger  volume  (I  L)  of  LB 
containing  50  /.  tg/ml  kanamycin  was  inoculated  with  the  overnight  culture  to  an  OD  600 
nm  between  0.07  -  0.1  and  incubated  in  a  shaking  incubator  at  371  C.  When  the  OD  600 
nm  reached  0.9,  the  growing  bacteria  were  induced  by  the  addition  of  IPTG  (Melford, 
UK.  )  to  a  final  concentration  of  1  mM  and  incubated  for  19  hrs  in  a  shaking  incubator  at 
30'  C.  The  culture  was  then  centrifuged  at  4000  xg  at  4'  C  for  10  min.  The  supernatant 
was  discarded  and  the  pellet  was  resuspended  in  four  aliquots  each  of  15  ml  of  cold  PBS 
pH  7.4. 
Bacterial  cells  were  disrupted  by  sonication  (Jencons  Scientific,  Inc.  USA)  for  20  min  with 
11  %  sonication  power  using  alternating  of  10  sec  cycles  of  sonication  and  cooling.  The 
bacterial  lysate  was  centrifuged  at  4000  xg  at  4'  C  for  jo  min.  The  supernatant  was 
collected  and  exchanged  with  column  binding  buffer  (20  mm  phosphate  buffer,  0.5  M 
NaCl,  pH7.2)  using  Amicon  Ultra-4  centrifugal  filter  units  with  a  10  kDa  cut-off 
(Millipore,  UK). 
2.4  Purification  of  the  protein  by  affinity  chromatography 
A5  ml  HiTrap  chelating  IHP  column  (Amersharn  Pharmacia  Biotech,  UK)  was 
washed  with  5  column  volumes  of  distilled  water.  The  column  was  then  charged  with  0.5 
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column  volume  of  0.1  M  nickel  sulfate  and  washed  again  with  5  column  volumes  of 
distilled  water.  The  column  was  washed  with  5  column  volumes  of  binding  buffer 
containing  50  mM  imidazole  (Sigma,  UK)  and  again  with  5  column  volumes  of 
unmodified  binding  buffer.  Bacterial  lysate  in  binding  buffer  was  filtered  though  a  0.2  pm 
filter  (Sartorius,  Germany)  and  immediately  loaded  to  the  column.  The  column  was  then 
washed  with  5  column  volumes  of  binding  buffer  containing  20  MM  imidazole  and  then 
with  5  column  volumes  of  unmodified  binding  buffer.  The  column  was  then  washed  with  5 
column  volumes  of  0.2  M  citric  acid-phosphate  buffer  (Appendix)  at  pH  6.0  and  then  with 
the  same  buffer  at  pH  5.0.  The  recombinant  protein  was  eluted  by  stripping  the  column 
with  5  column  volumes  of  0.2  M  citric  acid-phosphate  buffer  at  pH  3.4.  Five,  5  ml 
fractions  were  collected  into  an  equal  volume  of  2x  PBS. 
2.5  Protein  assay 
To  determine  the  concentration  of  the  purified  recombinant  Toxin  A,  the  BCA 
Protein  Assay  Kit  (Pierce,  USA)  was  used.  BSA  standards  of  known  concentrations  were 
prepared  along  with  the  working  reagent.  Samples  of  0.1  ml  each  standard  and  the  purified 
protein  were  added  to  2  ml  of  the  working  reagent.  Tubes  were  then  incubated  at  37'  C  for 
30  min  and  then  brought  to  room  temperature.  The  colorimetric  reaction  in  each  tube  was 
measured  at  562  nm  using  a  UNICAM  UV/Vis  spectrophotometer. 
2.6  SDS-PAGE  analysis 
SDS-PAGE  analysis  carried  out  using  standard  methods  (Laemmli,  1970). 
Polyacrylamide  gels  were  cast  with  5%  stacking  and  12  %  separating  layers.  Twenty  Al  of 
recombinant  protein  was  boiled  for  5  min  in  10  itl  of  a3x  sample  buffer  (0.24  M  Tris-HCI 
pH  6.8,6  %  SDS,  30  %  (v/v)  glycerol,  16  %  (v/v)  P-mercaptoethanol  and  0.6  mg/mI 
Bromophenol  Blue).  Twenty  jil  of  each  boiled  sample  was  loaded  to  the  polyacrylamide 
gel.  Electrophoresis  was  carried  out  in  25  mM  Tris,  0.2  M  glycine  buffer  containing  0.1  % 
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(w/v)  SDS  at  200  Volts  for  1  h.  The  gel  was  stained  with  Commassie  Brilliant  Blue 
solution  (0.2  %  stain  in  45  :  45  :  10  %  methanol  :  water  :  acetic  acid)  for  30  min.  The 
staining  solution  was  then  discarded  and  the  gel  was  destained  overnight  in  45  :  45  :  10  % 
methanol  :  water:  acetic  acid  mix,  with  agitation. 
2.7  Electroblotting 
After  electrophoresis,  proteins  were  blotted  to  nitrocellulose  membrane  following  a 
standard  protocol  for  Western  blotting  (Sambrook,  1989).  Briefly,  4  pieces  of  Watman 
filter  paper  were  cut  to  the  same  size  as  the  gel  and  soaked  together  with  2  fiber  pads  and  a 
nitrocellulose  membrane  in  transfer  buffer  for  at  least  20  min.  The  nitrocellulose 
membrane  was  placed  on  top  of  the  gel  and  covered  on  both  sides  with  two  filter  papers 
and  one  fiber  pad.  The  sandwich  was  assembled  into  a  blotting  cassette  and  packed  along 
with  a  frozen  insert  into  a  BioRad  electrophoresis  tank.  The  tank  was  filled  with  transfer 
buffer  and  was  circulated  with  a  magnetic  stirrer.  Transfer  of  proteins  was  carried  out  at 
100  volts  for  1  hr.  after  that,  the  membrane  was  washed  3  times  with  PBS  and  stained  with 
Ponceau  red  dye  (Sigma,  UK)  to  demonstrate  successful  transfer.  The  membrane  was 
washed  3  times  with  distilled  water  to  remove  the  stain.  The  membrane  was  probed  with 
goat  anti-Toxin  A  antibody  and,  after  washing,  with  an  HRP  conjugate.  Finally,  the  blot 
was  developed  using  chloronaphthol  substrate  (15  mg  4-chloronaphthol  substrate  dissolved 
in  5  ml  methanol  added  to  25  ml  of  developing  buffer  (Appendix)  and  15  111  30  % 
hydrogen  peroxide).  The  reaction  was  stopped  by  washing  the  membrane  with  distilled 
water. 
2.8  Recognition  in  ELISA 
To  assess  the  recognition  of  the  recombinant  carboxy-terminal  protein  (hereafter 
designated  recombinant  Toxin  A)  by  polyclonal.  antibody,  two  rows  of  an  ELISA  plate 
(Nunc,  Denmark)  were  coated  with  100  Al  of  purified  protein  in  PBS,  using  doubling 
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dilutions  from  20  jig/ml.  The  plate  was  incubated  overnight  at  40  C.  Next  day,  the  plate 
was  washed  3  times  with  PBS.  Then  each  well  was  blocked  by  addition  of  200  ill  of  3% 
BSA  in  PBS  and  incubation  for  2  hrs  at  371  C.  The  plate  was  then  washed  3  times  with 
PBS.  Subsequently,  each  well  received  100  Itl  of  goat  anti-Toxin  A  antiserum  (list 
Biological  Laboratories,  USA).  The  serum  was  diluted  to  1:  500  in  blocking  buffer  and  the 
plate  was  incubated  for  1h  at  37'  C.  After  that,  wells  were  washed  3  times  with  PBS 
containing  0.05  %  Tween-20  and  probed  by  addition  of  100  Id  HRP-labeled  rabbit  anti- 
goat  antibody  (1:  5000)  in  blocking  buffer  and  incubation  for  1  hr  at  37'  C.  Wells  were 
washed  with  PBS  containing  0.05  %  Tween-20  and  developed  with  100,  ul  of  developing 
solution  (5  mg  o-phenylene-diamine  (OPD),  15  ml  of  0.1  M  citri  acid-citrate  buffer  pH  4.5 
and  6  jil  of  30  %  hydrogen  peroxide).  The  reaction  was  stopped  after  10  min  by  adding  50 
jil  IM  sulphuric  acid  and  absorbance  was  measured  at  590  nm  using  a  microplate  reader 
(ELx808  IU,  Ultra  Microplate  Reader,  Fisher  Scientific,  UK.  ). 
2.9  Binding  of  native  and  recombinant  Toxin  A  to  cellular 
receptors 
To  assess  the  ability  of  the  purified  recombinant  protein  to  bind  to  its  receptor,  the 
mouse  embryonal  carcinoma  cell  line  F9  (European  Collection  of  Cell  Cultures,  UK.  ) 
which  possesses  a  high  density  of  Toxin  A  cell  receptors  (Tucker  et  al.,  1990)  was  grown 
in  DMIEM  medium  (BioWhittaker,  Belgium)  with  10  %  (v/v)  fetal  bovine  serum  and  1  mM 
L-glutamine  supplemented  with  streptomycin-penicillin.  Freshly  trypsinized  F9  cells  were 
sub-cultured  by  transfer  of  5x  103  cells  to  the  wells  of  8-well  chamber  slides  (Nunc, 
Denmark).  The  cells  were  allowed  to  recover  for  18  h  at  37"  C  in  a5%  C02  atmosphere. 
The  medium  was  removed  and  the  slides  were  then  allowed  to  dry  at  room  temperature  for 
30  min.  After  that,  cells  were  fixed  with  2%  paraformaldehyde  in  PBS  for  20  min  at  room 
temperature.  Cells  were  then  saturated  with  1%  BSA  in  PBS  for  15  min.  One  hundred  jil 
of  20  jig/ml  native  Toxin  A  (Biogenesis,  UK)  or  100  jil  of  20  jig/ml  recombinant  Toxin  A 
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was  added  onto  the  cells  and  incubated  for  1h  at  41  C.  After  washing  with  PBS,  the  bound 
molecules  of  toxin  were  detected  by  addition  of  100  jil  of  goat  anti-Toxin  A  antiserum 
(1:  400)  in  PBS  and  incubated  for  1  hr  at  room  temperature.  After  washing  with  PBS,  100 
Al  of  FITC-labeled  rabbit  anti-goat  antibody  (1:  400)  was  added  and  incubated  as  for  the 
primary  antibody.  The  slide  was  washed  briefly  3  times  with  PBS  and  each  well  was 
mounted  with  50  jil  immunofluorescence  mounting  medium  (90  %  glycerol  in  phosphate- 
buffered  saline)  and  inspected  using  an  immunofluorescence  microscope  (Ziess,  Germany) 
with  illumination  at  490  nm. 
2.10  Haemagglutination  activity  of  recombinant  Toxin  A 
To  assess  the  haemagglutination  activity  of  the  recombinant  Toxin  A,  25  ld  of  PBS 
was  added  to  4  rows  of  a  U-shaped  microtitre  plate  except  the  first  well  in  each  row.  Fifty 
lil  of  recombinant  Toxin  A  (256  jig/ml)  or  native  Toxin  A  (51.2  jig/ml)  was  added  to  the 
first  well  in  the  row  and  25  /A  taken  for  two  fold  dilutions  across  the  plate.  The  last  four 
wells  received  only  50  jil  PBS  to  serve  as  negative  controls.  All  wells  then  received  25  jil 
of  2%  (v/v)  washed  rabbit  erythrocytes  and  suspended  in  PBS.  The  plate  was  incubated 
for  2  hrs  at  4'  C.  The  end-point  was  taken  as  the  last  dilution  of  toxin  that  showed 
complete  haernagglutination.  The  titer  was  defined  as  the  reciprocal  of  that  value. 
2.11  Sensitivity  of  F9  and  Vero  cell  lines  to  native  Toxin  A 
To  assess  the  ability  of  the  native  Toxin  A  to  bind  to  its  receptor  and  exerts  its  effect, 
the  murine  cell  line  F9  and  Vero  cells,  were  grown  in  DMEM  medium  with  10  %  fetal 
bovine  serum,  1  MM  L-glutamine,  supplemented  with  streptomycin-penicillin.  Freshly 
trypsinized  cells  were  sub-cultured  into  100  jil  of  medium  in  flat  bottom  96-well  cell 
culture  plates  (Nunc,  Denmark)  at  5x  103  cells  per  well.  Cells  were  allowed  to  recover  for 
18  h  at  37'  C  in  a5%  C02  atmosphere.  The  plate  was  then  washed  two  times  with 
complete  growth  medium.  Native  Toxin  A  was  added  in  ten-fold  serial  dilutions  starting 
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from  100  ng/well  to  0.1  ng/well  in  100  jil  volumes  to  F9  and  Vero  cells.  The  experiment 
was  carried  out  in  duplicate  for  each  cell  line.  The  plate  was  then  incubated  for  5  hrs,  at  37' 
C  in  a5%  C02-  Cells  were  inspected  by  microscopy  to  find  the  minimum  concentration  of 
toxin  able  to  elicit  a  cell  rounding  response. 
2.12  Kinetics  of  action  of  native  Toxin  A  on  F9  and  Vero  cell 
To  assess  the  speed  with  which  native  Toxin  A  acted  upon  F9  and  Vero  cells,  the 
cells  were  cultured  as  described  earlier.  After  18  hrs,  the  cells  were  washed  once  with 
complete  medium.  Eight  wells  of  each  cell  line  received  100  ng/ml  of  native  Toxin  A  in 
100  jil  complete  medium  and  were  incubated  at  37'  C  in  a5%  C02  atmosphere.  Two  wells 
from  each  cell  line  were  washed  after  4  min,  8  min,  16  min  and  32  min.  The  plate  was  then 
incubated  at  37'  C  in  a5%  C02  atmosphere.  Cells  were  regularly  observed  over  the 
following  3  hrs. 
2.13  Inhibition  of  native  Toxin  A  with  polyclonal  anti-Toxin  A 
and  recombinant  Toxin  A  in  vitro 
To  assess  the  ability  of  polyclonal  anti-Toxin  A  antibody  or  recombinant  Toxin  A  to 
block  the  activity  of  native  Toxin  A,  the  murine  cell  line  F9  was  sub-cultured  in  100  111 
volumes  as  described  above.  After  18  hrs,  the  cells  were  washed  once  with  complete 
medium.  In  a  separate  microtitre  plate,  10  ng  of  native  Toxin  A  was  mixed  with  50  tLl  of 
200  jig/ml  recombinant  Toxin  A  or  Polyclonal  anti-Toxin  A  polyclonal  antibody  diluted  to 
1:  200  in  PBS.  The  plate  was  then  incubated  for  30  min  at  room  temperature.  The  mixtures 
were  then  transferred  to  a  cell  culture  plate  containing  the  growing  F9  cells  in  150  Itl 
complete  medium.  The  cells  were  then  incubated  at  37'  C  in  a5%  C02  atmosphere  for  4 
hrs.  The  plate  was  observed  every  25  min. 
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2.14  Inhibition  of  native  Toxin  A  with  polyclonal  Fab  fragments 
To  assess  the  ability  of  anti-Toxin  A  Fab  fragment  to  block  the  activity  of  native 
Toxin  A,  polyclonal  IgG  against  the  toxin  antibody  was  digested  with  papain  to  release 
Fab  fragment.  Fab  fragment  was  then  used  for  inhibition  experiments  with  native  Toxin  A 
in  vitro. 
2.14.1  Digestion  of  polyclonal  anti-Toxin  A  antibody  with  papain 
Ten  jil  of  goat  anti-Toxin  A  anti-serum  was  digested  with  papain  2.5  %  v/v  (Sigma, 
USA)  in  PBS.  To  start  the  reaction,  a  stock  solution  of  L-cysteine  (Sigma,  USA)  was 
added  at  0.13  M  to  a  final  concentration  of  10  %  (v/v)  and  5  mM  EDTA  (USP;  Merck 
Speciality  Chemicals)  in  PBS  pH  7.5.  The  mixture  was  then  incubated  at  30'  C  for  7  hrs  in 
a  water  bath.  The  reaction  was  stopped  by  the  addition  of  a  0.15  M  stock  solution  of  E64 
to  10  %  (v/v)  (Cresswell  et  al.,  2005). 
2.14.2  SDS-PAGE  gel  electrophoresis 
SDS-PAGE  electrophoresis  was  carried  out  as  described  earlier.  Twenty  jil  of  goat 
anti-Toxin  A  digested  with  papain  or  undigested  with  the  enzyme  was  boiled  in  10  /11  of  3 
x  non-reducing  sample  buffer  for  2  minutes.  Ten  jil  of  each  boiled  sample  was  loaded  to  a 
lane  of  the  polyacrylamide  gel.  Electrophoresis  was  carried  out  in  25  mM  Tris,  0.2  M 
glycine  buffer  containing  0.1  %  (w/v)  SDS  at  200  Volts  for  1  h.  The  gel  was  stained  and 
destained  as  described  before. 
2.14.3  Electroblotting 
After  SDS-electrophoresis  had  finished,  proteins  were  blotted  to  nitrocellulose 
membrane  following  the  standard  protocol  for  Western  blotting  (Sambrook,  1989).  The 
membrane  was  then  probed  with  rabbit  anti-goat  IgG-Fab  antibody  (1:  500)  and  detected 
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with  HRP-labeled  goat  anti-rabbit  antibody  (1:  500).  The  membrane  was  developed  until 
clear  bands  were  seen.  The  reaction  was  then  stopped  by  washing  the  membrane  with 
distilled  water. 
2.14.4  Detection  of  native  Toxin  A  by  Fab  fragment  in  ELISA 
After  digesting  anti-Toxin  A  IgG  with  papain  the  ability  of  Fab  fragment  to 
recognize  native  Toxin  A  was  tested  in  ELISA.  Briefly,  an  ELISA  plate  was  coated  with 
100  /.  Ll/well  Toxin  A  at  20  tig/ml  in  PBS.  After  incubation  and  washing  as  described 
before,  wells  were  incubated  with  100  jil  digested  or  undigested  goat  anti-Toxin  A 
polyclonal  antibody.  After  washing,  the  binding  of  Fab  fragments  was  detected  with  100  jil 
rabbit  anti-goat  IgG-Fab  fragment  (Bethyl  Laboratory,  USA)  at  1:  500.  After  washing, 
rabbit  antibodies  were  then  detected  with  HRP-labeled  goat  anti-rabbit  antibody  (1:  1000). 
The  colour  reaction  was  developed  as  previously  described. 
2.14.5  Inhibition  of  native  Toxin  A  with  polyclonal  Fab  fragments 
in  vitro 
The  ability  of  Fab  fragments  of  the  polyclonal  anti-Toxin  A  to  block  the  activity  of 
native  Toxin  A  was  tested  using  the  murine  cell  line  F9,  grown  as  described  above.  After 
18  hrs,  the  cells  were  washed.  In  a  sterile  microtitre  plate  (Iwaki,  Japan),  native  Toxin  A 
was  mixed  with  the  Fab  preparation  as  shown  in  Table  2.1.  The  plate  was  incubated  at 
room  temperature  for  30  min  to  allow  toxin-antibody  recognition.  The  mixtures  were  then 
transferred  to  a  cell  culture  plate  containing  the  growing  F9  cells  in  150  Al  per  well  of 
complete  medium.  The  culture  was  then  incubated  at  371  C  in  a5%  C02  atmosphere  for  4 
hrs.  The  plate  was  observed  every  25  min.  The  number  of  cells  in  each  well  undergoing  a 
rounding  reaction  was  counted  every  25  min. 
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Table  2.1:  Inhibition  of  native  Toxin  A  with  polyclonal  Fab  fragments  in  vitro 
experimental  design: 
Rows  50  jxI  1.0  ILI  1.0141  1.0  ILI  1.0  Itl  1.01LI  undigested  1.3  ILI  papain 
PBS  nTA  papain  E64  goat  goat  anti-Toxin  digested  goat 
serum  A  anti-serum  anti-Toxin  A 
lOAg1ml  19mg/ml  0.15M  anti-serum 
I  1  (1:  1) 
A  X  X  X 
B  X  X  X 
c  X  X  X 
D  X  X  X 
E  X  X  X  _  T_ 
C:  inhibition  of  the  toxin  with  Fab  fragments.  B:  positive  control.  A,  D  and  E:  Negative  controls. 
nTA:  native  Toxin  A. 
56 Chapter  2,  Materials  &  memous 
2.15  Tomlinson  scFv  libraries 
The  Tomlinson  I  and  J  libraries  are  one  of  the  most  recent  phage  display  resources  to 
be  released  by  the  MRC  HGMP  Resource  Center.  Each  contains  over  100  million  different 
scFv  fragments  incorporated  into  phagemid  vector  and  transformed  into  E.  coli  TG1  cells. 
Phage  can  be  produced  from  the  stocks  and  used  in  display  experiments  to  select  specific 
binders  to  target  molecules  that  are  attached  to  the  surface  of  a  tube.  This  is  termed 
"panning".  After  each  round  of  panning,  those  scFv  which  fail  to  bind  to  the  target  are 
washed  away  and  the  phage  that  are  bound  are  eluted  and  amplified  by  infection  into  fresh 
TG1  cells.  Phage  from  the  previous  round  of  panning  can  be  used  again  in  further  rounds 
of  selection.  Two  or  three  rounds  of  panning  are  normally  required  to  recover  and  enrich 
scFvs  with  the  ability  to  bind  to  the  target.  The  monoclonal  scFvs  can  then  be  screened 
individually  for  binding  and  used  for  further  analysis.  Soluble  scFv  can  be  purified  using 
an  attached  histidine  tag,  and  detected  with  reagents  against  an  attached  c-myc  epitope. 
Library  I  and  J  are  based  on  a  single  human  framework  for  VH  (V3-23/DP-47  and 
JH4b)  and 
VK  (012/  0  2/DPK9  and 
JK  1).  The  structure 
(VH:  1-3,  Vk:  2-1-1)  encoded  by 
this  framework  is  the  most  common  in  the  human  antibody  repertoire.  The  CDR3  of  the 
heavy  chain  was  designed  to  be  as  short  as  possible  while  retaining  the  ability  to  fonn  a 
binding  surface  for  antigens.  Diversity  is  synthetically  incorporated  at  positions  in  the 
antigen  binding  site  that  are  known  to  contact  antigen  in  identified  structures.  Their 
positions  are  naturally  diverse  in  the  mature  human  repertoire.  This  strategy  was  intended 
to  provide  libraries  that  would  be  successfully  expressed  in  bacteria. 
The  repertoire  in  these  libraries  was  generated  by  diversification  of  18  residues 
(H50,  H52,  H52a,  H53,  H  55,  H56,  H58,  H95,  H96,  H97,  H98,  LSO,  L53,  L91,  L92,  L93, 
L94  and  L96).  In  each  case,  more  than  1x  108  clones  are  thought  to  make  up  the  library 
with  more  than  95  %  carrying  full-length  scFv  inserts. 
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The  libraries  were  constructed  in  the  display  vector  pIT2  (Figure  2.1  and  2.2).  This 
provides  c-myc  and  histidine  tags,  and  an  amber  stop  codon  separates  the  scFv  sequence 
from  gIll,  the  gene  for  a  minor  component  of  the  phage  coat.  The  VH  sequence  can  be 
excised  by  digestion  with  NcoI  and  XhoL  Saff  and  Notl  remove  the  VL  sequence. 
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Xhol 
SMiNcol  I  Sall 
Notl 
Lac  RIBS  pelB  Linker 
Promoter  leader 
pIT2 
ColEl  ori 
ori 
Figure  2.1:  Structure  of  phagemid  pIT2 
His  amber  gill 
myc  tag 
amp  M13 
Transcription  starts  at  lac  promotor  and  in  a  suppressor  strain  of  E.  coli,  translated 
product  comprises  a  PelB  leader,  the  single-chain  antibody  created  by  insertion  of 
VH  and  VL  sequences  at  the  sites  indicated  separated  by  a  linker,  peptide  tags, 
and  the  phage  pIll  protein. 
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RBS 
CAGGAAACAGCTATOACCATGATTACGCCAAGCTTGCATGCAAATTCTATTTCAAGGAGACAGTCATA  ATG  AAA  TAC  CTA 
................  >MKYL 
LMB3 
Sf  ii  Ncol 
TTG  CCT  ACG  GCA  GCC  GCT  GGA  TTG  TTA  TTA  CTC  GCG  GCC  CAG  CCG  GCC  ATG  GCC  GAG  GTG  TTT 
LPTAAAGLLLLAA0PAMAEVF 
Xhol  linker 
GAC  TAC  TGG  GGC  CAG  GGA  ACC  CTG  GTC  ACC  GTý 
-TCGAGC 
GGT  GGA  GGC  GGT  TCA  GGC  GGA  GGT 
DYWG0GTLVTVSSGGGGSGGG 
SaII  NotI  HIS-tag 
GGC  AGC  GGC  GGT  GGC  GGG  TCG  ACG  GAC  ATC  CAG  ATG  ACC  CAG  GCG  GCC  GC  CAT  CAT  CAT  CAC 
GSGGGGSTD10MT0AAAHH  H_  9-- 
........................ 
link  seq  new 
myc-tag 
CAT  CAC  GGG  GCC  GCA  GAA  CAA  AAA  CTC  ATC  TCA  GAA  GAG  GAT  CTG  AAT  GGG  GCC  GCA  TAG  ACT 
RGAAE0KLISEEDLNGAAtT 
<  ..................... 
pHEN  seq 
Figure  2.2:  DNA  sequence  of  pIT2  vector 
Restriction  sites  are  underlined.  Nco  I  and  Xho  I  sites  confines  the  VH  sequence 
while  Sal  I  and  Not  I  sites  confines  VL  sequence.  Dotted  arrows  indicate  primers 
used  for  sequencing.  The  star  indicates  the  stop  codon.  Histidine  and  myc  tags 
are  underlined. 
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2.15.1  KM13  helper  phage 
In  order  to  produce  virus  for  display  and  selection  of  scFv,  bacterial  cells  carrying 
the  phagemid  must  be  infected  with  helper  phage.  As  the  viral  progeny  assemble,  the 
phagemid  is  packaged  into  the  particle.  The  capsid  is  capped  with  a  mixture  of  pIH  species, 
-some  derived  from  the  helper  phage  genome,  others  from  the  phagemid.  Control  of  the 
proportions  of  this  mixture  is  difficult  to  achieve,  and  if  only  the  helper  phage-derived 
protein  is  incorporated,  the  specificity  of  the  panning  on  a  target-coated  surface  may  be 
compromised.  This  problem  has  been  tackled  with  the  development  of  modified  helper 
phage  such  as  KM13. 
Phage  generated  using  KM13  are  used  as  normal  in  a  panning  experiment.  Once 
interaction  with  target  has  taken  place  and  the  surface  has  been  thoroughly  washed,  viruses 
are  eluted  with  trypsin  treatment.  Those  viruses  that  are  bound  through  the  scFv 
component  (potentially  in  specific  interaction  with  target)  are  released  by  proteolytic 
cleavage  between  the  scFv  and  p1I1  moieties  (Figure  2.3,1).  As  pRI  remains  intact,  these 
viruses  can  infect  E  coli,  undergo  amplification  and  be  used  in  the  next  round  of  selection. 
In  contrast,  any  phage  that  lack  a  scFv-pHI  protein  (potentially  a  non-specific  interaction 
with  target)  carry  the  pIII  variant  encoded  by  KM13.  Trypsin  treatment  will  cleave  pHI 
between  domains  2  and  3  (Figure  2.3,  H)  rendering  these  viruses  non-infective.  This  should 
exclude  them  from  further  participation  in  the  selection  procedure. 
The  pRI  protein  contains  3  domains  D1,  D2  and  D3.  These  three  domains  are  all 
essential  for  infectivity  of  the  filamentous  bacteriophage  (Riechmann  &  Holliger,  1997), 
but  the  attachment  or  insertion  of  peptide  sequences  between  the  domains  does  not  lead  to 
loss  of  phage  infectivity.  However,  proteolytic  cleavage  of  any  part  of  pIH  including  the 
inserted  peptides  renders  the  filamentous  phage  non-infectious.  KM13  helper  phage  was 
generated  (Kristensen  &  Winter,  1998)  to  exploit  this  property. 
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not 
Ckovahk 
by  trypsin 
Figure  2.3  :  Principle  of  proteolytic  selection  (Goletz  et  aL,  2002) 
The  figure  shows  a  scFv-phage  from  a  phagemid  library  using  KM13  as  helper 
phage  During  packaging  and  rescue  of  a  phagemid  scFv  library,  the  pill  from  the 
helper  phage  (11)  competes  with  the  phagemid-encoded  scFv-pIII  fusion  protein  (1) 
for  incorporation  into  the  phage  particles  (Goletz  et  al.,  2002).  The  trypsin- 
sensitive  site  was  inserted  between  D2  and  D3.  Infectivity  of  the  phage  was  not 
affected  by  this  insertion  while  the  existence  of  the  three  domains  was  important. 
After  trypsin  treatment  phage  can  still  be  infective  because  pill  fusion  protein  (1)  is 
not  cleavable  (Goletz  et  al.,  2002). 
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A  protease  cleavage  site  was  introduced  between  the  D2  and  D3  domains  to  generate  a  pHI 
variant  that  could  not  mediate  bacterial  infection  after  treatment  with  trypsin.  In  contrast, 
the  pBI  translated  from  pI7F2  and  to  which  the  scFv  is  attached  is  insensitive  to  trypsin. 
Therefore,  the  ability  of  this  variant  to  mediate  infection  to  bacteria  is  preserved. 
2.15.2  Objectives 
The  objective  of  this  section  of  the  project  was  to  use  human  semi-synthetic 
Tomlinson  library  I  for  the  isolation  of  recombinant  single-chain  antibodies  against 
purified  recombinant  C-terminal  domain  of  Toxin  A.  The  goal  was  to  characterize  isolated 
scFvs  and  assess  activity  in  detection  and  neutralization  of  recombinant  and  native  Toxin 
A. 
2.15.3  Tomlinson  Library  I 
Library  of  Tomlinson  I  was  supplied  by  the  MRC,  Center  for  Protein  Engineering, 
Cambridge,  UK.  The  materials  composed  of  500  jil  of  library  in  E.  coli  TG1,  glycerol 
stocks  of  positive  control  scFv  against  BSA  and  ubiquitin,  a  glycerol  stock  of  T-phage 
resistant  E.  coli,  TG1  for  proliferation  of  phage  (K12  ara,  &(Iac-proAB)  supE  thi  hsdD5/F' 
proA+B  laclq  lacZ  AM15),  a  glycerol  stock  of  E.  coli  BB2151  for  expression  of  antibody 
fragments  (K12  ara  A(lac-proAB)  thi/F'proA+B  laclq  lacZAM15)  and  100  jil  KM13  phage 
(10'  pfu/ml).  Materials  were  stored  at  -70'  C. 
2.15.3.1  Propagation  of  KM13  helper  phage, 
A  stock  of  KM13  helper  phage  was  prepared  by  inoculating  one  colony  of  TG1 
from  a  plate  of  minimal  medium  into  5  ml  2xTY  broth  (1.6  %  tryptone,  1%  yeast  extract 
and  0.5  %  sodium  chloride)  containing  100  jig/ml  ampicillin  and  1%  glucose.  This  was 
incubated  overnight  at  371  C in  a  shaking  incubator  at  200  rpm.  Next  day,  500  141  from  the 
overnight  culture  was  added  into  50  ml  of  2xTY  and  grown  until  OD  600  nm  reached  0.4. 
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Then  200  Al  aliquots  of  the  culture  were  infected  with  10  ILI  of  10x  serial  dilutions  of 
KM13  helper  phage  and  incubated  at  37'  C  in  a  water  bath  for  30  min.  Then  the  content  of 
each  tube  was  mixed  with  3  ml  of  H-top  agar  (Tryptone  10g,  NaCl  8g,  Agar  6g  and 
distilled  water  up  to  1  litre)  warmed  at  42'  C  and  after  mixing,  the  tubes  were  poured  onto 
warm  TYE  agar  plates  (1.0  %  tryptone,  0.5  %  yeast  extract,  0.8  %  NaCl,  1.5  %  agar) 
containing  100  jig/ml  ampicillin  and  1%  glucose.  The  plates  were  incubated  overnight  at 
37'  C.  The  following  day,  a  single  plaque  was  inoculated  into  5  ml  of  fresh  TG1  at  an  OD 
600  nm  of  0.4  and  incubated  for  2  hrs  in  a  shaking  incubator  at  370  C.  The  culture  was  then 
added  to  500  ml  of  2xTY  in  a  large  flask  and  incubated  in  a  shaking  incubator  at  370  C  for 
1  hr.  Before  the  culture  was  incubated  overnight  at  30'  C,  kanamycin  was  added  to  the 
culture  to  a  final  concentration  of  50  Ag/ml.  the  next  day,  the  culture  was  pelleted  by 
centrifugation  at  10800x  g  for  15  min  and  100  ml  PEG/NaCl  (20  %  polyethylene  glycol 
6000,2.5  M  NaCI)  was  added  to  400  ml  of  supernatant.  The  mixture  was  incubated  on  ice 
for  1  hr  and  then  centrifuged  at  10800x  g  for  30  min.  The  pellet  was  resuspended  in  8  ml  of 
PBS  and  2  ml  of  PEG/NaCl.  The  mixture  was  incubated  on  ice  for  20  min  after  which  it 
was  centrifuged  at  11600x  g  for  10  min.  To  remove  any  remaining  bacterial  material,  the 
pellet  was  redissolved  in  PBS  500  jil  and  recentrifuged.  The  supernatant  was  then  stored  at 
-200  C. 
2.15.3.2  Titration  of  KM13  helper  phage  stock 
A  trypsin  stock  solution  was  prepared  by  dissolving  the  protease  (Fluka,  UK)  in  50 
MM  Tris-HCI  pH  7.4  and  1  mM  CaC12.  The  final  concentration  of  trypsin  was  0.5  mg/500 
III  PBS.  Forty-five  jil  of  phage  was  trypsinized  by  adding  5  jtl  trypsin  stock  solution.  The 
mixture  was  incubated  for  30  min  at  37'  C.  An  aliquot  of  I  jil  of  the  trypsinized  phage  was 
diluted  into  1  ml  of  PBS  and  five  serial  100  fold  dilution  were  prepared  in  1  ml  of  PBS. 
Fifty  ILI  from  each  dilution  was  transferred  to  separate  tubes  containing  1  ml  of  TG1  grown 
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to  an  OD  600  nm  0.4.  Then  each  tube  received  3  ml  of  molten  H-top  agar.  After  mixing, 
tube  contents  were  poured  onto  TYE  plates. 
2.15.3.3  Growing  the  library 
Library  stock  (500  til)  was  added  to  200  ml  pre-warmed  2xTY  containing  100 
Itl/ml  ampicillin  and  I%  glucose  and  incubated  in  a  shaking  incubator  at  37'  C  until  OD 
600  nm  reached  0.4.  Fifty  ml  of  the  culture  was  then  taken  and  2x  1011  KM13  helper 
phage  were  added.  The  remaining  150  ml  was  used  to  make  a  secondary  bacterial  stock  of 
the  library  for  storage  at  -70'  C  in  glycerol.  The  infected  bacterial  culture  was  incubated 
without  shaking  in  a  water  bath  for  30  min.  The  Bacteria  were  pelleted  at  3000x  g  for  10 
min  and  resuspended  in  100  ml  of  2xTY  containing  100  tig/ml  ampicillin,  50  /ig/ml 
kanamycin  and  0.1  %  glucose.  The  culture  was  then  incubated  in  a  shaking  incubator  at 
30'  C  overnight.  Next  day,  the  culture  was  spun  at  3000x  g  for  30  min  and  20  ml 
PEG/NaCI  was  added  to  80  ml  of  the  recovered  supernatant.  After  mixing  well, 
precipitating  mixture  was  left  for  1  hr  one  ice  and  then  pelleted  at  3300x  g  for  30  min.  The 
supernatant  was  poured  out.  The  pellet  was  then  resuspended  in  4  ml  PBS  and  pelleted  at 
11,600x  g  for  10  min  in  a  micro  centrifuge  to  remove  any  debris.  The  supernatant  was  then 
stored  at  4'  C. 
2.15.3.4  Titration  of  phage  libraries 
For  titration  of  phage  stock,  1  jil  of  phage  was  diluted  in  100  jjI  PBS,  1111  of  this  in 
100  [d  PBS  and  this  was  repeated  to  generate  6  serial  100  fold  dilutions.  Before  incubation, 
E.  coli  TG1  was  grown  to  an  OD  600  nrn  of  0.4,  and  900  jil  was  added  to  each  tube  at  37" 
C  in  a  water  bath  for  30  min.  Ten  fd  of  each  dilution  was  inoculated  to  a  TYE  plate 
containing  100  jig/ml  ampicillin  and  1%  glucose  and  spread  for  single  colonies.  The 
culture  was  incubated  at  37'  C  and  the  number  of  colonies  was  counted  the  following  day. 
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2.15.3.5  Growing  TG1  and  HB2151  cells 
Secondary  stocks  of  TGI  and  HB2151  were  generated  by  inoculating  a  loopful  of 
each  strain  from  the  frozen  glycerol  suspensions  onto  minimal  agar  plates.  The  plates  were 
incubated  overnight  at  37'  C.  A  colony  from  each  plate  was  picked  and  inoculated  into  5 
ml  of  2xTY  for  overnight  culture  in  a  shaking  incubator  at  37'  C.  Next  day,  the  cultures 
were  pelleted  at  3300x  g  for  10  min  and  the  supernatant  was  discarded.  The  pellets  were 
then  resuspended  in  1  ml  2xTY  containing  15  %  glycerol  and  stored  at  -80'  C. 
2.15.4  Experiments  before  selection 
Before  using  the  Tomlinson  I  library  in  selection,  some  preliminary  experiments 
were  perfonned. 
2.15.4.1  Growing  positive  controls 
A  positive  control  scFv  was  prepared  for  the  selection  experiments.  E.  coli  TG1 
carrying  anti-BSA  and  anti-ubiquitin  antibodies  were  inoculated  onto  TYE  containing  100 
Al/mI  ampicillin.  and  1%  glucose  and  grown  overnight  at  37"  C.  Next  day,  a  single  colony 
from  each  plate  was  inoculated  into  5  ml  of  2xTY  containing  100  jil/ml  ampicillin  and  1% 
glucose.  The  cultures  were  incubated  at  37'  C  and  200  rpm  in  a  shaking  incubator.  Plasmid 
DNA  was  extracted  and  2  jil  of  each  DNA  sample  was  transformed  into  100  111  of 
competent  E.  coli  HB2151  (Sambrook,  1989).  Cells  were  plated  onto  TYE  plates 
containing  100  Al/mI  ampicillin  and  I%  glucose  and  incubated  overnight  at  37"  C. 
2.15.4.2  Production  of  soluble  positive  control 
Single  colonies  of  BB2151  containing  anti-BSA  and  anti-ubiquitin  scFvs  were 
inoculated  into  5  ml  of  2xTY  containing  100  Id/ml  ampicillin  and  1%  glucose  and 
incubated  overnight  at  37"  C  in  a  shaking  incubator  at  200  rpm.  One  ml  of  each  culture 
was  inoculated  into  100  ml  of  2xTY  containing  100  jig/ml  ampicillin  and  0.1  %  glucose. 
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The  cultures  were  incubated  in  a  shaking  incubator  at  200  rpm  and  371  C  until  OD  600  nm 
reached  0.9.  IPTG  was  then  added  to  a  final  concentration  of  1  mM.  The  cultures  were 
then  transferred  to  a  shaking  incubator  at  200  rpm  and  37'  C  for  20  hrs.  Next  day,  the 
cultures  were  centrifuged  at  3000x  g  for  10  min.  The  supernatants  were  then  concentrated 
about  20  times  and  buffer  was  exchanged  to  PBS  using  Amicon  Ultra-4  Centrifugal  Filter 
Units  with  a  10  kDa  cut-off.  The  concentrated  soluble  scFvs  were  stored  at  -20'  C. 
2.15.4.3  Detection  of  anti-BSA  and  anti-ubiquitin  scFvs  by  Western  blot 
To  optimize  the  detection  method  for  expressed  scFv,  concentrated  culture 
supernatant  were  separated  by  SDS-PAGE.  The  proteins  were  then  transferred  to  a 
nitrocellulose  membrane  using  a  standard  protocol  for  1  hr  at  200  Volts.  The  protocol  is 
detailed  earilier.  The  membrane  was  blocked  with  3%  MPBS  for  1  hr  at  room 
temperature.  Monoclonal  anti-c-myc  antibody  was  then  added  onto  the  membrane  at 
1:  3000  dilution  in  a2%  solution  of  MPBS.  Blots  were  probed  for  90  min  at  37'  C  and 
shaking  at  150  rpm.  The  secondary  antibody  (anti-mouse  IgG  HRP  conjugate  [sigma])  was 
added  at  1:  1000  dilution  in  2%  MPBS  and  incubated  at  37*  C  with  shaking  at  150  rpm  for 
1  hr.  After  washing,  the  blot  was  developed  with  4-chloro-naphthol  substrate. 
2.16  Antibody  selection 
2.16.1  Panning  library  I  against  purified  recombinant  C- 
terminal  domain  of  Toxin  A 
2.16.1.1  First  round  of  selection 
An  immunotube  was  coated  with  4  ml  of  50  jig/ml  recombinant  C-terminal  domain 
from  Toxin  A  and  incubated  overnight  at  room  temperature.  The  next  day,  the  tube  was 
washed  3  times  with  PBS  by  pouring  PBS  in  and  out  of  the  tube.  The  tube  was  then  filled 
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to  the  top  with  2%  MPBS  and  incubated  vertically  at  room  temperature  for  2  hrs.  The  tube 
was  washed  3  times  with  PBS.  After  that,  approximately  1012  cfu  of  phage  from  library  I 
were  added  to  4  ml  of  2%  MPBS.  To  avoid  the  selection  of  phages  against  milk  proteins, 
the  suspension  was  incubated  at  room  temperature  for  30  min.  The  suspension  was  added 
to  the  coated  immunotube  and  incubated  for  1  hr  at  room  temperature  with  continuous 
rotation.  Then  the  tube  was  allowed  to  stand  for  a  further  1  hr  at  room  temperature.  After 
that,  the  supernatant  was  discarded  and  the  tube  was  washed  10  times  with  PBS  containing 
0.1  %  Tween-20.  The  excess  PBS  was  shaken  out  and  the  phages  were  eluted  by  adding 
500  jil  of  trypsin-PBS  solution  and  rotating  for  10  min  at  room  temperature. 
Infecting  TGI  cell  with  elutedphage  antibodies 
From  the  500  Al  eluate,  250  lil  was  used  to  infect  E.  coli  TG1  grown  to  OD  600  nm 
of  0.4.  The  bacteria  were  prepared  from  growth  on  minimal  medium,  as  described  earlier. 
The  infected  culture  was  incubated  at  37'  C  in  a  water  bath  for  30  min,  and  10  jil  samples 
were  inoculated  to  TYE  plates  containing  100  Ag1ml  ampicillin  and  1%  glucose.  Aliquots 
were  sampled  directly  from  the  infected  culture  or  prepared  at  dilutions  of  102  and  104. 
Plates  were  incubated  overnight  at  30'  C  and  colonies  counted  to  calculate  the  number  of 
output  phage  for  the  first  round  of  selection.  The  remaining  250  jil  of  phage  were  stored  at 
4'  C  for  future  use.  Titration  plates  were  stored  at  4'  C  for  future  use. 
The  remaining  culture  of  the  infected  TG1  bacteria  was  centrifuged  at  11,600x  g 
for  5  min,  the  pellet  was  resuspended  in  50  Al  of  2xTY  and  plated  onto  a  TYE  plate 
containing  100  Itg/ml  ampicillin  and  1%  glucose.  The  plate  was  incubated  overnight  at 
37'  C.  The  growing  colonies  were  then  resuspended  in  2  ml  of  15  %  glycerol  and  stored  in 
1  ml  aliquots  at  -70'  C.  Fifty  Al  of  the  bacterial  suspension  was  used  in  phage  rescue  for 
the  next  round  of  selection. 
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Rescue  of  selected  phage  antibodies 
A  50  Al  aliquot  of  the  resuspended  bacteria  from  the  first  round  of  selection  was 
inoculated  to  50  ml  of  2xTY  containing  100  jig/ml  ampicillin  and  1%  glucose.  The  culture 
was  incubated  at  37'  C  in  a  shaking  incubator  at  200  rpm.  When  the  OD  600  nm  reached 
0.4,  KM13  helper  phage  were  added  at  a  concentration  of  5x  1010  phage  to  10  ml  of 
culture.  The  mixture  was  incubated  in  a  water  bath  for  30  min,  and  then  pelleted  at  3000x  g 
for  10  min.  The  bacterial  pellet  was  resuspended  in  50  ml  of  2xTY  containing  100  149/ml 
ampicillin,  50  jig/ml  kanamycin  and  0.1  %  glucose  then  incubated  overnight  in  a  shaking 
incubator  at  200  rpm and  30"  C.  Next  day,  the  bacterial  culture  was  centrifuged  at  330OX  9 
for  15  min.  To  precipitate  the  phage  from  the  supernatant,  10  ml  PEG/NaCl  was  added  to 
40  ml  supernatant.  After  mixing  well,  the  mixture  was  left  for  1  hr  on  ice.  The  mixture  was 
then  centrifuged  at  3300x  g  for  30  min,  and  the  supernatant  was  then  discarded.  The 
precipitated  phage  were  resuspended  in  2  ml  PBS.  To  remove  the  remaining  bacterial 
debris,  the  suspension  was  pelleted  at  11600x  g  for  10  min.  One  ml  of  the  rescued  phage 
supernatant  was  stored  at  4"  C  and  the  remaining  1  ml  was  used  for  the  next  round  of 
selection. 
Titration  of  rescued  phage 
To  titrate  the  phage  amplified  from  the  first  round  of  selection,  a  series  of  6,100- 
fold  dilutions  were  prepared  and  100  jil  samples  were  mixed  with  900  Al  of  TG1  at  an  OD 
600  nm  of  0.4.  Mixtures  were  incubated  at  37"  C for  30  min.  Ten  /Al  samples  from  each 
dilution  were  spotted  onto  a  TYE  plate  containing  100  Aglml  ampicillin  and  1%  glucose 
and  incubated  overnight  at  30'  C.  Colonies  were  then  counted  to  estimate  the  number  of 
phage  in  the  amplified  stock. 
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2.16.1.2  Second  round  of  selection 
The  approach  of  the  second  and  third  rounds  of  selections  was  based  on  the  gradual 
reduction  in  the  concentration  of  recombinant  Toxin  A  coated  to  the  immunotube  in  each 
round  (Shadidi  &  Sioud,  2001).  This  approach  has  led  to  isolation  of  more  specific 
antibodies  with  higher  affinity.  An  immunotube  was  coated  with  protein  at  50  AgIml  in 
PBS  and  blocked  as  for  the  first  round  of  selection.  The  input  phage 
(1012  CfU)  in  2% 
MPBS  were  added  and  incubated  as  before.  The  tube  was  then  washed  20  times  with  PBS 
containing  0.1  %  Tween-20.  The  steps  of  the  second  round  of  selection  including  elution  of 
phage,  infection  of  TG1  and  recovery  of  phage  were  performed  as  described  for  the  first 
round  of  selection. 
2.16.1.3  Third  round  of  selection 
All  stages  of  the  third  round  of  selection  were  carried  out  in  the  same  way  as  for 
rounds  one  and  two  except  that  recombinant  C-terminal  domain  of  Toxin  A  was  coated  to 
the  immunotube  at  a  lower  concentration  (10  jig/ml). 
2.16.2  Screening  phage  by  ELISA 
In  phage  display,  each  round  of  selection  recovers  a  polyclonal  population  of  phage 
particles.  These  can  be  checked  for  their  overall  recognition  of  target  by  polyclonal  phage 
ELISA.  Alternatively,  phage  can  be  rescued  after  each  round  of  selection  from  single 
bacterial  colonies  and  amplified  virus  can  be  tested  for  recognition  of  target  (monoclonal 
phage  ELISA). 
2.16.2.1  Screening  phage  particles  by  ELISA  (polyclonal  ELISA) 
Phage  populations  recovered  from  each  round  of  selection  were  screened  for 
binding  to  the  C-terminal  domain  of  Toxin  A  by  ELISA.  Two  rows  of  an  ELISA  plate 
(Nunc)  were  divided  for  coating  with  either  recombinant  Toxin  A  or  MPBS  to  check  for 
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recovery  of  phage  against  milk  proteins.  Two  wells  coated  with  20  jig/ml  of  purified 
recombinant  Toxin  A  in  100  Itl  PBS  and  2  wells  coated  with  20  jig/ml  skimmed  milk  in 
PBS,  were  coated  designated  for  each  round  of  selection. 
The  plate  was  then  incubated  overnight  at  41  C.  The  next  day,  the  wells  were 
washed  3  times  with  PBS  and  blocked  with  3%  BSA  in  PBS  for  2  hrs  at  room 
temperature.  Wells  were  then  washed  3  times  with  PBS.  Ten  Al  of  PEG  precipitated  phage 
from  each  round  of  selection  were  mixed  with  100  Itl  3%  BSA  in  PBS  and  added  to  the 
wells allocated  for  each  round.  The  plate  was  incubated  for  1  hr  at  room  temperature  after 
which  the  plate  was  washed  3  times  with  PBS  containing  0.1  %  Tween-20.  Wells  were 
then  probed  with  a  1:  5000  dilution  of  HRP-labeled  anti-M13  (Amersham)  in  3%  BSA  in 
PBS  and  incubated  for  1  hr  at  room  temperature.  After  three  washes  with  PBS  containing 
0.1  %  Tween-20,  the  assay  was  developed  by  addition  100  jil  of  developing  solution  (5  mg 
OPD,  15  ml  0.1  M  trisodium-citrate  buffer,  pH  4.5  and  6  itl  of  30  %  H202)  to  each  well. 
The  reaction  was  stopped  after  10  min  by  adding  50  jil  1M  sulfuric  acid  and  the 
absorbance  was  measured  at  490  nm. 
2.16.2.2  Screening  phage  particles  by  ELISA  (monoclonal  ELISA) 
Monoclonal  Phage  ELISA 
Sixteen  individual  colonies  from  the  titration  plate  for  round  I  and  40  colonies 
from  plates  prepared  after  rounds  2  and  3  were  inoculated  into  100  111  of  2xTY  containing 
100  Ag/ml  ampicillin  and  1%  glucose  in  a  96  well  culture  plate  (Nunc,  Denmark).  The 
plate  was  incubated  overnight  at  37'  C  in  a  shaking  incubator.  The  following  day,  2  Al  was 
transferred  from  each  well  to  another  96  well  culture  plate  containing  200  Al  of  2xTY  with 
100  Ag/mI  ampicillin  and  1%  glucose  per  well.  The  plate  was  grown  in  a  shaking 
incubator  at  250  rpm  and  37'  C  for  2  hrs.  Then  25  Al  2xTY  containing  100  jig/ml 
ampicillin,  1%  glucose  and  109  helper  phage  was  added  to  each  well.  Shaking  was 
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continued  at  37'  C  for  I  more  hour.  After  that,  the  plate  was  spun  at  1,800x  g  for  10  min, 
and  supernatant  was  aspirated  off  all  the  wells.  Pellets  were  then  resuspended  in  200  Al 
2xTY  containing  100  jig/ml  ampicillin  and  50  /ig/ml  kanamycin.  The  plate  was  then 
incubated  overnight  at  30'  C  in  a  shaking  incubator  at  250  rpm.  The  following  day,  the 
plate  was  spun  again  at  1,800x  g  for  10  min.  Fifty  Al  of  the  supernatant  from  each  well  was 
used  in  phage  ELISA. 
Each  well  in  an  ELISA  plate  was  coated  with  100  jil  of  20  Itg/ml  of  purified 
recombinant  Toxin  A  in  PBS.  The  plate  was  incubated  in  4'  C  overnight.  Next  day,  the 
plate  was  washed  3  times  with  PBS.  Then  each  well  was  blocked  with  200  [LI  of  3%  BSA 
in  PBS  and  the  plate  was  incubated  for  2  hrs  at  room  temperature.  The  plate  was  washed  3 
times  with  PBS.  After  that,  50  jil  of  monoclonal  phage  stock  was  added  to  each  well, 
followed  by  50  jil  of  6%  BSA  in  PBS.  The  plate  was  incubated  for  90  min  at  room 
temperature.  After  the  plate  was  washed  3  times  with  PBS,  each  well  was  probed  with 
monoclonal  anti-M13  antibody  (1:  5000)  in  the  blocking  buffer  and  plate  was  incubated  at 
room  temperature  for  90  min.  After  washing  with  PBS  containing  0.1  %  Tween-20,  each 
well  was  probed  with  HRP-labeled  anti-mouse  antibody  (1:  5000)  in  blocking  buffer  and 
plate  was  incubated  at  room  temperature  for  90  min.  After  washing  with  PBS  containing 
0.1  %  Tween-20  each  well  was  developed  with  100  jil  of  developing  solution.  The  reaction 
was  stopped  after  10  min  by  adding  50  Id  1M  sulfuric  acid  and  light  absorbance  was 
measured  at  490  nm. 
2.17  Production  of  soluble  antibody  fragments 
In  E.  coli  TG1,  the  stop  codon  between  scFv  and  gUl  reading  frames  is  suppressed 
and  scFv  is  fused  to  pl[I.  Transfer  of  the  phagemid  to  E.  coli  HB2151  (a  non-suppressor 
strain)  allows  expression  of  soluble  scFv  for  testing  in  ELISA  experiments. 
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Ten  jil  of  phage  eluted  from  each  round  of  selection  was  added  to  200  Itl  BB2151 
grown  to  an  OD  600  nm  of  0.4  and  the  mixture  was  incubated  for  30  min  at  37"  C  in  a 
water  bath.  Serial,  100-fold  dilutions  were  prepared  and  50  jil  of  each  were  plated  on  TYE 
plates  containing  100  Itg/ml  ampicillin  and  1%  glucose  and  incubated  at  37'  C  overnight. 
Then  18,40  and  40  single  colonies  were  picked  from  rounds  1,2  and  3  respectively  and 
inoculated  into  individual  wells  in  a  96  well  culture  plate,  each  well  containing  100  jil 
2xTY  with  100  Ag/mI  ampicillin  and  1%  glucose  and  incubated  at  37'  C  for  overnight  in  a 
shaking  incubator  (250  rpm).  The  following  day,  2  Itl  was  transferred  from  each  well  to 
another  96  well  culture  plate  containing  200  Al  of  2xTY  with  100  jig/ml  ampicillin  and  0.1 
%  glucose  per  well.  The  plate  was  grown  in  a  shaking  incubator  (250  rpm)  at  37*  C  until 
OD  600  nm  was  approximately  0.9.  Then  25  Id  of  2xTY  containing  100  Aglml  ampicillin 
and  9.0  mM  IPTG  was  added  to  give  a  final  EPTG  concentration  of  1  mM.  The  plate  was 
then  incubated  overnight  at  30'  C  in  a  shaking  incubator  at  250  rpm.  Then  next  day,  the 
plate  was  spun  at  1,800x  g  for  10  min.  Fifty  jil  of  the  supernatant  was  used  for  ELISA. 
The  wells  of  an  ELISA  plate  were  coated  with  20  jig/ml  of  purified  recombinant  Toxin  A 
in  100  jil  PBS  and  incubated  at  4*  C  overnight.  The  following  day,  the  plate  was  washed  3 
times  with  PBS.  Each  well  was  then  blocked  with  200  Al  3%  of  BSA  in  PBS  and  for  2  hrs 
at  room  temperature.  Subsequently,  the  plate  was  washed  3  times  with  PBS.  After  that, 
each  well  received  50  jil  of  monoclonal  scFv  antibody  and  50  141  of  6%  BSA  in  PBS.  The 
plate  was  then  processed  as  described  previously  for  monoclonal  phage  ELISA.  Rabbit 
anti-c-myc  antibody  (1:  100)  was  used  for  probing  and  HRP-labeled  goat  anti-rabbit 
antibody  (1:  1000)  was  used  for  detection.  The  color  reaction  was  developed  as  previously 
described  and  the  final  absorbance  of  each  well  was  measured  at  490  nm  on  an  ELISA 
plate  reader. 
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2.18  Genetic  characterization  of  selected  scFvs 
Before  further  steps  were  taken  to  characterize  the  selected  scFv,  sequencing  was 
used  to  verify  the  size  and  integrity  of  the  inserts  and  their  diversity.  Twenty  selected 
clones  in  E.  coli  BB2151  were  chosen  from  rounds  2  and  3  on  the  basis  of  the  strength  of 
signal  in  ELISA  with  soluble  scFv. 
Plasmid  DNA  was  purified  by  growing  each  clone  in  5  ml  of  2xTY  containing  100 
jig/ml  ampicillin  and  1.0  %  glucose.  The  cultures  were  incubated  overnight  in  a  shaking 
incubator  200  rpm  at  37'  C.  Plasmid  DNA  was  extracted  using  miniprep  reagents. 
2.18.1  Plasmid  digestion 
Plasmid  DNA  was  purified  from  the  20  clones  and  digested  with  restriction 
enzymes.  In  each  digest,  3  jil  of  DNA  was  mixed  with  1  [d  of  NcoI  (Promega,  UK.  ),  1  Itl 
of  NotI  (Promega,  UK.  ),  1  Itl  of  buffer  D  (60  mM  Tris-HC1  (pH  7.9),  1.5  M  NaCl,  60  MM 
M902  and  10  mM  DT'F)  and  the  volume  made  up  to  10  jil  with  water.  The  reactions  were 
incubated  at  37*  C for  2  hrs.  Five  td  of  each  digest  was  analysed  by  electrophoresis  on  a2 
%  agarose  gel  for  45  min  at  100  V.  The  gel  was  visualized  under  UV  light.  SyberSafe  (In 
Vitrogen)  was  used  to  stain  the  DNA  fragments. 
2.18.2  Sequence  of  selected  clones 
To  predict  amino  acid  sequence,  diversity  and  integrity  of  the  selected  clones, 
sequencing  was  perfonned  using  the  forward  pelB  and  reverse  gUI  primers  (Table  2.4). 
DNA  sequencing  was  carried  out  at  Sir  Henry  Wellcome  Functional  Genomics  Facility, 
University  of  GaIsgow.  Big  Dye  (Applied  Biosystems)  and  ET-Dye  Terminator 
(Amersham  Bioscience)  were  used.  A  MegaBACE  1000  sequencing  machine  was  used  to 
analyze  the  samples.  DNA  Star  software  was  used  for  sequence  data  analysis.  For 
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alignment,  the  DNAPLOT  database  (MRC  Center  for  Protein  Engineering,  Cambridge, 
UK)  was  employed.  Amino  acid  sequence  was  aligned  using  MEGALIN  software. 
2.19  SDS-PAGE  and  Western  blot  analysis  of  selected  clones 
Selected  BB2151  clones  were  grown  in  100  ml.  2xTY  containing  100  jtg/mI 
ampicillin  and  0.1  %  glucose  to  an  OD  600  nm  of  0.9.  Bacterial  cultures  were  then  induced 
by  the  addition  of  IPTG  to  a  final  concentration  of  I  mM  and  transferred  to  a  shaking 
incubator  at  30'C  for  18  to  22  hrs.  Next  day,  the  cultures  were  allowed  to  cool  down  on  ice 
for  10  min  and  were  then  centrifuged  at  3000x  g  for  10  min  at  4*C.  The  supernatant  was 
then  concentrated  30  times  with  Amicon  Ultra-4  centrifugal  filters.  The  concentrate  was 
then  exchanged  with  PBS.  Twenty  Al  of  each  sample  was  added  to  10  Al  SDS-loading 
buffer  and  heated  in  boiling  water  for  5  min.  Sample  were  loaded  to  12  %  SDS- 
polyacrylamide  gels.  Gels  were  run  at  200  Volts  for  1  hr  in  a  BioRad  electrophoresis 
apparatus. 
Gels  were  blotted  to  4  nitrocellulose  membranes  by  a  standard  protocol  as  outlined 
earlier.  After  blocking  with  3%  MPBS  for  I  hr,  the  membrane  was  washed  3  times  with 
PBS  and  probed  with  anti-c-myc  monoclonal  antibody  at  a  dilution  of  1:  3000  in  3% 
MPBS  for  1  hr  at  37'  C  in  a  shaking  incubator.  The  membrane  was  then  washed  3  times 
with  PBS  containing  0.05  %  Tween-20.  The  membrane  was  probed  with  HRP-labelled 
rabbit  anti-mouse  antibody  in  3%  MPBS  and  incubated  for  I  hr  at  37"  C  with  shaking. 
The  membrane  was  then  washed  3  times  with  PBS  and  color  was  developed  with  4-chloro- 
1-naphthol  substrate. 
2.20  High  level  expression  and  purification  of  soluble  scFv 
In  order  to  further  study  the  properties  of  selected  scFv  antibodies,  these  antibodies 
were  expressed  in  a  soluble  form  and  purified.  One  single  HB2151  colony  representing 
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each  selected  scFv  was  inoculated  to  5  ml  of  2xTY  containing  100  pg/ml  ampicillin  and  1 
glucose.  The  culture  was  incubated  at  37*  C  in  a  shaking  incubator.  The  following  day,  2 
ml  of  the  overnight  culture  was  inoculated  to  200  ml.  2xTY  containing  100  /.  Lg/ml 
ampicillin  and  0.1  %  glucose.  The  culture  was  incubated  at  37*  C  in  a  shaking  incubator  at 
200  rpm  until  the  OD  600  nm  reached  0.9.  IPTG  was  then  added  to  a  final  concentration  of 
1  mM.  The  cultures  were  then  transferred  to  a  shaker  at  200  for  rpm  incubation  at  30'  C 
for  20  hrs.  After  centrifuging  at  3000x  g  for  10  min,  culture  supernatants  were 
concentrated  about  20  times  using  Amicon  Ultra-4  centrifugal  filters  with  a  10  kDa  cut-off. 
The  devices  were  centrifuged  at  4000x  g  at  4'  C.  The  buffer  was  exchanged  with  column 
binding  buffer  (20  mM  phosphate  buffer,  0.5  M  NaCl,  pH  7.2). 
2.20.1  Purification  of  the  scFvs  by  affinity  chromatography 
A  HiTrap  Chelating  BP  column  was  prepared  as  described  earlier  before  loading 
with  scFv.  Concentrated  culture  supernatant,  exchanged  into  column  binding  buffer  was 
filtered  though  a  0.2  ltm  filter  and  25  ml  was  immediately  loaded  to  the  column.  The 
column  was  then  washed  with  5  column  volumes  of  binding  buffer,  containing  20  mM 
imidazole  and  then  with  5  column  volumes  of  binding  buffer  containing  70  mM  imidazole. 
The  scFv  attached  to  the  column  was  eluted  by  striping  with  binding  buffer  containing  200 
mM  imidazole.  Five  fractions  of  5  ml  were  collected  and  concentrated  5  times  with  Ultra-4 
centrifugal  filters  (10  kDa  cut-off)  at  4*  C  with  centrifugation  at  4000x  g.  The  concentrated 
scFv  was  then  exchanged  into  PBS  at  4*  C. 
In  all,  nine  selected  scFv  were  prepared  in  this  way,  with  anti-BSA  scFv  as  a  control.  All 
preparations  were  quantified  for  total  protein  control  using  BCA  Assay  Kit  (Pierce,  USA) 
as  described  before. 
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2.21  Biological  activity  and  immunochemical  characterization 
of  purified  scFv 
2.21.1  Recognition  of  native  Toxin  A  by  selected  scFv 
ELISA  was  carried  out  assess  whether  native  Toxin  A  could  be  recognized  by  scFv 
antibodies  isolated  by  phage  display.  Rows  on  an  ELISA  plate  were  coated  with  purified 
native  Toxin  A,  starting  with  100  jil  of  20  jig/ml  Toxin  A  and  diluted  in  serial  two-fold 
steps  down  the  plate  to  generate  7  dilutions  in  total.  The  last  well  in  each  row  received  100 
Al  of  20  Ag/mI  BSA  in  PBS.  The  plate  was  then  incubated  overnight  at  4"  C.  Next  day,  the 
plate  was  washed  3  times  with  PBS  and  blocked  with  200  /il  2%  MPBS.  The  plate  was 
incubated  for  2  hrs  at  room  temperature.  After  the  plate  was  washed  3  times  with  PBS,  100 
Al  of  10  Aglml  of  purified  monoclonal  anti-Toxin  A  scFv  antibody  in  blocking  buffer  was 
added  to  wells  containing  diluted  toxin  while  100  jil  of  10  jig/ml  of  purified  monoclonal 
anti-BSA  scFv  antibody  was  added  to  wells  containing  dilutions  of  BSA.  The  plate  was 
then  incubated  at  room  temperature  for  1.5  hrs.  The  plate  was  washed  3  times  with  PBS 
containing  0.1  %  Tween-20  and  all  wells  were  probed  with  100  ill  of  a  1:  3000  dilution  of 
monoclonal  anti-c-myc.  The  plate  was  incubated  at  room  temperature  for  1  hr.  The  plate 
was  then  washed  3  times  with  PBS  containing  0.1  %  Tween-20.  Finally,  100  ill  of  a  1:  5000 
dilution  of  HRP-labeled  rabbit  anti-mouse  was  added  to  each  well.  The  plate  was  then 
incubated  at  room  temperature  for  1  hr  and  washed  3  times  with  PBS  containing  0.1  % 
Tween-20.  To  generate  signal,  100  Al  of  developing  solution  was  added  to  each  well.  After 
10  min,  50  Al  of  sulphuric  acid  was  added  to  each  well  to  stop  the  reaction  and  plate  was 
then  read  with  an  ELISA  reader  at  492  nm. 
2.21.2  Haemagglutination  inhibition  assay 
It  has  been  shown  that  rabbit  erythrocytes  carry  a  carbohydrate  receptor  for  Toxin 
A  on  their  surface  (Krivan  et  al.,  1986),  and  thus  haernagglutination  can  be  triggered  in  the 
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presence  of  the  toxin.  An  inhibition  assay  was  designed  to  test  whether  scFv  antibodies 
isolated  against  the  binding  domain  of  recombinant'Toxin  A  would  prevent  toxin  binding 
to  rabbit  erythrocytes,  and  hence  their  agglutination. 
2.21.2.1  Preparation  of  Rabbit  erythrocytes 
Fresh  heparinized  rabbit  blood  was  obtained  from  the  University  animal  facility. 
The  blood  was  centrifuged  at  top  speed  in  a  microcentrifuge  for  5  min,  and  after  discarding 
the  supernatant,  the  pellet  was  resuspended  in  PBS.  Erythrocytes  were  washed  with  PBS 
until  supernatant  was  clear. 
2.21.2.2  Haemagglutination  inhibition 
Samples  of  purified  scFv  at  200  Aglml  were  diluted  in  a  two-fold  series  of  25  tLI  of 
PBS  across  the  wells  of  a  round  bottom  microtiter  plate  (Iwaki,  Japan).  Goat  anti-Toxin  A 
was  prepared  in  the  same  way  to  serve  as  a  positive  control  and  a  scFv  against  BSA  was 
used  as  a  negative  control.  The  last  well  of  each  row  contained  only  PBS  to  serve  as  a 
further  control.  Then  25  jil  of  native  Toxin  A  at  a  concentration  of  400  ng/ml  was  added  to 
each  well.  The  plate  was  incubated  at  37'  C  for  30  min  to  allow  interaction  of  antibody  and 
toxin.  Each  well  then  received  25  jil  of  2%  rabbit  erythrocytes  before  incubation  at  4'  C. 
Samples  were  monitored  for  2  hrs.  After  2  hrs,  the  highest  dilution  of  antibody  able  to 
inhibit  haernagglutination  was  designated  as  the  titre  of  inhibition. 
2.21.3  Rabbit  erythrocyte  haemolysis  assay 
As  an  alternative  to  haernaggluti  nation,  haemolysis  was  adopted  to  provide  a  more 
sensitive  assay  for  inhibition  of  the  interaction  of  native  Toxin  A  with  rabbit  erythrocytes. 
Samples  of  200  jil  native  Toxin  A  at  30  jtg/ml  were  diluted  in  PBS  across  an  ELISA  plate 
and  incubated  overnight  at  room  temperature.  Next  day,  the  plate  was  washed  3  times  with 
PBS  and  blocked  with  3%  BSA  in  PBS  for  2  hrs,  at  room  temperature.  The  plate  was  then 
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washed  3  times  with  PBS.  Rows  1  and  2  of  the  plate  received  200  jil  of  PBS  to  serve  as  the 
negative  control.  The  first  well  of  rows  3  and  4  received  200  jil  of  goat  anti-Toxin  A 
diluted  1:  200  in  PBS  to  serve  as  positive  control.  Serial,  two-fold  dilutions  were  prepared 
across  the  plate.  The  first  well  in  rows  11  and  12  received  200  Itl  of  200  AgIml,  of  purified 
anti-BSA  scFv  antibody.  Again,  this  was  diluted  in  two-fold  steps  across  the  rows.  The 
first  well  of  the  remaining  rows  received  200  jil  of  200  jig/ml  of  purified  scFv  antibodies 
C5,  D4,  and  a  mixture  (C5,  D4  and  D5)  in  duplicate.  Two-fold  serial  dilutions  were 
prepared.  The  plate  was  then  incubated  at  37'  C  for  1  hr  to  allow  antibody-toxin 
interaction  and  washed  3  times  with  PBS  containing  0.1  %  Tween-20.  Two  hundred  ttl  of  3 
%  rabbit  erythrocytes  were  added  to  each  well  and  incubated  for  2  hrs  at  40  C.  The  plate 
was  then  washed  3  times  by  submersion  in  a  PBS  buffer.  Captured  erythrocytes  were 
haemolysed  by  adding  100  jil  of  distilled  water  to  each  well,  mixing  with  a  pipette  and 
incubation  for  30  min  to  allow  complete  haemolysis.  The  plate  was  read  with  an  ELISA 
reader  at  540  nm. 
2.21.4  Indirect  immunofluorescent  antibody  test  with  fixed  cells 
Murine  F9  cells  were  used  to  assess  the  ability  of  purified  scFvs  antibodies  to 
inhibit  the  binding  of  native  Toxin  A  to  its  receptor.  Cells  were  grown  in  DMEM  medium 
(BioWhittaker,  Belgium)  with  10  %  fetal  bovine  serum  (BioWhittaker,  Belgium)  and 
1  MM  L-glutarnine,  supplemented  with  streptomycin-penicillin.  Freshly  trypsinized  F9  cells 
were  sub-cultured  into  200  ILI  multi-well  cell  culture  slides  (BD  Falcon  Biosciences,  USA) 
at  5000  cells  per  well  and  allowed  to  grow  for  24  h  at  37"  C  in  a5%  C02  atmosphere. 
Wells  were  then  allowed  to  dry  at  room  temperature  for  30  min.  After  that,  cells  were  fixed 
with  fresh  2%  paraformaldehyde  for  20  min  at  room  temperature.  Cells  were  then 
saturated  with  1.0  %  BSA  in  PBS  for  15  min.  One  hundred  jil  of  native  Toxin  A  (50 
j4g/mI)  was  mixed  with  100  ItI  (200  tLg/ml)  samples  of  3  different  purified  anti-Toxin  A 
scFvs.  As  a  positive  control,  100  itl  of  polyclonal  goat  anti-Toxin  A  antibody,  diluted 
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1:  400,  was  mixed  with  toxin.  As  a  negative  control,  scFv  anti-BSA  was  mixed  with  toxin. 
The  antibody  antigen  mixtures  were  then  incubated  at  371  C  for  1  hr.  Then  100  Al  of  each 
mixture  was  added  to  2  separate  wells on  the  cell  culture  slide  and  incubated  for  1  hr  at  37' 
C.  The  slide  was  then  washed  3  times  with  1.0  %  BSA  in  PBS.  The  slide  was  fixed  with  4 
%  paraformaldehyde  for  20  min  at  4'  C,  washed  3  times  with  1.0  %  BSA  in  PBS  and 
probed  with  100  ttl  of  diluted  polyclonal  goat  anti-Toxin  A  antibody  (1:  400).  Slides  were 
incubated  at  37'  C  for  1  hr  and  washed  3  times  with  1.0  %  BSA  in  PBS.  Toxin  was 
localized  with  100  jil  of  FITC  labeled  rabbit  anti-goat  antibody  1:  500  (Sigma).  The  slide 
was  incubated  at  room  temperature  for  1  hr  and  washed  3  times  with  1.0  %  BSA  in  PBS. 
The  slide  was  then  mounted  with  immunofluorescence  mounting  medium  (90  %  glycerol 
in  phosphate-buffered  saline)  and  examined  using  an  immunofluorescence  microscope 
(Ziess,  Germany)  with  illumination  at  490  nm. 
2.21.5  Indirect  immunofluorescent  antibody  test  with  cells  in 
suspension 
To  assess  the  ability  of  scFv  antibodies  to  inhibit  the  binding  of  native  Toxin  A  to 
its  receptor,  murine  F9  were  grown  as  before,  scraped  from  the  culture  dishes,  and  adjusted 
to  50,000  cells/ml.  Five  1.5  ml  eppendorff  tubes  were  coated  with  3%  BSA  in  PBS  and 
were  then  set  up  with  100  jil  (200  jig/ml)  of  native  Toxin  A  (200  jil/ml).  Three  tubes  were 
then  inoculated  with  100  jil  of  the  purified  scFv  antibodies  (C5,  D4  and  D5)  (200  ill/ml).  A 
forth  tube  received  100  /A  of  polyclonal  goat  anti-Toxin  A  antibody  as  a  positive  control, 
and  the  fifth  tube  was  set  up  with  purified  scFv  against  BSA  (200  jig/ml)  as  a  negative 
control.  The  antibody  antigen  mixtures  were  then  incubated  at  37*  C  for  1  hr.  Aliquot  of 
100  /Al  of  suspended  F9  cells  was  added  to  each  tube  and  incubated  at  4"  C  for  45  min. 
Cells  were  washed  3  times  by  cold  centrifugation  at  300x  g.  The  supernatant  was 
discarded  and  cells  were  resuspended  in  100  jil  of  diluted  polyclonal  goat  anti-Toxin  A 
antibody  1:  400.  The  tubes  were  then  incubated  at  4'  C  for  45  min.  After  washing  3  times 
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with  centrifugation  at  300x  g,  they  were  then  probed  with  100  Al  of  FITC-labeled  rabbit 
anti-goat  antibody  1:  500.  The  tubes  were  then  incubated  at  room  temperature  for  45  min 
and  washed  3  times  as  before  and  resuspended  in  PBS.  Fifty  Al  sample  of  cell  suspension 
from  each  tube  was  finally  spotted  on  a  glass  microscope  slide  covered  with  a  cover  slip 
and  examined  using  an  immunofluorescence  microscope  with  illumination  at  490  nm. 
2.21.6  SDS-polyacrylamide  gel  electrophoresis  and  Western 
blotting 
Western  blotting  was  used  to  assess  the  ability  of  selected  scFv  to  recognize  Toxin 
A  after  its  denaturation  with  SDS,  P-mercaptoethanol  and  heat  treatment.  A  crude  bacterial 
lysate  was  prepared  from  E.  coli  pET767  and  it  was  separated  on  an  SDS-polyacrylamide 
gel  electrophoresis  as  described  before.  The  gel  was  then  blotted  to  a  nitrocellulose 
membrane  following  the  standard  protocol  for  Western  blotting.  Culture  supernatant 
containing  selected  scFv  was  used  to  test  for  recognition  of  the  carboxy-terminal  domain 
of  Toxin  A.  Supernatants  for  the  experiment  were  prepared  as  follows. 
Single  colonies  of  E.  coli  BB2151  carrying  the  phagemid  for  each  selected  scFv 
were  inoculated  separately  to  5  ml  of  2xTY  containing  100  ýtg/ml  ampicillin  and  1% 
glucose.  The  cultures  were  incubated  at  37'  C  overnight  in  a  shaking  incubator.  The 
following  day,  2  ml  of  the  overnight  incubated  culture  was  inoculated  to  200  ml  2xTY 
containing  100  Ag/ml  ampicillin  and  0.1  %  glucose.  Each  culture  was  incubated  at  370  C  in 
a  shaking  incubator  at  200  rpm  until  OD  600  nm  reached  0.9.  IPTG  was  then  added  to  a 
final  concentration  of  1  mM.  The  cultures  were  then  transferred  to  a  shaking  incubator  at 
200  rpm  with  300  C  for  20  hrs.  Next  day,  the  cultures  were  centrifuged  at  3000x  g  for  10 
min.  Twenty  ml  of  each  supernatant  was  then  used  to  detect  denatured  recombinant  Toxin 
A  on  Western  blots.  Toxin  was  separated  by  SDS-PAGE  as  described  earlier.  The  binding 
of  scFv  to  the  blot  was  detected  using  mouse  anti-c-myc  monoclonal  antibody,  and  HRP- 
labelled  anti-mouse  reagent  as  described  earlier. 
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2.21.7  Expression  levels  of  selected  scFvs 
In  order  to  compare  the  level  of  expression  of  the  scFvs  chosen  for  further 
characterization  and  as  an  alternative  method  for  concentration,  each  scFv  was  expressed 
in  100  ml  cultures,  spun  down  at  3000x  g  for  10  min  at  4'  C  and  concentrated  to  25  times 
with  exchange  into  PBS  using  Amicon  Ultra-4  Centrifugal  Filter  Units  with  a  10  kDa  cut- 
off  (Millipore,  UK).  Aliquots  of  20  fil  from  each  sample  were  mixed  with  40  jil  of  3 
sample  buffer  and  heated  for  5  min  in  boiling  water.  Samples  of  18  gI  were  then  loaded  to 
lanes  of  duplicate  polyacrylamide  gels.  Electrophoresis  was  run  under  the  same  conditions 
as  described  previously.  For  protein  visualization,  one  gel  was  removed  from  the  glass 
plate  assembly  and  stained  with  Commassie  Brilliant  Blue  for  30  min.  The  staining 
solution  was  discarded  and  gel  was  destained  with  destaining  solution.  The  second  gel  was 
used  from  Western  blotting. 
Protein  was  transferred  to  a  nitrocellulose  membrane  following  the  standard  protocol 
for  Western  blotting.  The  membrane  was  then  blocked  with  3%  MPBS  washed  3  times 
with  PBS,  and  probed  with  monoclonal  anti-c-myc  and  HRP-labeled  rabbit  anti-mouse 
antibodies. 
2.22  Epitope  analysis 
Two  approaches  were  employed  to  analyse  the  epitopes  recognized  in  the  carboxy- 
terminal  domain  of  Toxin  A.  In  the  first,  experiments  assessed  if  scFvs  recognized  unique 
or  common  regions  of  Toxin  A.  Initial  work  established  saturating  levels  for  each  scFv. 
Later  experiments  tested  if  ELISA  signals  could  be  increased  by  adding  in  a  second  scFv. 
To  identify  Toxin  A  epitopes,  a  series  of  recombinant  fusion  proteins  were  generated  and 
tested  for  recognition  by  scFvs. 
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2.22.1  Epitope  saturation  curve 
Before  epitope  sharing  experiments  were  carried  out,  curve  was  first  plotted  for 
each  selected  purified  scFv  to  determine  the  saturation  point.  Two  rows  of  an  ELISA  plate 
were  coated  with  100  itl  of  2  tig/ml  native  Toxin  A  to  provide  a  low  concentration  of  the 
target  for  analysis.  After  overnight  incubation  at  4'  C,  the  plate  was  washed  3  times  with 
PBS  and  blocked  with  3%  BSA  in  PBS.  After  washing,  well  number  1  in  both  rows 
received  100  ttl  of  200  jtg/ml  purified  scFv  C5  in  blocking  buffer.  Wells  number  2  to  7  in 
both  rows  received  only  200  itl  of  blocking  buffer.  The  plate  was  incubated  for  1  hr  at  37' 
C.  After  washing  the  plate  3  times  with  PBS  containing  0.05  %  Tween-20,  well  number  1 
and  2  in  both  rows  received  100  jil  of  200  jtg/ml  purified  scFv  C5  in  blocking  buffer. 
Wells  number  3  to  7  in  both  rows  received  only  200  jil  of  blocking  buffer.  The  plate  was 
incubated  for  1  hr  at  37'  C.  After  washing  the  plate  3  times  with  PBS  containing  0.05  % 
Tween-20,  wells  I  to  3  in  both  rows  received  100  Id  of  200  jtg/mI  purified  scFv  C5  in 
blocking  buffer.  Wells  number  4  to  7  in  both  rows  received  only  200  /il  of  blocking  buffer. 
The  plate  was  incubated  for  1  hr  at  370  C.  After  washing  the  plate  3  times  with  PBS 
containing  0.05  %  Tween-20,  well  number  1  to  4  in  both  rows  received  100  itl  of  200 
ttg/ml  purified  scFv  C5  in  blocking  buffer.  Wells  number  5  to  7  in  both  rows  received  only 
200  jil  of  blocking  buffer.  The  plate  was  incubated  for  1  hr  at  370  C.  After  washing  the 
plate  3  times  with  PBS  containing  0.05  %  Tween-20,  wells  number  1  to  6  in  both  rows 
received  100  IAI  of  200  pg/ml  purified  scFv  C5  in  blocking  buffer.  Well  number  7  in  both 
rows  received  only  200  jtl  of  blocking  buffer  to  serve  as  negative  control.  The  plate  was 
incubated  for  1  hr  at  37'  C.  After  washing  the  plate  3  times  with  PBS  containing  0.05  % 
Tween-20,  all  wells  were  probed  with  100  jil  of  monoclonal  anti-c-myc  antibody  1:  3000  in 
blocking  buffer.  The  plate  was  then  incubated  at  room  temperature  for  1  hr  and  washed 
with  PBS  containing  0.05  %  Tween-20.  All  wells  then  probed  with  100  ill  of  1:  500  rabbit 
anti-mouse  antibody,  incubated,  and  developed  as  described  earlier.  Absorbance  was 
measured  at  490  nm. 
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2.22.2  Epitope  saturation  experiment  using  two  different  scFvs 
Having  established  the  conditions  required  for  saturation  binding  of  a  selected 
scFv,  two  different  scFvs  were  used  together  in  a  similar  experiment.  The  principle  of  this 
assay  was  that  if  the  competing  scFv  bound  to  non-overlapping  epitope,  further  elevation 
of  the  ELISA  signal  would  arise.  If  however  the  scFvs  bound  to  the  same  or  adjacent 
epitope,  no  increase  in  the  EIJSA  would  be  detectable.  Two  rows  of  an  ELISA  plate  were 
coated  with  a  low  concentration  of  recombinant  Toxin  A  as  before.  Next  day,  the  plate  was 
washed  3  times  with  PBS  and  blocked  with  3%  BSA  in  PBS.  After  washing,  the  scFvs 
under  test  were  added  in  100  jil  aliquots  of  (200  jig/ml)  in  blocking  buffer  in  3  cycles 
detailed  below.  Blocking  buffer  was  added  as  (Table  2.2)  indicated.  For  each  cycle,  the 
plate  was  incubated  for  1  hr  at  37'  C  and  washed  3  times  with  PBS  containing  0.05  % 
Tween-20.  The  experiment  therefore  allowed  the  binding  of  scFv  D4  after  2  cycles  of 
addition  of  C5  to  be  compared  with  1,2,  or  3  cycles  of  addition  of  C5  (wells  4,3  or  2 
respectively).  As  controls,  a  single  addition  of  D4  (well  5)  was  tested,  with  blanks  (well  6 
and  7).  To  detect  scFv  binding,  the  wells  were  then  probed  with  100  jil  of  monoclonal  anti- 
c-myc  antibody  (1:  3000).  The  plate  was  then  incubated  at  room  temperature  for  1  hr  and 
washed  with  PBS  containing  0.05  %  Tween-20.  All  wells  then  probed  with  100  ILI  of  rabbit 
anti-mouse  antibody  (1:  500)  washed  and  developed.  Absorbance  was  measured  at  490  nm. 
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2.22.3  Blocking  of  monoclonal  phage  antibody  epitopes  by  scFv 
of  the  same  specificity 
Antibody  saturation  experiments  proved  unsatisfactory  and  so,  a  competitive 
ELISA  was  set  up  in  which  scFv  and  phage  antibody  of  the  same  clone  and  specificity 
were  mixed  and  allowed  to  compete  for  binding  to  the  target  (Boel  et  al.,  1998). 
2.22.3.1  Preparation  of  phage  antibodies 
Plasmid  DNA  was  extracted  from  9  E.  coli  IHB2151  clones  by  growing  each  clone 
in  5  ml  of  2xTY  containing  100  /ig/ml  ampicillin  and  0.1  %  glucose.  The  cultures  were 
incubated  overnight  in  a  shaking  incubator  200  rpm  at  37*  C.  Plasmid  DNA  was  extracted 
using  reagent  as  described  earlier. 
E  coli  TG1  was  prepared  for  transformation  using  a  calcium  chloride  method 
(Sambrook,  1989).  Bacteria  were  grown  on  an  LB  plate  without  antibiotic  overnight  at  371, 
C.  Next  day,  one  colony  was  transferred  to  100  ml  of  LB  and  incubated  for  3  hrs  at  37'  C 
with  brisk  shaking  at  300  rpm.  Bacterial  cells  were  transferred  to  an  ice  cold  tube  and  left 
on  ice  for  10  min.  Bacterial  cells  were  then  pelleted  by  centrifugation  at  3200x  g  for  10 
min  at  4'  C.  The  supernatant  was  discarded  and  the  pellet  was  resuspended  in  10  ml  of 
cold  0.1  M  CaC12.  The  tube  was  incubated  on  ice  for  15  min.  Bacterial  cells  were  then 
centrifuged  at  3200x  g  for  10  min  at  4"  C  and  the  pellet  was  resuspended  in  2  ml  of  ice 
cold  0.1  M  CaC12.  Two  hundred  itl  aliquots  of  the  resuspended  bacterial  cells  were 
transferred  to  sterile  microcentrifuge  tubes  using  cooled  sterile  tips.  Plasmid  DNA  (2.5  [d) 
was  added  to  the  tube  and  mixed.  The  tube  was  incubated  on  ice  for  20  min  and  was  then 
transferred  to  a  warm  water  bath  at  42'  C  for  60  sec  After  incubation  on  ice  for  10  min, 
800  Itl  of  2xTY  medium  was  added  to  the  tube  and  the  cells  were  incubated  in  a  shaking 
incubator  at  370  C  for  45  min.  Samples  of  50  14  were  then  spotted  on  TYE  containing  100 
Ag/mI  ampicillin  and  spread  to  allow  growth  of  single  colonies  during  overnight  culture  at 
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37*  C.  Next  day,  a  single  colony  was  picked  from  each  plate  and  grown  into  5  ml  2XTY. 
The  following  day,  500  itl  of  the  transformed  E.  coli  TG1  was  used  to  produce  phage 
antibodies  as  described  previously.  The  supernatant  containing  phage  was  then  stored  at  4* 
C  until  required. 
2.22.3.2  Optimization  of  epitope  blocking  by  ELISA 
To  optimize  the  conditions  for  epitope  blocking  in  ELISA,  a  single  scFv  C5 
antibody  was  titrated  against  D5  and  C5  phage  antibodies.  To  perform  the  assay,  4 
columns  of  an  ELISA  plate  were  coated  with  100  jil  of  2  tig/ml  recombinant  Toxin  A  in 
PBS.  The  plate  was  incubated  overnight  at  4'  C.  Next  day,  the  plate  was  washed  3  times 
with  PBS.  The  plate  was  then  blocked  with  200  jil  of  2%  MPBS  and  incubated  for  2  hrs  at 
room  temperature.  The  plate  was  then  washed  3  times  with  PBS. 
Before  the  addition  of  C5  or  D5  scFvs  to  the  toxin-coated  plate,  each  were  pre- 
diluted  on  a  separate  microtitre  plate  by  a  checkerboard  titration  as  follows:  200  tfl  of  200 
itg/ml  of  each  scFv  was  added  to  each  of  four  wells number  (C5:  1,2,3  and  4,  D5:  5,6,7, 
and  8).  Each  sample  was  serially  diluted  in  4  two-fold  steps.  In  another  plate,  100  Al  of  1:  2 
diluted  phage  antibody  of  C5  was  prepared  in  two-fold  steps.  Each  aliquot  of  phage  was 
added  to  8  wells,  organized  in  the  opposite  orientation  to  the  scFv  samples  and  serially 
diluted  in  4  two-fold  steps.  Ten  itl  of  the  diluted  phage  was  then  added  to  90  Al  of  the 
diluted  C5  and  D5  scFvs  in  a  checkerboard  pattern.  Phage-scFv  mixes  were  then 
transferred  to  separate  wells  of  a  Toxin  A-coated  plate  and  incubated  for  I  hr  at  room 
temperature  after  which  the  plate  was  washed  3  times  with  PBS  containing  0.05  %  Tween- 
20.  Wells  were  then  probed  with  dilution  of  HRP-labeled  anti-M13  antibody  (1:  5000  in  2 
%  MPBS)  and  incubated  for  1  hr  at  room  temperature.  Then  wells  were  washed  3  times 
with  PBS  containing  0.05  %  Tween-20  and  developed.  After  10  min,  absorbance  was 
measured  at  450  nm. 
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2.22.3.3  Blocking  of  phage  antibody  by  scFv 
Seven  monoclonal  scFvs  were  prepared  for  use  in  a  blocking  ELISA  with  their 
phage  antibody  versions.  To  perform  the  test,  7  rows  of  an  ELISA  plate  were  coated  with 
100  jil  of  2  Itg/ml  of  recombinant  Toxin  A  in  PBS.  The  plate  was  incubated  overnight  at  4* 
C.  Next  day,  the  plate  was  washed  3  times  with  PBS.  The  plate  was  then  blocked  with  200 
Id  of  2%  MPBS  and  incubated  for  2  hrs  at  room  temperature.  The  plate  was  washed  3 
times  with  PBS. 
Ninety  Id  aliquots  of  the  selected  scFvs  (B9,  C5,  D4,  D5,  D6,  E4  and  G9)  at  50 
ttgImI  in  2%  MPBS  were  set  up  in  competition  with  10  ld  of  1:  8  diluted  phage  antibodies 
2%  MPBS,  in  all  combinations.  Mixtures  were  transferred  to  the  toxin  coated  plate  after 
which  the  plate  was  washed,  probed,  and  developed  as  described  earlier  to  assess  binding 
of  phage  antibodies. 
2.23  Assay  for  toxin  neutralizing  activity 
To  characterize  the  ability  of  recombinant  antibodies  to  neutralize  Toxin  A,  F9  cells 
were  cultured  and  tested  in  flow  cytometry  and  cell  culture  experiments. 
2.23.1  Flow  cytometric  analysis  of  toxin  binding 
To  assess  the  ability  of  purified  anti-Toxin  A  scFvs  to  inhibit  the  binding  of  the 
toxin  to  its  receptor,  murine  F9  cells  were  grown  as  described  earlier,  trypsinized  and 
grown  on  in  20  ml  full  culture  medium.  After  3  hrs  incubation  the  cells  were  scraped, 
washed  into  washing  buffer  (2.5  mM  Hepes,  2%  FBS  and  4  mM  CaC12  in  PBS)  and 
adjusted  to  5x  104  cells/ml  (Demarest  et  al.,  2005). 
Five  tubes  were  coated  with  3%  BSA  in  PBS  to  block  protein  binding  and  each 
received  100  jil  of  native  Toxin  A  (50  jig/ml),  anti-Toxin  A  scFvs  antibodies  (C5,  D4  and 
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D5)  or  100  /.  tl  of  diluted  polyclonal.  goat  anti-Toxin  A  antibody  as  a  positive  control.  A  100 
jil  aliquot  of  purified  anti-BSA  scFv  (200  ILI/ml)  served  as  a  negative  control.  The  antibody 
antigen  mixtures  were  then  incubated  at  371  C  for  1  hr  before  addition  of  100  Al  of 
suspended  F9  cells.  Tubes  were  incubated  at  4'  C  for  45  min. 
Cells  were  then  washed  3  times  with  washing  buffer  and  centrifuged  at  300x  g,  4' 
C.  Supernatants  were  discarded  and  cells  were  resuspended  in  100  jtl  of  diluted  polyclonal 
goat  anti-Toxin  A  antibody  (1:  400).  The  tubes  were  then  incubated  at  41  C  for  45  min.  The 
cells  were  washed  as  before  and  were  then  probed  with  100  /Al  of  FITC-labeled  rabbit  anti- 
goat  antibody  (1:  500).  The  tubes  were  incubated  at  room  temperature  for  45  min,  washed 
as  before  and  resuspended  in  1  ml  of  cold  washing  buffer.  Cells  were  analysed  on  a 
FACSCAN  flow  cytometer  (Becton  Dickenson)  using  Cell  Quest  Software. 
2.23.2  Inhibition  of  Toxin  A  cytotoxicity  in  vitro 
2.23.2.1  Preparation  of  F9  cell  line 
F9  cells  was  grown  and  maintained  as  described  above.  Freshly  trypsinized  cells 
were  sub-cultured  into  100  Al  volumes  in  flat  bottom  96-well  cell  culture  plates  (Nunc, 
Denmark)  at  5x  103  cells  per  well  and  allowed  to  recover  for  IS  hrs  at  37'  C  in  a5%  C02 
atmosphere.  The  plate  was  then  washed  two  times  with  complete  growth  medium  and  85 
14  of  complete  medium  was  added  to  each  well. 
2.23.2.2  Addition  of  Toxin  A-  antibody  mixtures 
Twenty-five  jil  aliquots  of  the  scFvs  under  test  (C5,  D4,  D5,  and  a  mixture  these 
scFvs  each  at  200  jig/ml;  anti-BSA  scFv)  were  added  to  2  wells  in  a  96-well  microtitre 
plate  (Iwaki,  Japan).  A  25  /il  sample  of  BSA  (200  jig/ml)  in  PBS  was  added  to  2  wells 
containing  polyclonal  anti-Toxin  A  (1:  400)  as  a  positive  control,  and  2  empty  wells  as 
negative  control.  Native  Toxin  A  was  added  to  a  final  concentration  of  2  ng/well  to  all 
wells.  The  plate  was  incubated  for  30  min  at  room  temperature  in  a  humid  atmosphere. 
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After  that,  each  antibody-Toxin  A  mixture  was  transferred  into  a  separate  well  in  the  cell 
culture  plate.  The  plate  was  then  incubated  for  2  hrs  at  37'  C  in  a5%  C02  atmosphere. 
Cell  morphology  was  monitored  and  cells  were  counted  at  25  min  intervals  over  a2  hr  test 
period. 
This  experiment  was  repeated  with  some  modification  (Sauerbom  et  al.,  1997).  After 
the  addition  of  antibody-Toxin  A  mixtures  to  the  cell  culture  plate,  the  plate  was  incubated 
at  4'  C for  30  min  and  wells  were  then  washed  with  chilled  PBS.  Each  well  then  received 
100  Al  of  complete  medium  and  plate  was  shifted  to  37'  C  in  a5%  C02  atmosphere. 
Rounding  up  of  cells  was  monitored  and  counted  every  25  min  over  a2  hrs  period. 
2.24  Epitope  mapping 
2.24.1  Materials  and  methods 
General  bacteriological  procedures 
2.24.1.1  Bacteria  and  plasmids 
Bacterial  strains  used  in  this  section  of  the  study  are  in  Table  2.3. 
2.24.1.2  Preparation  of  pET767 
E.  coli  carrying  the  plasmid  was  sub-cultured  on  LB  agar  plates  containing 
kanamycin  at  50  jig/ml.  Colonies  were  transferred  to  liquid  culture  and  grown  in  Universal 
containers  overnight  and  plasmid  DNA  was  extracted  using  Qiagen  reagents.  DNA  was 
eluted  from  the  QIAprep  column  with  distilled  water  and  stored  at  -20'  C. 
The  plasmid  pET767  was  used  as  the  starting  point  for  epitope  mapping  since  it 
carried  that  part  of  the  Toxin  A  carboxy-terminal  domain  used  in  phage  display.  As 
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described  later,  regions  of  the  sequence  were  recovered  by  PCR.  The  products  were  cloned 
into  pCR  2.1-TOPO  (Invitrogen)  for  analysis  before  excision  by  restriction  digest  and 
ligation  into  pCG806  (di  Guan  et  al.,  1988).  This  is  a  vector  that  allows  the  convenient 
fusion  of  foreign  sequence  to  the  carboxy-terminus  of  MaIE,  the  maltose-binding  protein 
of  E  coli.  With  the  exception of  pET767,  all  plasmids  carried  an  ampicillin  resistance 
marker. 
2.24.2  Polymerase  chain  reaction 
2.24.2.1  PCR  primers 
PCR  primers  were  obtained  from  Sigma-Genosys,  UK.  PCR  primers  were  checked 
for  strong  secondary  structure,  and  pairs  were  chosen  to  provide  Tms  that  were  compatible. 
The  primers  were  redissolved  in  sterile  distilled  water  to  give  stock  concentrations  of  100 
jtM.  Table  2.4  shows  the  primers  used  in  this  study. 
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Table  2.3:  Bacterial  strains  used  for  epitope  mapping 
Strain  Genotype  Source/Remarks 
E.  coli 
F-  80lacZ.  M15.  (1acZYA-argF)  U169  deoR  recAl  endAl 
hsd  R17  (rk-,  mk+)  phoA  supE44  L-  thi-1  gyrA96  relAl 
Invitrogen 
DH5a 
F-  mcr  A.  (mrr-hsd  RMS-mcr  BC)  80  lac  Z.  M1  5 
TopolO  Jac  X  74  rec  Al  araD1  39.  (araln)  7697  gat  U  gal  K  Invitrogen 
rps  L  (StrR)  end  Al  nup  G 
E.  coli  Plasmid  from  Dr.  N. 
DH5a  See  above  Fairwealter,  Imperial  college, 
pET767  London 
E.  coli 
Plasmid  from  Dr.  P.  Riggs, 
DH5a  See  above 
New  England  BioL 
pCG806 
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Table  2.4:  List  of  primers  used  for  epitope  mapping  and  characterization  of 
scFv  genes 
Primer 
Primer  sequence  Primer 
name  position 
5'  to  3'  t 
rTA  ATATAAGCTTCTACTAAGGGCTMACTCC 
995  b 
rev  11 
rTA  ATATAAGCTTCTAAGCTGTATTAGGCTCGAAG 
684  b 
rev  2 
rTA  ATATAAGCTTCTAAGAAGTGTTAGTATTAAAG 
306  b 
rev  3 
rTA  36  b 
for  1  TGATATCGCCTCAACTGGTTATACAAG 
rTA  247  b 
for  2  TGATATCAAAGCAGTTACCGGACTG 
rTA  586  b 
for  3  TGATATCAAAGCGGCTACTGGTTGG 
ToxA 
repeat  GATCCTTAAGTATCAGGCATAAAGTAATATACMAC-  921  b 
rev  CATTAATA  =  GCCATCCAGTAACTGCTTTCGAGCT 
(RR1) 
ToxA 
repeat  CGAAAGCAGTTACTGGATGGCAAACTATTAATG-  859  b 
for  GTAAAGTATATTACTTTATGCCTGATACTTAAG 
(FR1) 
gIII  CCCTCATAGTTAGCGTAACG 
pelB  ATGAAATACCTATTGCCTACGGCAGC 
Underlined  sequences  indicate  inserted  restriction  sites.  'Primers  position  on  rTA  DNA  sequence. 
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2.24.2.2  PCR  reactions 
The  reactions  were  set  up  to  a  total  volume  of  25  ILI  containing  10  mM  Tris-HCI 
(pH  8.4),  50  mM  KCI,  3.0  MM  M902,0.2  mM  of  each  deoxynucleoside  triphosphate 
(dNTPs)  100  pmol  each  primer,  1.0  U  of  Taq  DNA  polymerase  (Promega,  USA)  and  2.5 
[d  of  template  DNA  preparation. 
Amplifications  were  performed  using  a  Hybaid  thermal  cycler  (Hybaid  Ltd, 
Middlesex,  UK).  Conditions  used  were  denaturation  at  94'  C  for  5  min,  followed  by  30 
cycles  of  denaturation  94'  C  for  1  min,  annealing  52'  C  to  60'  C (for  different  primer  sets) 
for  1  min,  extension  at  72*  C  for  1  min.  A  final  extension  step  at  70'  C  for  5  min  was 
included.  PCR  products  were  stored  at  -201  C  or  used  immediately. 
Samples  from  the  PCR  reactions  were  mixed  with  6x  loading  buffer  (40%  (w/v) 
sucrose  and  0.25%  (w/v)  Bromophenol  blue  dissolved  in  sterile  distilled  water)  and 
electrophoresed  on  0.7-1.0  %  (w/v)  agarose  gels.  The  1  Kb  DNA  ladder  (Promega,  USA) 
was  used  as  a  DNA  molecular  weight  marker. 
Agarose  was  prepared  in  Tris-Acetate-EDTA  buffer  and  5  14  of  SYBR  Safe  DNA 
gel  stain  (Invitrogen,  USA)  was  added  to  each  100  ml  of  the  mixture. 
Gels  were  run  at  a  voltage  of  1-5  volts/cm2.  Electrophoresis  continued  until  the 
marker  dye  had  migrated  an  appropriate  distance. 
A  UV  transillurninator  was  used  to  visualize  the  SYBR  Safe  stained  DNA.  Images 
of  the  gel  were  either  stored  electronically  or  printed  out  for  further  analysis. 
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0  2.24.3  Elution  and  purification  of  DNA  from  agarose  gels 
Routinely,  DNA  fragments  were  eluted  and  purified  from  agarose  gels  by 
QIAquick  extraction  reagents. 
The  DNA  band  was  visualized  and  excised  from  a  SYBR  Safe  stained  gel  with  a 
scalpel  under  UV  light  (Chromato  VUE,  C-70  Viewing  system,  UVP.  Inc.,  USA).  Briefly, 
to  purify  DNA  from  the  gel,  the  gel  slices  were  weighed  in  a  microcentrifuge  tube.  About  3 
volumes  of  buffer  QG  were  added  to  each  tube  and  incubated  at  56'  C  for  10  min  in  a 
water  bath.  The  tubes  were  shaken  every  2  min  until  the  agarose  was  dissolved.  The  tubes 
were  then  centrifuged.  After  that,  1  gel  volume  of  isopropanol  was  added  to  the  tubes  and 
mixed  gently.  The  dissolved  gel  was  then  loaded  to  QIAquick  spin  column  and  centrifuged 
as  recommended.  The  flow-through  was  discarded  and  the  column  was  washed  with  0.5  ml 
of  buffer  QG.  After  centrifugation,  the  column  was  washed  with  0.75  ml  of  buffer  PE  and 
the  column  was  centrifuged  as  recommended.  The  flow-through  was  discarded  and  the 
column  was  put  onto  a  1.5  ml  sterile  microcentrifuge  tube.  DNA  was  then  eluted  with  30 
Al  of  sterile  distilled  water  and  recovered  by  centrifugation. 
2.24.4  Restriction  enzyme  digestion  and  ligation 
Restriction  enzyme  digests  were  routinely  performed  according  to  the 
manufacturer's  instruction  unless  otherwise  stated.  The  set  of  restriction  enzymes  used  are 
listed  in  Table  2.5.  Vector  and  insert  fragments  were  ligated  using  T4  DNA  ligase 
(promega  and  New  England  Biolabs).  Ligation  mixtures  were  transforned  into  competent 
K  coli  DH5a  (Invitrogen)  and  transfonnant  were  selected  on  LB  agar  with  ampicillin  100 
jtg/mI  as  described  earlier. 
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2.24.5  DNA  sequencing 
Plasmid  DNA  was  purified  from  selected  clones  of  E.  coli  DH5a  by  growing  each 
clone  in  5  ml  of  LB  containing  100  jtg/ml  ampicillin.  The  cultures  were  incubated 
overnight  in  a  shaking  incubator  200  rpm  at  37'  C.  Plasmid  DNA  was  extracted  using 
Qiagen  reagents.  Sequencing  was  performed  using  the  primers  appropriate  sets  at  Sir 
Henry  Wellcome  Functional  Genomics  Facility,  University  of  Galsgow  as  described 
earlier.  For  data  analysis,  Chromas  (versions  2.3  &  1.15)  and  DNA  star  software  were 
utilized. 
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Table  2.5:  List  of  restriction  enzymes  and  their  target  sequences 
Restriction  Enzyme  Target  sequence  Source 
Sac  I  5'...  GAGCTIC  ...  3'  Promega,  USA 
3'...  CTTCGAG  ...  5' 
Hin  dIll  5'...  AIAGCTr  ...  3'  Promega,  USA 
3'...  T  TCGATA  ...  51 
Eco  RV  5'...  GATIATC 
... 
31  Promega,  USA 
3'...  CTATTAG  ...  51 
Bam  HI  5'...  GIGATCIC 
...  3'  Promega,  USA 
3'...  CTCTAG  TG  ... 
5' 
Sma  I  5'...  CCCIGGG  ...  3'  BioLabs,  UK 
3 
...  GGGTCCC 
...  5' 
All  digests  were  carried  out  at  37'  C  except  for  Sma  1  (25'  C). 
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2.24.6  Cloning 
2.24.6.1  Cloning  into  pCR  2.1-TOPO  vector 
PCR  products  were  cloned  using  the  pCR  2.1-TOPO  vector  system  (Invitrogen). 
PCR  products  were  purified  from  the  gel  and  resuspended  in  sterile  distilled  water  to  a 
concentration  of  50  ng/jil.  Ligation  step  was  done  according  to  the  manufacturer's 
instructions.  Briefly,  4  itl  of  PCR  product  was  added  to  1  itl  of  TOPO  vector.  The  vector 
solution  contains  topoisomerase,  the  linearised  vector  and  ligation  buffer.  The  mixture  was 
incubated  for  5  min  at  room  temperature  after  which  it  was  transferred  to  ice.  After 
thawing  one  vial  of  TOPIOF  One  Shot  competent  cells  on  ice,  2  /Al  of  the  ligation  mix  was 
added  with  gentle  mixing  using  pre-cooled  tips.  After  the  mixture  was  incubated  on  ice  for 
30  min,  the  cells  were  heat-shocked  at  42'  C  for  30  sec  in  water  bath.  The  cells  were  then 
incubated  on  ice  for  2  min  before  addition  of  250  jil  of  warm  SOC.  Tubes  were  incubated 
with  shaking  at  37'  C for  2  hrs.  After  that,  50  jil.  was  spread  on  an  LB  plate  containing  100 
Itg/ml  ampicillin  and  incubated  overnight  at  37'  C. 
2.24.6.2  Cloning  into  pCG806 
Vector  and  insert  DNA  were  routinely  digested  with  restriction  endnucleases  to 
generate  complimentary  cohesive  overhangs  or  blunt  ends.  The  resultant  fragments  were 
gel  purified  and  DNA  concentrations  were  measured.  DNA  fragments  were  mixed  to 
provide  high  molar  excess  of  insert  over  vector. 
2.24.6.3  Ligation 
Ligation  reactions  were  performed  in  a  total  volume  of  20  jil.  Briefly,  compatible 
vector  and  insert  fragments  were  prepared  as  above  with  300  ng  of  vector  DNA  and  an 
appropriate  quantity  of  insert  DNA  for  each  reaction.  After  that,  2  itl  of  10  x  buffer,  and  I 
Itl  T4  DNA  ligase  (400,000  U/ml;  New  England  BioLabs)  were  added.  The  reaction 
volume  was  completed  to  20  /A  with  sterile  distilled  water.  After  snap  centrifugation,  tubes 
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were  incubated  at  room  temperature  for  20  min.  After  incubation  the  ligation  mixture  was 
then  stored  at  -20'  C  if  not  used  immediately  in  transformation. 
2.24.6.4  Transformation 
One  vial  of  commercially  prepared  E.  coli  DH5a  was  thawed  on  wet  ice.  Cells 
were  mixed  gently  and  50  Al  aliquots  were  transferred  into  sterile  chilled  polypropylene 
tubes.  Samples  of  ligated  DNA  were  added  to  the  cells  and  mixed  gently.  The  tubes  were 
then  incubated  on  ice  for  30  min.  Cells  were  then  heat-shocked  for  20  sec  at  371  C  in  water 
bath  without  shaking.  The  tubes  were  then  returned  ice  for  2  min  and  then  received  950  ttl 
of  pre-warmed  SOC.  The  tubes  were  then  incubated  at  37'  C  for  1  hour  in  a  shaking 
incubator  at  225  rpm.  After  incubation,  100  jil  of  each  transformation  was  spread  on  an  LB 
agar  plate  containing  100  jig/ml  ampicillin.  Plates  were  incubated  overnight  at  37'  C. 
2.24.6.5  Preparation  of  synthetic  DNA  duplex 
Oligonucleotides  (FRI  and  RR1)  were  resuspended  in  sterile  distilled  water  to  100 
AM.  16  Al  of  the  mixed  oligonucleotides  was  added  to  a  PCR  tube  with  of  an  annealing 
buffer  (50  mM  KCI,  10  mM,  Tris-HC1  pH  9.0,1.5  MM  M902  and  0.1  Triton  X-  100)  and  2 
Al  of  sterile  distilled  water.  The  annealing  mixture  was  then  incubated  in  a  small  volume 
water  bath  at  960  C.  The  water  was  left  to  return  gradually  to  room  temperature. 
2.24.6.6  Phosphorylation  of  annealed  oligonucleotides 
In  order  to  enable  the  DNA  duplex  to  ligate  to  the  digested  vector,  samples  were 
phosphorylated  using  T4  polynucleotide  kinase.  Briefly,  2  ill  of  the  annealed  duplex  was 
mixed  with  2  til  of  5x  forward  buffer  (  350  mM  Tris-HCI  7.6  pH,  50  MM  M902,500  MM 
KC1  and  5  mM  2-mercaptoethanol),  2  Itl  of  10  U/pl  T4  phosphokinase,  2  til  of  10  MM 
ATP  and  12  Al  sterile  distilled  water.  The  phosphorylation  mixture  was  then  mixed, 
centrifuged  briefly  and  incubated  in  a  water  bath  at  37'  C  for  15  min.  The  reaction  was 
99 Chapter  2,  Materials  &  Methods 
then  stopped  by  heating  at  65'  C  for  10  min.  The  mixture  was  then  purified  using  a  PCR 
purification  kit  (Qiagen,  UK).  Phosphorylated  linker  DNA  was  then  eluted  in  warmed  30 
jil  sterile  distilled  water  and  its  DNA  concentration  was  determined.  Ligation  and 
transformation  were  carried  out  as  described  earlier. 
2.25  Protein  expression 
Bacteria  were  grown  in  LB  medium  with  100  jig/ml  ampicillin.  When  the  OD  at  600 
nm  reached  0.4,  expression  of  MaIE  fusion  proteins  was  induced  by  the  addition  of  IPTG 
to  a  concentration  of  1  mM  and  incubated  for  3  hrs,  in  a  shaking  incubator  at  37'  C.  The 
culture  was  recovered  by  centrifugation  at  4000x  g  at  4'  C  for  10  min.  The  supernatant  was 
discarded  and  pellet  was  resuspended  in  10  ml  aliquots  of  cold  PBS  pH  7.4. 
Bacterial  cells  were  sonicated  (Status  US200,  Philip  Harris  Scientific,  Gennany)  for 
5  min  with  20  %  sonication  power  using  10  sec  cycle  sonication  and  cooling.  The  bacterial 
lysate  was  centrifuged  at  10000x  g  at  4'  C  for  10  min.  Supernatant  was  collected  and 
stored  at  -20'  C  or  used  immediately. 
2.25.1  SDS-PAGE  and  electrobloting 
SDS-electrophoresis  was  carried  out  as  described  earlier.  On  completion,  proteins 
were  blotted  to  nitrocellulose  membrane  following  the  standard  protocol  for  Western 
blotting  described  earlier.  The  membrane  was  then  blocked,  probed  with  appropriate 
reagents  and  developed  using  4-chloronaphthol  substrate.  The  reaction  was  stopped  by 
washing  the  membrane  with  distilled  water. 
For  enhanced  sensitivity,  blots  were  also  developed  using  ECL  substrate  (Pierce 
Biotechnology,  USA).  Briefly,  working  solutions  of  the  substrates  were  prepared 
according  to  the  manufacturers'  instructions  and  added  to  the  membranes  for  1  minute.  The 
membranes  were  removed  from  the  substrates  and  placed  between  plastic  sheets.  Each 
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membrane  was  exposed  to  CL-XPosure  film  for  20  seconds.  The  CL-Xposure  film  was 
developed  with  M35-XO  mart  processor. 
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3  Results 
3.1  Confirmation  of  sequences  encoding  Toxin  A  C-terminal 
binding  domain 
The  presence  of  the  coding  sequence  for  the  C-terminal  domain  of  Toxin  A  in 
pET767  was  assessed  using  plasmid  DNA  sequencing  (Figure  3.1)  and  restriction  analysis 
of  the  extracted  plasmid.  The  insert  encoded  a  reading  frame  for  320  an-ýno  acids  from 
Toxin  A,  preceeded  by  a  repeat  of  6  histidine  residues.  The  Toxin  A  sequence  carried  14  of 
the  peptide  repeat  sequences  prominent  in  the  carboxy-terminal  domain  of  the  toxin.  This 
includes  regions  recently  analysed  at  the  structural  level  by  Ho  and  collegues  (Ho  et  al., 
2005).  In  this  study,  the  folding  of  peptide  sequence  into  short  repeats  (SRs)  and  long 
repeats  (LRs)  was  characterized.  Locations  of  SRs  and  LRs  sequences  are  shown  with 
colour  codes  in  Figure  3.1.  The  SRs  and  LRs  of  Toxin  A  have  been  shown  to  form 
interactions  with  the  carbohydrate  receptor  on  target  cells  (Greco  et  al.,  2006),  explaining 
the  receptor  binding  activity  of  this  part  of  the  toxin. 
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3.2  Purification  of  the  protein  by  affinity  chromatography 
The  C-terminal  domain  of  Toxin  A  was  expressed  as  histidine  tagged  fusion  protein 
and  immobilized  on  a  nickel-chelation  column.  Acid  elusion  was  used  to  recover  five 
fractions  that  were  collected  into  2x  PBS.  Fractions  were  then  immediately  exchanged 
with  cold  PBS  using  centrifugal  filter  units  and  stored  at  -20*  C  until  further  analysis.  In 
initial  experiments,  protein  was  eluted  from  the  column  using  200  MM  imidazole  buffer. 
Problems  of  protein  precipitation  became  evident  on  prolonged  storage  that  were  overcome 
by  acid  elution.  The  concentration  of  protein  in  the  pooled  acid  elutions  was  400  Ag/ml. 
3.3  SDS-electrophoresis 
The  C-terminal  domain  of  Toxin  A  representing  14  repetitive  sequences  of  the 
binding  domain  was  successfully  expressed  and  purified  in  recombinant  form.  The 
bacterial  extract  (Figure  3.2;  lane  1)  showed  several  dominant  proteins  of  10-220  kDa.  The 
expected  molecular  weight  of  the  recombinant  protein  was  37  kDa.  The  extract  was 
exchanged  into  column  binding  buffer,  filtered  through  a  membrane  of  0.2  Jim  and  loaded 
to  the  affinity  column.  Washing  with  binding  buffer  containing  20  mM  imidazole  removed 
many  of  the  proteins  seen  in  the  bacterial  extract  (lane  3),  and  further  washing  with 
unmodified  binding  buffer  (not  shown)  further  depleted  the  column.  The  column  was  then 
washed  with  buffer  of  pH  6.0  and  then  pH  5.0  (lane  4  and  5).  Rather  few  proteins  eluted 
from  the  column  at  pH  6.0  (lane  4),  but  reduction  to  pH  5.0  removed  several  species,  the 
most  prominent  being  of  45  kDa  molecular  weight.  Having  done  this,  the  pH  was  then 
lowered  to  pH  3.4.  This  eluted  a  protein  of  the  expected  size  for  recombinant  Toxin  A 
(lane  6).  No  other  protein  contaminants  were  present  (Figure  3.2;  lane  6). 
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Figure  3.2:  SDS-PAGE  analysis  of  recombinant  Toxin  A  by  affinity 
chromatography 
Lysate  from  induced  bacterial  culture  was  exchanged  into  binding  buffer  (lane  1) 
and  applied  to  the  column.  Flow  through  (lane  2)  was  discarded.  Washings  with 
imidazole  buffer  (lane  3)  and  buffer  of  pH  6.0  (lane  4)  and  pH  5.0  (lane  5)  were 
discarded.  Protein  bound  to  the  column  was  eluted  with  buffer  of  pH  3.4  (lane  6). 
Lane  M  shows  the  migration  of  protein  molecular  weight  marker/size  as  indicated. 
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00  3.4  Electroblotting  ana  ysis 
The  identity  of  protein  recovered  by  affinity  chromatography  was  determined  by 
Western  blotting.  These  experiments  confirmed  that  the  commercial  polyclonal  anti-Toxin 
A  raised  against  native  toxin  would  recognise  recombinant  Toxin  A  after  its  preparation 
for  SDS-PAGE  with  boiling  and  reduction.  Proteins  were  separated  by  SDS-PAGE  (Figure 
3.3)  and  transferred  to  a  nitrocellulose  membrane  for  probing  with  polyclonal  anti-Toxin  A 
(Figure  3.3).  This  showed  that  the  bacterial  extract  contained  a  prominent  band  of  37  kDa 
molecular  weight,  consistent  with  the  predicted  size  of  recombinant  Toxin  A.  Other 
proteins  of  lower  molecular  weight  also  reacted  with  the  antibody.  The  flow-through 
fraction  (lane  2)  showed  that  some  protein  of  a  size  37  kDa,  consistent  with  that  predicted 
for  the  recombinant  C-terminal  domain  failed  to  bind  to  the  column.  A  similar  range  of 
proteins  were  also  eluted  when  the  column  was  washed  with  20  mM  imidazole  (lane  3). 
Washing  with  a  buffer  of  pH  6.0  did  not  appear  to  release  protein  reactive  with  the 
antiserum  from  the  column  (lane  4).  Elution  started  when  the  column  was  washed  with 
buffer  of  pH  5.0  (lane  5)  and  high  yields  of  the  recombinant  Toxin  A  was  achieved  by 
further  reduction  of  the  pH  to  3.4  (lane  6) 
3.5  Recognition  in  ELISA 
ELISA  was  used  to  assess  recognition  of  undenatured  purified  recombinant  Toxin  A 
by  the  polyclonal  serum  raised  against  native  Toxin  A  (Figure  3.4).  The  concentration  of 
recombinant  protein  in  initial  wells  was  225  Ag/ml.  The  protein  was  serially  diluted  and 
remained  detectable  to  concentrations  less  than  480  ng/ml.  The  specificity  of  the  ELISA 
was  confirmed  by  the  negative  controls  (wells  11  and  12)  which  were  coated  with  BSA 
instead  of  recombinant  protein. 
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Figure  3.3:  Western  blotting  analysis  of  recombinant  Toxin  A  purified  by 
affinity  chromatography 
Fractions  from  the  affinity  column  were  prepared  as  in  Figure  3.2.  After  separation 
by  SDS-PAGE,  proteins  were  blotted  to  nitrocellulose  and probed  with  a  goat  anti- 
Toxin  A  antiserum.  Fractions:  bacterial  extract  (lane  1),  flow-through  (lane  2), 
washing  with  20  mM  imidazole  (lane  3),  washing  with  buffer  of  pH  6.0  (lane  4), 
washing  with  buffer  of  pH  5.0  (lane  5),  recombinant  protein  eluted  with  buffer  of  pH 
3.4  (lane  6).  Lane  M  shows  the  migration  of  protein  molecular  weight  marker/size 
as  indicated. 
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Figure  3.4:  Detection  of  recombinant  Toxin  A  in  ELISA. 
Purified  recombinant  Toxin  A  was  serially  diluted  and  coated  to  an  ELISA  plate 
and  then  probed  with  goat  anti-Toxin  A  antibody  and  HRP-conjugated  antibodies. 
Negative  control  wells  were  coated  with  3%  BSA  in  PBS.  The  coating 
concentrations  of  toxin  are  shown  on  the  x-axis.  ELISA  signal  at  490  nm  is  shown 
on  the  y-axis. Chapter  3,  Results 
3.6  Binding  of  native  and  recombinant  Toxin  A  to  cellular 
receptors 
The  binding  activity  of  native  and  recombinant  Toxin  A  was  tested  using 
paraformaldehyde-fixed  F9  cells  immobilized  on  a  slide  (Figure  3.5).  Strong 
immunofluorescence  signal  was  observed  out-lining  the  cell  membrane  reflecting  the 
degree  of  binding  activity  of  Toxin  A  to  its  receptor.  When  recombinant  Toxin  A  was  used 
(Figure  3.5;  B),  a  positive  immunofluorescence  reaction  was  seen  out-lining  the  cell 
membrane  of  F9  cell  line  but  of  lower  intensity.  This  batch  of  recombinant  protein  was 
purified  only  early  in  the  project  using  imidazole  elution  from  an  affinity  column. 
3.7  Haemagglutination  activity  of  recombinant  Toxin  A 
Native  Toxin  A  is  known  to  possess  the  ability  to  agglutinate  rabbit  erythrocytes, 
through  interaction  with  surface  carbohydrates  moieties.  The  recombinant  Toxin  A  was 
tested  for  this  property  (Figure  3.6).  Assays  with  rabbit  red  blood  cells  showed  that 
haernagglutinating  activity  was  detectable  and  that  after  serial  dilutions,  this  persisted  to  a 
concentration  of  32  jig/ml  and  0.2  jig/ml  for  recombinant  and  native  Toxin  A  respectively. 
These  finding  are  consistant  with  previous  studies  (Ward  et  al.,  1999a). 
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Figure  3.5:  Immunofluorescence  assay  to  detect  the  binding  of  recombinant 
and  native  Toxin  A  to  receptors  on  F9  cells 
F9  cells  were  grown,  fixed  on  8-well  chamber  slides  and  incubated  with  native  (A) 
or  recombinant  Toxin  A  (B).  After  washing,  the  cells  were  incubated  with 
polyclonal  anti  Toxin  A  antibody  and  FITC-labeled  anti-goat  antibody.  In  the 
negative  control  (C),  cells  were  incubated  with  FITC-labeled  anti-goat  antibody. 
Cells  were  then  examined  under  immunofluorescence  microscope. 
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Figure  3.6: Haemaggluti  nation  activity  of  recombinant  Toxin  A 
Rabbit  red  blood  cells  were  added  to  two-fold  serially  diluted  recombinant  Toxin  A 
in  a  microtiter  plate  and  incubated  at  40  C.  Haemagglutination  became  evident 
after  2  hrs.  PBS  was  used  as  a  negative  control  (N).  The  titer  was  defined  as  the 
final  dilution  in  which  haemagglutination  was  evident.  The  initial  concentration  of 
recombinant  Toxin  A  was  256  pg  /ml  (well  1).  For  native  Toxin  A,  the  starting 
concentration  was  51.2  jig/ml  (well  1). 
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00*  3.8  Sensitivity  of  F9  and  Vero  cell  lines  to  native  Toxin  A 
To  assess  the  ability  of  the  native  Toxin  A  to  bind  to  its  receptor  and  exerts  its  effect, 
tests  were  carried  out  with  the  murine  cell  line  F9  and  Vero  cells.  The  F9  cell  line  is 
thought  to  carry  a  high  density  of  receptors  for  Toxin  A  (Tucker  et  al.,  1990).  Cells  were 
sub-cultured  in  100  jil  volumes  in  flat  bottom  cell  culture  plates  at  5x  103  cells  per  well 
and  allowed  to  recover  for  18  hr.  Native  Toxin  A  was  then  diluted  in  ten-fold  series  and 
added  to  each  well  starting  at  100  ng/ml  and  continuing  down  to  0.1  ng/ml.  The  plate  was 
then  incubated  for  5  hrs  at  37'  C.  Sensitivity  of  F9  and  Vero  cells  to  native  Toxin  A  was 
monitored.  F9  and  Vero  cells  showed  a  high  sensitivity  to  the  toxin  (0.1  ng/ml  for  F9  and  1 
ng/ml  for  Vero  cells).  For  F9  cells,  some  rounding  could  be  observed  at  the  lowest 
concentration  tested  whereas  for  Vero  cells  1  ng/ml  was  required  to  elicit  a  response.  All 
cells  were  observed  rounding  at  10  ng/mI  for  both  F9  and  Vero  cells  (Figure  3.7,3.8  and 
3.10).  However,  this  cytopathic  reaction  was  achieved  after  4  hrs  for  F9  cells  and  5  hrs  for 
Vero  cells.  At  low  toxin  concentrations  (0.1  ng/ml)  Vero  cells  did  not  show  any  reactivity 
after  5  hrs  of  incubation  whereas  some  F9  cells  observed  undergoing  a  rounding  response. 
The  response  of  F9  cells  to  toxin  was  also  faster  than  for  Vero  cells.  For  example,  when 
cells  were  challenged  at  the  highest  toxin  dose,  60  %  of  F9  cells  had  undergone  rounding 
within  1  hr  of  addition  (Figure  3.8).  By  comparison,  Vero  cells  had  failed  to  respond  to 
their  dose  of  toxin  after  I  hr  (Figure  3.9).  After  2  hrs,  about  70  %  had  rounded  in  response 
to  Toxin  A. 
3.9  Kinetics  of  action  of  native  Toxin  A  on  F9  and  Vero  cell  lines 
To  assess  the  time  required  for  native  Toxin  A  to  bind  and  enter  F9  and  Vero  cells,  a 
time  course  experiment  was  set  up.  Cells  were  sub-cultured  as  described  earlier.  Eight 
wells  of  each  cell  line  were  inoculated  with  Toxin  A  at  100  ng/ml  and  incubated  at  37*  C. 
Two  wells  from  each  cell  line  were  washed  with  PBS  after  4  min,  8  min,  16  min  and  32 
113 Chapter  3,  Results 
min.  After  replacement  with  complete  medium,  the  plate  was  then  incubated  at  371  C  and 
observations  were  taken  every  10  min  for  3  hrs  (Figure  3.10) 
Results  showed  that  F9  cells  responded  to  Toxin  A  after  a  short  exposure  whereas 
longer  contact  with  Vero  cells  was  required  to  elicit  an  equivalent  response.  F9  cells  also 
responded  to  toxin  more  quickly  than  Vero  cells  after  identical  exposure.  For  example,  a2 
min  exposure  of  F9  cells  to  toxin  was  sufficient  to  elicit  50  %  rounding  with  2  hrs.  In 
contrast,  toxin  had  to  be  in  contact  with  Vero  cells  for  16  hrs  to  achieve  this  biological 
response  within  a2  hrs  period.  Similarly,  F9  cells  showed  100  %  rounding  with  16  and  32 
min  exposures  and  reached  this  response  after  160  and  100  min  respectively.  In  contrast, 
Vero  cells  showed  100  %  rounding  up  after  only  32  min  of  exposure  to  toxin  and  180  min 
of  incubation  was  required  for  complete  rounding  (Figure  3.10). 
3.10  Inhibition  of  the  action  of  native  Toxin  A 
Experiments  were  carried  out  to  assess  the  ability  of  polyclonal  anti-Toxin  A  and 
recombinant  C-terminal  domain  of  Toxin  A  to  block  the  activity  of  native  toxin. 
Recombinant  Toxin  A  or  anti-Toxin  A  polyclonal  antibody  were  incubated  with  Toxin  A 
in  PBS  in  a  microtiter  plate.  After  incubation,  the  mixtures  were  added  to  F9  cells  culture 
plate  as  described  earlier.  The  response  of  cells  to  the  toxin  was  then  observed. 
Results  showed  that  polyclonal  goat  anti-Toxin  A  was  a  very  effective  inhibitor  of 
the  toxin.  When  diluted  to  1:  200,  and  mixed  with  toxin  at  a  final  dose  of  10  ng/mI,  fewer 
than  7%  of  cells  underwent  a  rounding  response  over  a2  hr  period  (Figure  3.11).  This  was 
in  marked  contrast  to  the  recombinant  C-terminal  domain.  Mixing  this  with  active  toxin 
did  not  block  the  response  of  F9  cells  although  the  recombinant  protein  was  present  in 
approximately  1000-fold  more  excess. 
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Figure  3.7:  Sensitivity  of  F9  cell  lines  to  native  Toxin  A 
Native  Toxin  A  was  prepared  in  a  series  of  10-fold  dilutions  and  added  to  growing 
F9  cells  in  culture.  The  plate  was  then  incubated  for  5  hrs  at  37"  C.  Sensitivity  of 
F9  cells  to  native  Toxin  A  was  monitored  by  examining  the  cells  for  evidence  of 
loss  of  their  normal  shape  and  change  to  a  rounded  appearance.  100  %  cell 
rounding  was  observed  with  toxin  doses  as  low  as  10  ng/ml  (A).  PBS  was  used  as 
negative  control  (B). 
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Figure  3.8:  Sensitivity  of  F9  cell  lines  to  native  Toxin  A 
Native  Toxin  A  was  serially  diluted  and  added  to  growing  F9  cells.  The  plate  was 
then  incubated  for  5  hrs  at  370  C.  The  reaction  of  F9  cells  to  Toxin  A  was 
monitored.  Cell  rounding  being  taken  as  a  sign  of  toxin  action.  Fields  were 
examined  and  the  mean  percentage  of  rounded  cells  is  shown  in  the  figure.  Error 
bars  show  Standard  Deviation  Error  STDE.  PBS  was  used  as  negative  control, 
and  no  cell  rounding  was  observed  during  the  experiment  (data  not  shown).  Key 
shows  the  amout  of  toxin  per  well  added  to  the  cultures 
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Figure  3.9:  Sensitivity  of  Vero  cell  lines  to  native  Toxin  A 
Native  Toxin  A  was  serially  diluted  and  added  to  growing  Vero  cells.  The  plate  was 
then  incubated  for  5  hrs  at  37*  C.  The  reaction  of  Vero  cells  to  Toxin  A  was 
monitored.  Cell  rounding  being  taken  as  a  sign  of  toxin  action.  Fields  were 
examined  and  the  mean  percentage  of  rounded  cells  is  shown  in  the  figure.  Error 
bars  show  Standard  Deviation  Error  STDE.  PBS  was  used  as  negative  control, 
and  no  cell  rounding  was  observed  during  the  experiment  (data  not  shown).  Key 
shows  the  amout  of  toxin  per  well  added  to  the  cultures 
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Effect  of  exposure  time  on  the  action  of  Toxin  A  on  F9  &  Vero  cells 
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Figure  3.10:  Effective  time  of  exposure  on  the  action  of  native  Toxin  A  on  F9 
and  Vero  cells. 
Native  Toxin  A  (100  ng/ml)  was  added  to  wells  of  growing  F9  or  Vero  cells.  The 
plate  was  incubated  at  37*  C.  Two  wells  from  each  cell  line  were  washed  with  PBS 
after  4  min,  8  min,  16  min  and  32  min  exposure  to  remove  toxin  that  had  failed  to 
bind  or  enter  the  cells.  Cells  were  inspected  at  intervals  thereafter  and  the  mean 
percentage  of  rounded  cells  was  calculated.  In  the  key,  the  letter  indicates  the  cell 
line  tested  and  the  number  to  exposure  time  to  toxin. 
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3.11  Inhibition  of  native  Toxin  A  with  polyclonal  Fab  fragments 
To  assess  the  ability  of  Fab  fragments  from  an  anti-Toxin  A  antibody  to  block  the 
activity  of  native  Toxin  A,  a  polyclonal  IgG  antibody  was  digested  with  papain.  The  Fab 
preparation  was  then  used  in  neutralization  experiments  in  vitro. 
3.11.1  Digestion  of  polyclonal  anti-Toxin  A  antibody  with  papain 
3.11.1.1  SDS-PAGE  gel  electrophoresis 
Goat  antiserum  containing  anti-Toxin  A  IgG  was  cleaved  using  papain  and 
analysed  on  non-reducing  SDS  gel  in  order  to  assess  the  efficiency  of  digestion.  The 
results  are  shown  in  Figure  3.12.  Samples  of  untreated  antibody  (lane  2)  showed  a  range  of 
high  molecular  weight  bands,  probably  representing  intact  Ig,  albumin,  and  other  lower 
molecular  weight  proteins.  In  contrast,  papain-treated  Ig  sample  (lane  1)  contained  only 
bands  of  lower  molecular  weight. 
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Figure  3.11:  Inhibition  of  Toxin  A  by  polyclonal  anti-Toxin  A  and  rTA 
In  a  sterile  microtitre  plate,  native  Toxin  A  10  ng/ml  was  mixed  with  50  pi  of  (1:  200) 
polyclonal  anti-Toxin  A  or  50  pI  of  200  pg/ml  recombinant  C-terminal  domain  (rTA) 
in  PBS.  After  incubation  for  30  min  at  room  temperature,  the  mixture  was 
transferred  to  a  cell  culture  plate  containing  growing  F9  cells  in  150  pi  of  complete 
medium.  The  cells  were  incubated  at  370  C  in  a  5%  C02  atmosphere  for  2  hrs. 
The  plate  was  observed  every  25  min  and  the  percentage  of  cells  undergoing  a 
rounding  response  was  calculated. 
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Figure  3.12:  Non  reducing  SDS-PAGE  analysis  of  papain  digested  anti-Toxin 
A  antiserum. 
Goat  anti-Toxin  A  antiserum  was  digested  with  papain  for  7  hrs  at  309  C  in  a  water 
bath  and  a  sample  was  loaded  to  the  gel  (lane  1).  Undigested  goat  anti-Toxin  A 
was  also  analysed  (lane  2).  An  equal  volume  of  each  sample  was  run  on  12  % 
plyacrylamide  gel  and  stained  with  Commassie  Brilliant  Blue.  The  migration  of 
Rainbow  protein  molecular  weight  markers  is  shown  in  lane  M. 
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3.11.2  Electroblotting 
The  identity  of  Fab  fragments  was  determined  by  Western  blotting.  A  non-reducing 
SDS  gel  was  prepared  as  described  earlier  and  proteins  were  transferred  to  a  nitrocellulose 
membrane.  The  blot  (Figure  3.13)  was  then  probed  with  anti-goat  IoG  Fab  frauments 
C,  4:  1 
antiserum  raised  in  rabbit  (Bethyl  Laboratories,  Inc.  USA).  The  blot  showed  an  intensely 
staining  high  molecular  weight  band  in  untreated  samples  (lane  3).  This  was  likely  to  be 
intact  IgG.  After  digestion  with  papain  for  4  hours  (lane  1),  traces  ofthis  material  were  still 
detectable.  In  contrast,  digestion  with  papain  for  7  hours  removed  all  traces  (lane  2), 
leaving  only  bands  of  lower  molecular  weight.  Other  proteins  of'  lower  molecular  weioht  Lý 
also  reacted  with  the  antibody. 
3.11.3  Detection  of  native  Toxin  A  by  Fab  fragment  in  EIASA 
ELISA  was  used  to  assess  if  the  recognition  of  native  Toxin  A  by  polyclonal 
antibody  was  retained  after  conversion  to  Fab  fragments.  Wells  were  coated  with  100  ttl  of' 
20  [tg/ml  native  Toxin  A  in  PBS.  Ilapain  digested  antiseruill  was  added  and  hinding  was 
detected  as  described  before.  Untreated  antiserum  was  tested  for  comparison.  The  data  are 
shown  in  Figure  3.14,  This  experiment  showed  that  both 
Lgoat  anti-Toxin  A  polyclonal 
antibody  and  its  Fab  fi-agments  were  reactive  with  the  native  Toxin  A.  I  lowever,  slightly 
weaker  signal  was  observed  with  the  preparation  offab  fragments. 
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Figure  3.13:  Western  blotting  analysis  of  papain  digested  anti  Toxin  A 
antiserum 
Proteins  from  a  non-reducing  SIDS  gel  were  transferred  to  nitrocellulose 
membrane  by  Western  blotting.  The  membrane  was  then  probed  with  anti-Fab 
rabbit  antiserum.  Goat  anti-Toxin  A  antiserum  was  digested  with  papain  for  4  hrs 
(lane  1)  or  7  hrs  (lane  2)  at  309  C.  Undigested  goat  anti-Toxin  A  antiserurn  was 
also  analysed  (lane  3).  Rainbow  protein  molecular  weight  markers  are  shown  in 
lane  M. 
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Figure  3.14:  Reaction  of  intact  IgG  and  Fab  fragments  with  native  Toxin  A  in 
ELISA 
Native  Toxin  A  was  coated  to  an  ELISA  plate  and  probed  with  intact  and  papain 
digested  anti-Toxin  A  antiserum.  Binding  was  detected  with  an  HRP-labeled 
antibody.  Negative  control  wells  were  coated  with  2%  MPBS.  Samples  were 
tested  in  duplicate  and  the  mean  value  is  presented. 
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3.11.4  Inhibition  of  native  Toxin  A  with  polyclonal  Fab  fragments 
in  vitro 
To  assess  the  ability  of  polyclonal  anti-Toxin  A  Fab  fragments  to  inhibit  the 
activity  of  native  Toxin  A,  F9  cells  were  grown  as  described  earlier  and  challenged  with 
toxin-antibody  mixtures.  To  ensure  thorough  control  of  the  experiment,  toxin  was 
incubated  with  polyclonal  anti-Toxin  A,  its  Fab  derivatives  and  normal  goat  serum.  To 
check  for  effects  arising  from  carry-over  of  papain  or  its  inhibitor  E64,  a  series  of 
additional  controls  were  included.  Only  two  reactions  showed  inhibition  of  the  toxin- 
mediated  cell  rounding  and  the  experiment  showed  that  anti-Toxin  A  Fab  fragments  were 
as  efficient  as  the  intact  polyclonal  antibody  in  inhibiting  Toxin  A  (Figure  3.15). 
3.12  Tomlinson  scFv  library 
3.12.1  Growing  the  library 
Library  I  in  E.  coli  TGI  was  grown  according  to  the  protocol  provided  with  the 
materials  and  infected  with  KM13  helper  phage.  The  resulting  phage  particles  carrying 
scFv  were  precipitated  by  PEG/NaCl,  diluted  and  used  to  infect  exponentially  growing 
TG1.  After  plating  to  selective  medium,  the  colonies  were  counted  and  the  titre  of  the 
phage  library  was  estimated  to  be  5x  1013  cfu  per  ml. 
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Figure  3.15:  Inhibition  of  Toxin  A  by  papain  digested  polyclonal  anti-Toxin  A 
antiserum 
In  a  microtitre  plate,  10  ng/ml  of  native  Toxin  A  was  mixed  with  50  pl  of  (1:  50)  anti- 
Toxin  A  antiserum,  the  same  value  of  the  Fab  fragments,  components  of  the  same 
proteolysis  reaction  or  normal  goat  serum.  The  plate  was  then  incubated  for  30 
min  at  room  temperature.  The  mixtures  were  then  transferred  to  a  cell  culture  plate 
containing  grovAng  F9  cells  in  150  pl  complete  medium.  The  cells  were  incubated 
at  370  C  for  4  hrs.  The  plate  was  observed  every  25  min  and  the  proportion  of  cells 
that  had  undergone  rounding  was  recorded. 
126 Chapter  3,  Results 
3.12.2  Detection  of  anti-BSA  and  anti-ubiquitin  scFvs  by  Western 
blot 
The  detection  of  scFv  on  a  nitrocellulose  membrane  following  Western  blotting  had 
been  tested  by  others  in  the  laboratory  (Golchin,  2004)  using  anti-c-myc  antibody,  Protein 
L  and  Protein  A.  Anti-c-myc  antibody  was  found  to  be  superior  for  detection.  In  this 
study,  culture  supernatants  containing  anti-BSA  and  anti-ubiquitin  antibodies  were 
concentrated  20  times,  exchanged  into  PBS  and  analysed  by  SDS-PAGE.  Bacterial 
proteins  of  a  range  of  molecular  weights  were  detected  including  a  band  of  approximately 
29  kDa  (data  not  shown). 
3.12.3  Phage  display  against  the  C-terminal  domain  of  Toxin  A 
Phage  antibodies  against  recombinant  Toxin  A  were  isolated  in  3  successive  rounds 
of  selection.  A  simple  selection  strategy  was  used  in  which  immunotubes  were  coated  with 
recombinant  Toxin  A.  To  minimize  the  chance  of  isolation  of  nonspecific  antibodies  the 
concentration  target  was  decreased  progressively  in  the  second  and  third  rounds  of 
selection  and  an  absorption  step  was  included  before  each  selection  round  by  incubating 
the  input  phage  with  the  blocking  buffer  (2%  MPBS).  For  each  round  of  selection,  the 
input  and  output  phage  titers  were  measured  and  used  to  calculate  the  fraction  of  phage 
recovered  at  each  stage.  This  is  shown  in  Table  3.1. 
Input  and  output  of  phage  were  calculated  by  titration.  The  %  recovery  shows  the  number 
of  phage  recovered  from  a  selection  step  as  a  proportion  of  the  input. 
At  round  1,  a  significant  number  of  phage  were  recovered  from  the  Toxin  A-coated 
immunotube,  rather  more  than  is  typical  given  the  wide  diversity  of  the  Tomlinson  library 
(estimated  to  be  over  1x  108  different  specificities).  Phage  eluted  from  the  tube  with 
trypsin  were  amplified  to  form  the  input  for  round  2.  Compared  to  initial  selection, 
approximately  equivalent  number  of  phage  were  used  for  selection,  but  recovery  increased 
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by  about  1000-fold.  At  round  3,  a  very  high  number  of  phage  were  added  to  the  selection. 
In  absolute  terms,  the  recovery  at  round  3  was  roughly  equivalent  to  that  from  round  2  but 
because  of  the  size  of  the  input,  the  percentage  recovery  appeared  to  fall  to  a  value  similar 
to  that  for  round  1.  To  test  whether  Toxin  A-specific  scFvs  were  recovered  from  the 
selection,  ELISA  was  carried  out  initially  on  the  mixed  population  of  virus,  then  on 
individual  clones. 
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Table  3.1:  Recoveries  of  phage  during  selection 
Tomlinson  Library  I 
Selection  Input  Output  %  Recovery' 
Round  1  1.36  x  10"  2.28  x  10"  1.67  x 
10-4 
Round  2  3.4  x  10"  4.44  x  10"  1.3  x  10"' 
Round  3  2x 
1014  2.16  x  10' 
1.08  X  10-4 
a  Input  and  output  phage  titers  were  determined  by  transduction  of  E.  Coli  to 
ampicillin  resistance  using  serial  dilutions  of  sample. 
b  Percent  recovery  was  determined  by  division  of  output  phage  titre  by  input  titer 
and  multiplication  by  100. 
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3.12.4  Screening  polyclonal  phage  by  ELISA 
Phage  antibody  particles  recovered  from  each  round  of  selection  were  tested 
against  the  recombinant  C-tenrninal  domain  of  Toxin  A  in  ELISA.  The  initial  reaction  of 
the  library  stock  to  Toxin  A  was  low,  and  signal  of  equal  strength  was  detected  against  a 
control  target,  BSA.  Phage  recovered  from  a  single  round  of  selection  showed  a  higher 
response  in  ELISA,  and  this  reaction  was  noticeably  higher  than  against  BSA.  In  parallel 
with  the  viral  recoveries  shown  in  Figure  3.16,  a  very  large  jump  in  signal  strength  resulted 
when  phage  from  round  2  were  tested,  and  the  signal  was  sustained  for  virus  from  round  3 
in  spite  of  the  apparent  fall  in  percent  recovery  at  the  end  of  selection.  Reactions  against 
BSA  remained  steady  and  low  for  phage  recovered  throughout  the  screening. 
3.12.5  Screening  monoclonal  phage  by  ELISA 
TG1  colonies  were  picked  up  at  random  from  titration  plates  from  rounds  1,2  and  3 
and  were  inoculated  to  a  96-cell  culture  plate.  Colonies  were  grown  and  infected  with 
helper  phage  to  prepare  single  phage  stocks  carrying  scFv  at  the  viral  surface.  Phage  were 
then  added  to  an  ELISA  plate  that  had  been  coated  with  recombinant  Toxin  A  and  blocked 
with  3%  BSA  in  PBS.  The  binding  of  phage  was  then  detected  with  HRP-labeled 
antibody.  Surprisingly,  31  %  of  phage  antibodies  from  the  unselected  library  showed  some 
reaction  with  the  antigen  coated  surface  (Figure  3.17).  After  a  single  round  of  panning,  this 
rose  to  37  %.  A  sharp  increase  occurred  after  round  2  with  91  %  and  of  phage  binding  to 
Toxin  A.  This  rise  was  sustained  after  round  3  (96  %)  in  spite  of  the  lower  percentage 
recovery  of  phage  at  this  stage  in  the  process  (Table  3.1).  Signal  strength  in  the  ELISA  was 
variable  (Figure  3.17)  but  there  was  a  trend  towards  stronger  reaction  with  Toxin  A  at 
rounds  2  and  3.  This  and  the  leap  in  frequency  of  reaction  suggested  that  enrichment  for 
Toxin  A-specific  antibodies  was  taking  place. 
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Figure  3.16:  Polyclonal  phage  ELISA  of  Tomlinson  library  I  during  panning 
against  recombinant  Toxin  A 
Phage  from  the  original  library  and  recovered  at  each  round  of  selection  were 
tested  in  ELISA  against  purified  recombinant  Toxin  A  and  2%  BSA.  Recognition 
was  detected  using  monoclonal  anti-M13-HRP  conjugate.  Phage  samples  were 
tested  against  each  antigen  in  duplicate  and  the  mean  value  is  presented. 
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Figure  3.17:  Monoclonal  phage  ELISA  against  recombinant  Toxin  A 
Individual  phage  clones  from  the  original  library  and  each  round  of  selection  were 
tested  in  ELISA  against  purified  recombinant  Toxin  A.  Recognition  was  detected 
using  an  anti-Ml  3-HRP  conjugate. 
Phage  were  applied  as  follow: 
Section  L  16  clones  picked  at  random  from  unselected  library 
Section  Rl:  16  clones  picked  at  random  after  round  1  of  selection 
Section  R2:  32  clones  picked  at  random  after  round  2  of  selection 
Section  R3:  32  clones  picked  at  random  after  round  3  of  selection 
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3.12.6  Screening  monoclonal  soluble  scFv  antibodies  by  ELISA 
E  coli  BB2151  were  grown  to  an  OD  600  nm  of  0.4  and  infected  with  phage  eluted 
from  each  round  of  selection.  Colonies  were  selected  on  TYE  plates  containing  ampicillin, 
single  colonies  were  picked  from  unselected  library  and  rounds  1,2  and  3  grown,  and  the 
production  of  soluble  scFv  was  induced  with  IPTG.  Samples  of  individual  culture 
supernatant,  were  used  for  monoclonal  ELISA.  The  ELISA  plate  was  coated  with  purified 
recombinant  Toxin  A  at  20  pg/ml.  and  blocked  with  3%  BSA  in  PBS.  Each  well  received 
100  jil  of  monoclonal  scFv  antibody  in  blocking  buffer.  Binding  of  the  recombinant 
antibody  was  detected  with  rabbit  anti-c-myc  antibody  and  HRP-labeled  conjugate. 
Overall,  reactions  were  detected  at  lower  frequency  than  in  the  previous  assay.  In  contrast 
to  monoclonal  phage  ELISA,  soluble  scFv  prepared  from  the  unselected  library  failed  to 
show  any  reaction  with  Toxin  A  (data  not  shown).  Similarly,  clones  isolated  after  round  I 
did  not  produce  scFv  that  bound  to  Toxin  A  (Figure  3.18).  Some  clones  from  round  2  of 
selection  produced  strong  signals  in  the  assay.  Overall  37  %  were  judged  positive, 
indicating  the  successful  enrichment  of  scFv  at  this  round.  Given  the  result  in  phage 
ELISA,  it  was  surprising  to  find  that  the  number  of  clones  expressing  reactive  scFv  in 
round  3  were  very  few. 
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Figure  3.18:  Monoclonal  scFv  ELISA  against  recombinant  Toxin  A 
scFv  prepared  from  colonies  from  the  original  library  (data  not  shown)  and  each 
round  of  selection  were  tested  in  ELISA  against  purified  recombinant  Toxin  A. 
scFv  were  detected  by  an  anti-c-myc  antibody  and  HRP-labeled  antibody 
conjugate. 
scFv  were  applied  as  following: 
Section  Rl:  24  clones  picked  at  random  after  round  1  of  selection 
Section  R2:  32  clones  picked  at  random  after  round  2  of  selection 
Section  RI  40  clones  picked  at  random  after  round  3  of  selection 
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3.13  Genetic  characterization  of  selected  scFvs 
During  library  construction,  some  clones  arise  that  lack  VH  or  VL  components  of  the 
scFv  reading  frame.  Bacteria  that  carry  these  short  inserts  can  grow  more  quickly  than 
these  with  full  scFvs  and  if  the  antibodies  possess  affinity  for  the  target,  they  can  emerge 
from  selection.  Therefore,  genetic  characterization  was  used  to  verify  the  size  and  integrity 
of  the  inserts. 
Twenty  selected  clones  of  E.  coli  BB2151  were  picked  from  round  2  and  3  based 
upon  their  signal  in  monoclonal  ELISA  against  recombinant  Toxin  A.  The  20  clones  were 
grown,  plasmid  DNA  was  prepared,  and  this  was  digested  with  restriction  enzymes  NcoI 
and  NotI,  enzymes  that  excise  the  full  scFv  sequence  from  pIT2  (Figure  3.21).  Reaction 
mixtures  were  electrophoresed  on  an  agarose  gel.  Figure  3.19  revealed  that  19  out  of  21 
(90.4  %)  clones  contained  the  full-length  scFv  genes.  Two  clones  contained  smaller  scFv 
genes.  This  can  be  seen  in  lanes  I  and  10  of  the  lower  panel.  A  further  analysis  is  presented 
in  Figure  3.20,  confirming  the  presence  of  full-length  inserts  in  scFvs  against  Toxin  A. 
3.14  Sequence  of  selected  clones 
To  predict  amino  acid  sequence,  diversity  and  integrity  of  seven  selected  clones, 
sequencing  was  performed  as  described  earlier.  The  sequence  results  were  initially  checked 
for  the  presence  of  a  complete  VH-linker-VL  sequence.  This  is  illustrated  for  clones  2D4, 
2D5  and  2E4  in  Figures  3.22  and  3.23.  Since  Tomlinson  library  I  is  based  on  single  human 
VII  and  VL  frameworks,  the  sequences  are  identical  for  the  most  part.  At  construction, 
diversity  was  confined  to  the  heavy  chain  complementarity  determining  regions  CDR2 
(residues  H50,  H52,  H52a,  H53,  H55,  H56,  H58),  and  CDR3  (H95,  H96,  H97,  H98)  for 
the  heavy  chain  component,  and  CDR2  (L50,  L53)  and  CDR3  (L91  L92,  L93,  L94,  L96) 
for  the  light  chain  component.  The  data  indicate  diversity  of  the  selected  clones  in  these 
regions.  The  predicted  amino  acid  sequences  of  the  CDRs  for  more  clones  are  presented  in 
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Table  25.  Two  clones  showed  identical  amino  acid  sequences  in  most  of  CDR2  of  the 
heavy  chain  (B9  and  C5)  (Table  25)  but  carried  quite  different  light  chain  CDRs.  Overall, 
sequencing  showed  a  high  diversity  among  the  selected  clones. 
3.15  Detection  of  native  Toxin  A  by  selected  scFv 
To  assess  the  binding  activity  of  four  of  the  selected  scFv  against  native  Toxin  A, 
native  Toxin  A  was  diluted  across  96-well  ELISA  and  blocked  with  3%  milk  in  PBS. 
Equal  concentrations  of  the  purified  scFvs  were  added  to  each  well  across  the  plate.  scFv 
were  then  detected  with  anti-c-myc  antibody.  Figure  3.25  shows  that  the  scFvs  chosen  for 
analysis  recognized  recombinant  Toxin  A  across  5  serial  dilutions  and  were  therefore  able 
to  recognize  toxin  from  2  jig/well  down  to  62  ng/well.  Beyond  this  lower  limit,  reactivity 
was  indistinguishable  from  background.  Polyclonal  anti-Toxin  A  antibody  was 
substantially  more  sensitive  as  previously  demonstrated.  This  reagent  was  able  to  detect 
coating  concentrations  of  toxin  at  less  than  48  ng/well.  scFv  anti-BSA  antibody  showed 
very  low  reactivity  with  Toxin  A,  confirming  the  specificity  of  the  assay. Chapter  3,  Hesults 
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Figure  3.19:  Restriction  analysis  of  clones  from  Tomlinson  library  I 
Twenty  one  clones  were  chosen  randomly  from  Tomlinson  library  1.  Plasmid  DNA 
from  each  clone  was  digested  with  Nco  I  and  Not  1.  The  expected  size  of  the  small 
fragment  released  is  708  bp. 
M:  1  kb  DNA  Ladder  (Promega,  USA) 
Control  1:  positive  control  anti-BSA  scFv. 
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Figure  3.20:  Restriction  analysis  of  7  anti-Toxin  A  Tomlinson  library  I 
Seven  clones  were  chosen  after  screening  of  the  Tomlinson  library  I  on  the  basis 
of  their  reaction  to  recombinant  Toxin  A  in  ELISA  of  soluble  scFv.  Plasmid  DNA 
from  each  clone  was  digested  with  Ncol  and  NoM.  The  expected  size  of  the  small 
fragment  release  is  708  bp 
M:  1  kb  DNA  Ladder  (Promega,  USA) 
Lane  1:  A  negative  sample  from  the  previous  experiment  was  used  in  this 
experiment  as  a  negative  control. 
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Figure  3.21:  Structure  of  phagemid  pIT2 
gill 
VHinserts  are  cloned  between  Ncol  and  Xhol  sites,  whereas  VL  inserts  lie  between 
Safi  and  Not!  sites.  Digestion  with  Ncol  and  Not!  therefore  excises  the  complete 
scFv  insert. 
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3.16  Haemagglutination  inhibition 
To  assess  if  the  scFvs  chosen  for  analysis  were  able  to  inhibit  the  attachment  of 
native  Toxin  A  to  rabbit  erythrocytes,  evidence  of  inhibition  of  haernagglutination  was 
sought.  scFv  antibodies  at  a  fixed  concentration  were  mixed  with  serial  dilutions  of  toxin 
and  after  incubation,  a2%  suspension  of  rabbit  erythrocytes  was  added.  The  plate  was 
monitored  for  2  hrs.  Surprisingly,  there  was  no  significant  inhibition  of  haernagglutination 
with  any  of  the  selected  scFvs,  nor  was  inhibition  observed  with  the  control  polyclonal 
antibody.  This  assay  was  repeated  in  several  different  ways  (with  different  buffer 
concentrations,  different  buffer  pH,  different  components,  different  incubation 
temperatures  and  different  length  of  incubations)  but  the  original  result  was  observed 
consistently. 
3.17  Haemolysis  assay 
As  an  alternative  to  haernagglutination,  haemolysis  was  adopted  as  a  more  sensitive 
test  for  the  inhibition  of  recombinant  Toxin  A  binding  to  rabbit  erythrocytes.  To  perform 
the  test,  fixed  amounts  of  recombinant  Toxin  A  was  coated  to  an  ELISA  plate  and  serial 
dilutions  of  the  scFvs  under  test  were  added.  An  anti-BSA  scFv  served  as  a  negative 
control,  with  polyclonal  anti-Toxin  A  as  a  positive  control.  After  allowing  interaction, 
rabbit  erythrocytes,  were  added,  washed  and  attached  cells  were  lysed.  The  data  are  shown 
in  Figure  3.26.  This  assay  showed  an  improvement  in  the  positive  control  compared  to  the 
haemagglutination  assay. 
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Figure  3.25:  Reactivity  of  scFvs  with  native  Toxin  A  in  ELISA 
Native  Toxin  A  was  serially  diluted  and  coated  to  an  ELISA  plate  (A  to  G).  Each 
well  received  monoclonal  anti-Toxin  A  scFvs  as  indicated  by  the  clone 
designation,  or  polyclonal  goat  antibody  to  the  toxin,  or  a  scFv  against  BSA.  Row 
H  was  coated  only  with  blocking  reagent.  After  washing,  wells  were  probed  with 
anti  c-myc  and  HRP-conjugated  reagent.  Positive  control  wells  were  probed  with 
anti-goat  reagents.  Samples  were  tested  in  duplicate  and  the  mean  value  is 
presented. 
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As  the  polyclonal  anti-toxin  antibody  was  diluted  (A  to  F),  increasing  absorbance  values 
were  obtained.  This  indicated  that  more  erythrocytes  could  bind  to  the  toxin-coated  surface 
as  the  amount  of  antibody  fell.  A  reverse  profile  was  seen  with  Toxin  A  at  progressively 
lower  concentrations  (A  to  F;  Figure  3.26).  When  an  anti-BSA  scFv  was  used  in  the  assay, 
it  had  no  effect  on  the  extent  of  haemolysis  showing  no  significant  interference  with  the 
binding  of  erythrocytes  to  the  immobilized  toxin.  Broadly  similar  effects  were  seen  with 
the  anti-Toxin  A  scFvs  C5  and  B9.  No  inhibition  of  haemolysis  could  be  seen  with  a 
mixture  of  C5  and  B9  either  (Figure  3.26). 
3.18  Indirect  immunofluorescent  antibody  test  with  fixed  cells 
To  assess  the  ability  of  purified  scFv  anti-toxin  antibodies  to  inhibit  binding  of 
recombinant  Toxin  A  to  bind  to  its  receptor  ,  the  murine  cell  line  F9  which  possesses  a 
high  density  of  Toxin  A  cell  receptors,  was  grown  and  sub-cultured  into  multi-well  cell 
culture  slides.  These  allowed  experimental  conditions  to  be  varied  conveniently  and  cells 
to  be  examined  by  microscopy  to  assess  effects.  Cells  were  fixed  and  mixtures  of  native 
Toxin  A  and  purified  anti-Toxin  A  scFvs  antibodies  were  added.  The  binding  of  the  toxin 
to  cellular  receptors  was  assessed  using  polyclonal  antibody  and  FITC  reagents.  In  Figure 
3.27,  panel  A  shows  a  bright  florescence  visible  at  the  cell  surface  indicated  that  toxin 
successfully  bound  to  receptor  after  mixing  with  anti-BSA  scFv,  and  could  be  detected  at 
this  location  with  high  sensitivity.  In  contrast,  when  Toxin  A  was  pre-incubated  with 
polyclonal  anti-Toxin  A,  panel  B  shows  no  sign  of  toxin  binding.  Panels  C  and  D  show  the 
outcome  of  experiments  in  which  scFvs  D4  and  D5  were  used,  respectively.  A  level 
between  that  seen  in  panels  A  and  B  suggested  that  toxin  was  bound  to  receptor  at  an 
inten-nediate  level. 
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Figure  3.26:  Haemolysis  test 
Most  wells  were  coated  with  an  amount  of  recombinant  Toxin  A  and  blocked  with  3 
%  BSA.  scFvs  and  polyclonal  anti-Toxin  A  as  positive  control  were  serially  diluted 
(A  to  F)  and  added  as  indicated.  After  incubation  and  washing,  rabbit  erythrocytes 
were  added  to  the  wells  and  the  plate  was  incubated  at  a  cold  temperature.  The 
wells  were  then  washed  and  the  attached  cells  were  lysed.  Absorbance  values 
were  measured  at  540  nm.  In  wells  designated  "Toxin  A",  the  coating 
concentration  of  toxin  was  serially  diluted  and  no  antibodies  were  added.  In  wells 
designated  "negative",  no  Toxin  A  was  coated  to  the  plate. 
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3.19  Indirect  immunofluorescent  antibody  test  with  suspended 
cells 
His 
As  an  alternative  to  the  immunofluorescent  antibody  assay  with  slide-fixed  cells,  F9 
cells  were  used  in  suspension.  The  antibody-antigen  mixtures  were  incubated  at  37*  C 
before  the  addition  of  F9  cells  and  further  incubation  at  41  C. 
The  binding  of  Toxin  A  to  the  cells  surface  was  detected  as  before  using  diluted 
polyclonal  goat  anti-Toxin  A  antibody  and  an  FITC-labeled  reagent.  Cell  suspensions  were 
spotted  on  glass  slides,  covered  with  cover  slips  and  observed  by  normal  and 
immunofluorescence  microscopy.  Results  confirmed  the  previous  data  that  partial 
inhibition  of  the  binding  of  recombinant  Toxin  A  to  cells  could  be  achieved  with  scFvs 
under  test.  Of  the  two  scFvs  tested,  D4  scFv  showed  a  better  inhibition  effect.  In  the 
positive  control,  near  complete  inhibition  of  toxin  binding  was  achieved  with  polyclonal 
antibody.  In  contrast,  pre-incubation  of  toxin  A  with  an  anti-BSA  scFv  failed  to  block 
attachment  of  the  toxin  to  the  surface  of  F9  cells.  Results  are  shown  in  Figure  3.28. 
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Figure  3.27:  Immunofluorescence  assay  binding  activity  of  Toxin  A  to  F9 
cells. 
Recombinant  Toxin  A  was  pre-incubated  with  purified  scFvs  diluted  polyclonal 
anti-Toxin  A  antibody  (positive  control)  or  purified  anti-BSA  scFv  (negative 
control).  The  mixtures  were  then  added  to  paraformaldehyde-fixed  F9  cells  and 
the  binding  of  toxin  was  visualized  by  immuno-cytochemistry.  Antibodies  chosen 
for  pre-incubation  with  toxin  were  scFv  anti-BSA  (A);  polyclonal  anti-Toxin  A  (B); 
scFv  D4  (C);  scFv  D5  (D). 
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3.20  Characterization  of  selected  scFvs 
3.20.1  SDS-polyacrylamide  gel  electrophoresis  and  Western 
blotting 
Western  blotting  was  used  to  assess  the  specificity  of  selected  scFv  and  their  ability 
to  detect  Toxin  A  after  treatment  with  SDS  and  heat.  A  crude  bacterial  lysate  from  E.  coli 
pET767  was  separated  on  an  SDS-polyacrylamide  gel  and  blotted  to  a  nitrocellulose 
membrane.  The  blot  was  divided  into  a  set  of  strips  and  each  was  probed  with  an  HB2151 
culture  supernatant  containing  the  scFv  chosen  for  analysis.  Binding  of  scFvs  to  the  blot 
was  detected  with  monoclonal  anti-c-myc  and  HRP-labeled  reagent.  The  results  are  shown 
in  Figure  3.29.  All  the  scFvs  selected  for  analysis  were  reactive  with  heat-treated 
recombinant  Toxin  A  except  scFv  H10.  As  the  blots  also  carried  many  E.  coli  proteins 
present  in  the  lysate,  the  Figure  indicates  the  specificity  of  the  scFvs  for  the  recombinant, 
carboxy-terminal  domain  of  Toxin  A. 
3.21  Expression  levels  of  selected  scFvs 
SDS  polyacrylamide  gel  electrophoresis  and  Western  blotting  was  used  to  assess  the 
expression  of  selected  scFvs.  E.  coli  HB2151  cultures  for  each  antibody  were  grown  in  100 
ml  of  medium,  induced,  and  the  culture  supernatant  was  concentrated  25  fold.  The  buffer 
was  also  exchanged  with  PBS.  After  boiling  in  buffer,  aliquots  were  loaded  to  the  lanes  of 
duplicate  polyacrylamide  gels.  After  separation,  one  gel  was  stained  for  protein 
visualization  and  proteins  from  the  second  gel  were  transferred  to  nitrocellulose 
membrane.  After  blocking,  the  membrane  was  probed  with  monoclonal  anti-c-myc  and 
HRP-labeled  reagent. 
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Figure  3.28:  Immunofluorescence  assay  for  binding  activity  of  Toxin  A  to  F9 
cells  in  suspension. 
Recombinant  Toxin  A  was  pre-incubated  with  purified  scFvs,  diluted  polyclonal 
anti-Toxin  A  antibody  (positive  control)  or  purified  anti-BSA  scFv  (negative 
control).  The  mixtures  were  then  added  to  F9  cells  and  the  binding  of  toxin  was 
visualized  by  immunohistochernistry.  Antibodies  chosen  for  pre-incubation  with 
toxin  were  scFv  anti-BSA  (A);  polyclonal  anti-Toxin  A  (B);  scFv  D4  (C);  scFv  D5 
(D). 
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Figure  3.29:  Recognition  of  recombinant  Toxin  A  in  Western  blotting  using 
scFv 
Lysate  from  an  induced  culture  of  E.  coli  pET767  was  separated  by  SDS-PAGE 
and  blotted  to  nitrocellulose.  Individual  strips  from  the  blot  were  probed  with  scFv 
as  indicated.  The  binding  of  scFv  was  detected  with  anti-c-myc  antibody  and  HRP- 
labelled  reagent.  M:  Rainbow  protein  molecular  weight  markers  (Pharmacia). 
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The  results  are  shown  in  Figure  3.3  1.  The  total  proteins  composition  of  the 
concentrated  supernatants  was  complex  (upper  panel)  reflecting  the  leakage  of  periplasmic 
proteins  from  the  bacterial  cells  on  induction.  It  is  also  likely  that  some  lysis  of  bacteria 
taken  place.  The  most  abundant  single  protein  in  the  samples  was  of  a  size  consistent  with 
the  scFv  antibodies.  When  probed  with  anti-c-myc  reagents,  a  single  protein  was  detected 
on  the  blot  (Figure  3.31;  lower  panel),  confirming  that  the  dominant  protein  was  the  scFv 
present  in  each  sample.  Given  the  good  yield  of  scFv  from  each  clone  and  its  specific 
detection,  concentrated  supernatant  from  induced  cultures  was  used  in  some  experiments 
as  an  alternative  to  protein  purified  by  column  chromatography. 
3.22  Purification  of  the  scFvs  by  affinity  chromatography 
Anti-Toxin  A  scFvs  were  expressed  as  histidine  tagged  fusion  proteins,  concentrated 
and  immobilized  on  a  nickel-chelation  column  as  described  earlier.  In  order  to  elute  the 
protein,  imidazole  (200  mM)  was  passed  through  the  column  to  generate  five  fractions. 
Fractions  containing  the  scFv  (see  below)  were  pooled  and  the  buffer  containing  imidazole 
was  then  exchanged  with  PBS  using  centrifugal  filter  units  and  the  samples  were  stored  at  - 
20'  C  until  further  analysis. 
The  scFvs  chosen  for  further  analysis  were  successfully  expressed  and  purified. 
Supernatant  from  induced  culture  (Figure  3.30;  lane  1)  contained  several  prominent 
proteins  of  about  45  kDa.  The  expected  molecular  weight  of  the  scFv  being  30  kDa,  this 
corresponding  to  the  most  abundant  single  protein  in  the  supernatant.  The  culture 
supernatant  was  exchanged  into  column  binding  buffer,  filtered  through  a  membrane  of  0.2 
Am  and  loaded  to  the  affinity  column.  Binding  buffer  containing  imidazole  at  20  and  70 
mM  was  passed  through  to  remove  many  of  the  proteins  seen  in  the  culture  supernatant 
(lanes  3  and  4  ).  scFv  was  eluted  with  binding  buffer  containing  imidazole  200  mM  (Lanes 
6  and  7).  No  other  protein  contaminants  were  present  (Figure  3.30). 
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3.23  Epitope  saturation  curve 
To  assess  if  the  scFvs  chosen  for  further  analysis  recognized  the  same  or  over- 
lapping  epitopes  on  Toxin  A,  a  series  of  competition  ELISAs  were  devised.  the  first 
attempted  to  saturate  Toxin  A  with  one  antibody  using  cumulative  binding  with  successive 
rounds  of  incubation  and  then  with  another  scFv,  to  observe  whether  the  signal  could  be 
increased  further.  This  experiment  showed  that  saturation  was  incomplete  even  after  6 
rounds  of  addition  and  incubation.  The  ELISA  signal  continued  to  rise  even  after  6  rounds 
of  incubation  with  the  same  scFv,  evidence  suggested  that  a  plateau  was  not  reached 
(Figure  3.32). 
3.24  Epitope  saturation  experiment  using  two  different  scFvs 
To  test  the  result  of  the  previous  experiment,  two  different  scFvs  were  used  in  an 
antibody  saturation  experiment.  Two  rows  of  an  ELISA  plate  were  coated  with  a  low 
concentration  of  recombinant  Toxin  A.  After  washing  and  blocking,  wells  received  single 
applications  of  scFvs  C5  or  D4,  and  double  or  triple  applications  of  C5  or  D4  was  added 
after  double  applications  of  C5.  The  binding  of  scFv  was  detected  with  monoclonal  anti-c- 
myc  antibody  and  then  probed  with  HRP-labeled  reagent.  The  results  are  shown  in  Figure 
3.33.  Signals  from  wells  probed  with  single  applications  of  C5  or  D4  were  comparable  and 
further  testing  would  have  to  be  done  to  establish  if  the  slight  difference  evident  in  (Figure 
3.32)  was  meaningful.  A  higher  final  absorbance  was  obtained  after  two  or  three 
applications  of  C5,  consistent  with  findings  from  the  previous  experiment  (Figure  3.32). 
However,  no  difference  was  detectable  between  wells  probed  with  three  applications  of  C5 
and  those  probed  twice  with  C5  and  once  with  D4.  Hence,  it  could  not  be  established  if  C5 
and  D4  recognized  unique  or  over-lapping  epitopes  on  toxin  A. 
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Figure  3.30:  Purification  of  anti-Toxin  A  scFv  D5. 
Concentrated  supernatant  from  induced  cultures  (lane  1)  was  applied  to  a  column 
of  chelated  nickel.  Flow  through  (lane  2)  and  washings  with  binding  buffer 
containing  20  mM  (lane  3)  and  70  mM  (lane  4)  Imidazole  were  collected  for 
analysis.  scFv  was  eluted  by  pumping  binding  buffer  containing  200  mM  Imidazole 
through  the  column,  the  scFv  appearing  in  fractions  one  and  two  (lanes  5  and  6). 
M:  Rainbow  protein  molecular  weight  markers  (Pharmacia). 
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Figure  3.31:  Expression  of  the  panel  of  scFvs. 
Concentrated  supernatants  from  induced  cultures  of  E.  coli  HB2151  were  run  on 
SDS-PAGE,  blotted  and  probed  with  an  anti-c-myc  antibody.  The  upper  panel 
shows  a  gel  stained  with  Commassie  Blue.  The  lower  panel  shows  a  Western  blot 
of  duplicate  samples.  scFv  clones  are  indicated  over  each  lane.  M:  Rainbow 
protein  molecular  weight  markers  (Pharmacia). 
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Figure  3.32:  Epitope  saturation  with  scFv 
An  ELISA  plate  was  coated  with  a  low  concentration  of  recombinant  Toxin  A. 
Wells  number  1  to  7  were  exposed  to  7,6,5,4,3,2  or  1  rounds  of  scFv  addition 
and  incubation  respectively.  Samples  were  tested  in  duplicate  and  the  mean  value 
is  presented.  scFv  binding  was  detected  with  anti-c-myc  and  HRP-labelled 
reagents. 
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3.25  Competitive  ELISA  with  monoclonal  phage  antibodies  and 
scFv 
Because  of  the  unsatisfactory  result  of  the  saturation  experiments,  a  competitive 
assay  was  set  up  in  which  scFv  and  phage  antibodies  of  the  same  specificity  were  mixed 
and  allowed  to  compete  on  their  target  antigen  (Boel  et  al.,  1998). 
3.25.1  Preliminary  experiments 
The  experimental  system  was  optimized  by  titration  of  a  single  phage  antibody 
(C5)  against  its  scFv  derivative  and  against  a  different  scFv  (D5).  Wells  of  an  ELISA  plate 
were  coated  with  a  low  concentration  of  recombinant  Toxin  A.  The  two  scFvs  were  pre- 
diluted  in  a  separate  microtitre  plate  and  mixed  with  the  phage  antibody  in  a  checkerboard 
pattern.  Mixtures  were  then  transferred  to  the  coated  ELISA  plate.  After  incubation  and 
washing,  wells  were  probed  with  HRP-labeled  anti-M13.  Results  are  shown  in  Figure  3.34. 
The  titration  of  phage  antibody  C5  and  its  scFv  showed  a  weak  signal  in  all  wells  (area  Al 
to  C4)  indicating  low  binding  of  C5.  However,  wells  titrated  with  phage  antibody  C5  and 
scFv  D4  showed  a  stronger  signal.  In  this  area  of  the  plate,  readings  decreased  in  the 
direction  of  phage  dilutions  (wells  1  to  4)  and  dilution  of  the  scFv  had  little  impact.  This 
indicated  that  phage  antibody  C5  and  scFv  C5  competed  for  the  same  epitope  and  as  a 
result,  was  phage  inhibited  from  binding  to  the  toxin-coated  plate.  However,  there  was  no 
evidence  that  phage  antibody  C5  and  scFv  D5  competed  and  a  strong  signal  was  obtained 
in  the  assay.  This  result  indicated  that  competitive  ELISA  could  be  employed  to  study 
whether  antibodies  isolated  by  phage  display  recognised  the  same  or  overlapping  epitopes 
on  Toxin  A,  or  if  each  antibody  recognised  a  unique  feature  of  the  target  protein. 
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Figure  3.33:  Epitope  saturation  with  two  scFvs 
An  ELISA  plate  was  coated  with  a  low  concentration  of  recombinant  Toxin  A.  scFv 
antibodies  were  added  in  1,2,  or  3  rounds  as  indicated.  Negative  control  wells 
were  coated  with  BSA.  scFv  binding  was  detected  with  anti-c-myc  and  HRP- 
labelled  reagents.  Samples  were  tested  in  duplicate  and  the  mean  value  is 
presented. 
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Figure  3.34:  Competitive  ELISA  with  monoclonal  phage  antibodies  scFv 
preliminary  experiment 
The  plate  was  coated  with  recombinant  Toxin  A  and  mixtures  of  phage  antibodies 
and  scFvs  were  added  to  wells  after  checkerboard  dilutions  were  prepared.  scFv 
C5:  1,2,3  and  4  were  titrated  against  phage  antibody  C5:  A,  B,  C  and  D.  scFv 
D5:  1,2,3  and  4  were  titrated  against  phage  antibody  C5:  E,  F,  G  and  H.  Phage- 
scFv  mixes  were  then  transferred  to  separate  wells  of  Toxin  A-coated  plate.  After 
incubation  phage  were  detected  by  HRP-labelled  anti-M13  antibody.  Samples 
were  tested  in  duplicate  and  the  mean  value  is  presented 
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3.25.2  Competitive  ELISA  experiments 
Clones  chosen  for  analysis  were  expressed  as  monoclonal  scFvs  and  as  monoclonal 
phage  antibodies  for  use  in  the  competition  ELISA.  The  test  was  performed  by  coating  an 
ELISA  plate  with  a  low  concentration  of  recombinant  Toxin  A  and  adding  pre-diluted 
mixtures  of  scFv  and  phage  antibodies.  The  binding  of  the  phage  antibodies  was  detected 
as  described  earlier.  The  complexity  of  the  assay  meant  that  phage  and  the  competing 
scFvs  could  only  be  tested  at  single  concentrations.  In  spite  of  this,  the  data  obtained  were 
relatively  clear  cut  (Figure  3.35).  In  the  absence  of  competing  scFv,  all  6  anti-Toxin  A 
phage  antibodies  generated  strong  signals  in  the  assay.  The  specificity  of  the  assay  was 
confirmed  with  data  from  wells  to  which  anti-BSA  phage  antibodies  were  added.  Results 
from  these  wells  were  consistently  low,  reflecting  the  failure  of  these  viruses  to  bind  to 
Toxin  A,  and  the  specificity  of  the  detecting  reagents.  Similarly,  anti-BSA  scFv  failed  to 
compete  with  anti-toxin  phage  antibodies  in  the  assay.  when  phage  carrying  anti-Toxin  A 
antibodies  were  pre-mixed  with  soluble  scFv  (e.  g.  the  G9  phage)  high  levels  of  binding  to 
the  assay  surface  were  noted,  reflecting  the  failure  of  scFv  to  compete  on  either  a  specific 
(e.  g.  scFv  C5  with  G9  phage)  or  a  non-specific  (e.  g.  anti-BSA  scFv  with  G9  phage)  basis. 
The  consistent  exception  was  when  the  phage  antibodies  were  mixed  with  their  soluble 
scFv  derivatives  (e.  g.  scFv  G9  with  G9  phage);  in  these  assays,  results  were  suppressed  to 
near-background  levels,  indicating  the  efficiency  of  competition.  In  one  instance,  some 
evidence  suggestive  of  cross-competition  was  obtained:  the  E4  phage  appeared  to  bind  to 
Toxin  A  less  well  in  the  presence  of  soluble  scFvs  G9,  D6  and  D5.  However,  the  soluble 
fonn.  of  E4  showed  no  ability  to  block  bind  of  D5,  D6  or  G9  phage,  so  the  apparent 
inhibition  was  most  likely  to  be  due  to  variation  within  the  assay.  Overall,  the  assay 
indicated  that  all  recombinant  anti-Toxin  A  antibodies  probably  recognized  non- 
overlapping  epitopes. 
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Figure  3.36:  Toxin  A  competitive  ELISA  using  phage  antibodies  and  their 
soluble  scFv  derivatives 
The  plate  was  coated  with  recombinant  Toxin  A  and  mixtures  of  phage  antibody 
(designated  pAb)  and  scFv  were  added.  Bound  phage  were  detected  by  HRP- 
labelled  anti-M  13  antibody.  Samples  were  tested  in  duplicate  and  the  mean  value 
is  presented 
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3.26  Flow  cytometric  analysis  of  Toxin  A-receptor  interaction 
Flow  cytometry  was  used  to  assess  if  purified  anti-Toxin  A  scFvs  were  able  to 
inhibit  recombinant  Toxin  A  from  binding  to  its  receptor.  F9  cells  were  trypsinized  and 
sub-cultured  in  a  complete  medium  for  3  hrs.  Cells  were  then  scraped,  washed,  and 
mixtures  of  recombinant  Toxin  A  and  different  purified  scFvs  antibodies  were  added. 
Polyclonal  goat  anti-Toxin  A  antibody  was  used  as  a  positive  control  and  purified  anti- 
BSA  scFv  served  as  a  negative  control  in  these  experiments.  After  incubating  suspended 
cells  and  antibody-toxin  mixtures  together  at  4"  C  for  45  min,  toxin  attachment  to  the  cell 
surface  was  detected. 
The  cells  were  then  analysed  on  a  FACSCAN  flow  cytometer.  Cells  were  initially 
gated  using  forward  and  side  scatter.  Their  fluorescence  -a  measure  of  toxin  present  at  the 
cell  surface  -  was  quantified.  Results  confirmed  the  finding  of  the  earlier  experiment. 
Fluorescence  signals  from  cells  incubated  with  Toxin  A  without  antibody  were  resolved  as 
a  peak  separate  from  that  from  cells,  not  exposed  to  toxin  (Figure  3.36;  top  panel).  Pre- 
incubation  of  Toxin  A  with  a  polyclonal.  anti-toxin  antibody  appeared  to  completely  inhibit 
cell  binding.  When  Toxin  A  was  mixed  with  scFv  D4  (middle  panel)  or  D5  (bottom  panel), 
it  failed  to  bind  to  cells  efficiently,  but  neutralization  of  receptor  interaction  was 
incomplete.  A  scFv  against  BSA  failed  to  reduce  attachment  of  toxin  to  the  surface  of  F9 
cells  (data  not  shown). 
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Figure  3.36:  Flow  cytometry  assay  for  the  binding  of  Toxin  A  to  F9  cells. 
F9  cells  were  incubated  with  mixtures  of  Toxin  A  and antibodies,  and  toxin  binding 
detected  by  immunofluorescence.  Controls  included  cells  with  Toxin  A  and  no 
inhibitory  antibody  (positive  control;  all  panels)  and  cells  not  exposed  to  toxin 
(negative  control;  all  panels).  Pre-incubation  of  Toxin  A  with  polycional  antibody 
confirmed  successful  inhibition  of  binding  to  cells  (top  panel,  inhibition  control). 
scFvs  D4  (mid(Jie  panel)  and  D5  (bottom  panel)  were  pre-incubated  with  toxin 
before  application  to  F9  cells  to  test  their  receptor-blocking  activity. 
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3.27  Inhibition  of  Toxin  A  cytotoxicity  by  scFvs 
As  the  scFvs  showed  some  ability  to  block  the  interaction  of  Toxin  A  with  its 
receptor  at  the  surface  of  F9  cells,  assays,  were  set  up  to  test  if  the  antibodies  could  block 
cytotoxic  activity.  F9  cells  were  grown  and  sub-cultured  into  flat  bottom  96-well  plates.  In 
separate  plates,  scFvs  were  set  out  and  full-length  Toxin  A  was  added  to  a  final 
concentration  of  2  ng/well.  After  incubation  to  allow  scFv  interaction,  each  antibody-Toxin 
A  mixture  was  transferred  into  the  cell  culture  plate,  and  cell  morphology  was  monitored. 
The  proportion  of  cells  undergoing  a  rounding  response  was  used  as  an  indication  of 
successful  toxin  binding,  entry  and  intoxication  of  the  F9  cells.  The  data  are  shown  in 
Figure  3.37. 
In  each  panel  of  the  Figure,  data  are  shown  for  control  reactions.  When  cells  were 
challenged  with  Toxin  A  that  had  been  pre-incubated  with  a  scFv  against  BSA,  rapid  cell 
rounding  was  observed.  This  was  first  detectable  25  minutes  after  addition  of  the  toxin  and 
after  75  minutes,  approximately  half  of  all  cells  observed  were  rounded  in  their 
morphology.  Intoxication  was  essentially  complete  after  100  minutes.  The  kinetics  of  this 
assay  previously,  the  key  feature  being  the  rapid  increase  in  rounding  between  50  and  100 
minutes  post-challenge. 
When  toxin  was  mixed  with  polyclonal  antibody,  near-complete  neutralization  of 
cytotoxicity  was  observed.  Again,  the  data  are  shown  in  each  panel  of  Figure  3.37.  Modest 
proportion  of  cells  underwent  rounding  and  even  after  prolonged  incubation,  no  more  than 
10  %  had  undergone  morphological  change.  When  toxin  was  pre-incubated  with  scFv  C5, 
a  shift  in  the  cell  rounding  response  was  evident  (Figure  3.37;  top  panel).  The  response  of 
F9  cells  to  Toxin  A  could  not  be  detected  at  25  minutes  post-challenge,  but  by  50  minutes, 
the  proportion  of  rounded  cells  was  indistinguishable  from  the  anti-BSA  control. 
Thereafter,  however,  the  rate  of  cell  intoxication  was  slower  than  in  the  control  and 
complete  cell  rounding  was  achieved  with  a  delay  of  about  25  minutes. 
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The  obstruction  of  toxin  action  rather  than  its  neutralization,  could  also  be  seen  in 
tests  with  scFv  D4  (Figure  3.37;  middle  panel).  In  these  assays,  early  effects  of  the  scFv 
were  not  apparent  and  rounding  of  F9  cells  proceeded  in  a  way  very  similar  to  that  seen  in 
the  BSA  control.  The  assays  diverged  beyond  50  minutes  post-challenge  and  as  with  scFv 
C5,  a  delay  in  the  main  phase  of  the  intoxication  response  could  be  seen. 
Given  that  scFvs  C5  and  D4  recognised  different  features  of  Toxin  A,  tests  were 
carried  out  to  see  if  their  effects  on  cytotoxicity  were  additive.  The  data  are  shown  at  the 
foot  of  (Figure  3.37).  Interestingly,  a  mixture  of  three  scFvs  (C5,  D4  and  D5)  generated  a 
delay  in  the  cytotoxic  response  to  Toxin  A  that  was  most  similar  to  the  effect  of  D4  alone, 
but  no  enhancement  in  neutralizing  activity  could  be  seen. 
This  experiment  was  repeated  with  some  modification  (Sauerborn  et  al.,  1997).  After 
the  addition  of  antibody-Toxin  A  mixtures  to  the  cell  culture  plate,  the  plate  was  incubated 
at  4'  C  for  30  min  and  wells  were  then  washed  with  chilled  PBS.  Each  well  received  full 
medium.  The  plate  was  then  incubated  for  2  hrs  at  371  C.  Cell  morphology  change  was 
monitored  and  counted  for  statistical  purposes  every  25  min.  This  experiment  showed 
similar  results  (data  not  shown). 
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Figure  3.37:  Inhibition  of  Toxin  A  cytotoxicity  by  scFvs 
Toxin  A  and  purified  anti-Toxin  A  scFv  antibody  were  incubated  together  prior  to 
transfer  to  a  culture  plate  containing  growing  F9  cells.  The  culture  was  then 
incubated  at  370  C  for  4  hrs.  The  plate  was  observed  every  25  min,  and  the 
proportions  of  cells  that  had  undergone  rounding  was  determined  by  eye. 
Polyclonal  goat  anti-Toxin  A  antibody  and  purified  anti-BSA  scFv  were  used  as 
positive  and  negative  controls  respectively. 
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3.28  Epitope  mapping 
3.28.1  Cloning  of  three  regions  of  Toxin  A  into  pCR  2.1-TOPO 
vector 
Forward  and  reverse  primers  were  designed  using  the  sequence  of  Toxin  A  carried 
in  pET767  to  generate  shorter,  as  shown  schematically  in  3  overlapping  fragments  Figure 
3.40.  PCR  was  performed  to  amplify  three  fragments  as  described  before.  The  primer  pairs 
and  predicted  size  of  the  products  are  shown  in  Tables  3.2.  The  PCR  products  were 
electrophoresed  in  1.0  %  agarose  gel  (Figure  3.38)  and  the  DNA  bands  cut  out  from  the  gel 
and  purified  using  QlAquick  gel  extraction  kit.  All  reactions  successfully  amplified  DNA 
of  the  predicted  size. 
The  purified  PCR  fragments  cloned  into  pCR  2.1-TOPO  vector  and  the  ligation 
mixtures  were  transformed  into  competent  E.  coli.  Transformed  colonies  were  picked  at 
random  from  each  reaction,  grown  in  a  selective  liquid  LB  medium  and  plasmid  DNA  was 
isolated  for  analysis.  Samples  were  digested  with  EcoRV  and  HindIll  using  sites 
incorporated  into  the  primers. 
3.28.1.1  Restriction  analysis 
The  results  are  shown  in  Figure  3.39.  Each  lane  shows  release  of  a  prominent  DNA 
fragment  towards  the  top  of  the  gel  at  a  size  corresponding  to  the  pCR  2.1  vector.  Lower 
down,  insert  fragments  can  be  seen.  Since  products  I  and  II  only  differed  by  11  bp,  the  gel 
was  unable  to  resolve  a  difference  in  their  sizes.  Inserts  were  however  clearly  present  in  all 
clones  picked  for  analysis.  Product  III  is  predicted  to  be  270  bp  shorter  than  product  11  and 
the  smaller  size  of  the  release  insert  is  evident  in  Figure  3.39. 
To  express  the  protein  encoded  by  each  region  of  the  Toxin  A  sequence,  fusions  to 
maltose-binding  protein  were  created.  The  vector  pCG806  was  chosen  for  this  purpose. 
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Table  3.2  :  List  of  the  primer  pairs  and  predicted  size  of  the  products  used  In 
cloning  of  four  regions  of  Toxin  A 
Fragment  Primer  sets  bp 
3For-lRev  412 
2For-2Rev  403 
lFor-3Rev  270 
Rl  Rl  for  &  RI  rev  60 
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1,  la  lb  Ic  11.1  111)  lie  111.1  1111)  IIIc 
506I)p 
Figure  3.38:  PCR  amplification  of  fragments  1,11  and  III  from  pET767. 
Plasmid  DNA  was  extracted  from  E.  coli  pET767  and  amplified  by  PCR  using  3 
pairs  of  primers  Table  (3.2).  Amplicons  were  analysed  by  agarose  gel 
electrophoresis.  la,  lb  and  Ic  represent  separate  reactions  for  product  I  (Figure 
3.40);  Ila,  Ilb,  11c,  Illa,  Illb  and  IlIc  represent  reactions  for  products  fragment  11  and 
III  respectively.  L:  indicates  the  migration  of  a1  kb  DNA  ladder  (Invitrogen,  UK). 
169 
￿« Chapter  3,  Results 
1,  la  11)  Ic  Id  Ila  111)  IIc  Ild  [Ila  1111)  IlIc  lild  1, 
4000  bp 
506I)p 
Figure  3.39:  Restriction  analysis  of  recombinant  pCR2.1  plasmids. 
Plasmid  DNA  was  extracted  form  colonies  transformed  with  each  ligation  (as 
indicated)  and  digested  with  EcoRV  and  HindIll.  la,  lb,  Ic  Id  represent  separate 
digestion  reactions  for  clone  1;  Ila,  Ilb,  11c,  lid,  Illa,  Illb,  lic  and  Illd  represent 
digestion  reactions  for  products  fragment  11  and  III  respectively,  L:  indicates  the 
migration  of  a1  kb  DNA  ladder  (Invitrogen). 
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3.28.2  Cloning  Toxin  A  fragments  into  a  maltose-binding  protein 
vector 
DNA  fragments  generated  by  restriction  digestion  in  the  previous  experiment  were 
isolated.  The  MPB  fusion  vector  was  purified  and  digested  with  Smal  and  HindIII  to  create 
compatible  termini  in  the  appropriate  reading  frames.  The  ligated  products  were  then 
transformed  into  competent  E.  coli  DH5ct.  Colonies  were  picked  at  random  from  each 
transformation  for  restriction  analysis  to  confirm  the  presence  of  Toxin  A  sequences  1,11, 
and  IH.  To  confirm  the  presence  of  the  correct  insert  in  each  construct  and  ensure  the  MBP 
and  Toxin  A  reading  frames  were  fused  as  intended,  DNA  samples  were  sequenced  using 
an  M13  forward  primer.  This  anneals  to  a  site  downstream  of  the  polylinker  in  pCG806. 
Data  from  sequencing  are  shown  in  Figures  3.41,3.42  and  3.43. 
3.28.3  Cloning  of  DNA  linker  into  pCG806  MBP  vector 
Following  from  analysis  of  MBP  fusions  IA,  HW  and  IIIF,  a  smaller  construct 
taking  DNA  from  one  of  the  repetitive  sequences  of  the  Toxin  A  C-terminal  domain  was 
cloned  into  pCG806.  In  this  experiment,  complimentary  primers  were  annealed  to  generate 
a  synthetic  DNA  duplex  with  overhangs.  This  enabled  ligation  to  pCG806  after  digestion 
with  Baniffl  and  HindIll.  As  the  insert  was  very  small  (60  bp),  successful  ligation  into 
pCG806  was  initially  confirmed  by  loss  of  the  KpnI  site  located  in  the  vector  between 
BamIR  and  HindHI  sites.  The  construct  was  then  confirmed  by  sequencing  (Figure  3.44). 
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3.29  Characterisation  of  MBP  fusions 
E  coli  DH5a  carrying  fusions  IA,  11W,  and  11IF  were  grown,  induced  and  bacterial 
lysates  were  prepared  for  analysis  by  SDS-PAGE  and  Western  blotting.  As  a  control, 
lysate  was  also  prepared  from  DI-15a  carrying  the  unmodified  pCG806  vector.  To  check  for 
successful  expression  of  each  construct,  blots  were  first  probed  with  an  anti-MBP  serum 
(Figure  3.45).  Two  bands  of  about  40  kDa  and  50  kDa  were  seen  in  the  3  lysates  from 
plasmids  expressing  the  constructs  IA,  I1W  and  RIF  (lanes  1,2,3).  In  the  control  (lane  4) 
two  proteins  also  reacted  with  the  anti-MBP  serum.  The  upper  band  was  smaller  in  size 
that  its  equivalent  in  the  experimental  samples.  In  contrast,  the  lower  band  was  of 
approximately  the  same  size  in  all  samples,  suggesting  that  it  could  be  the  wild  type  MBP 
from  DI-15a.  Having  confirmed  that  recombinant  MBPs  were  expressed,  the  analysis  then 
sought  evidence  for  the  presence  of  Toxin  A  sequence.  Blots  were  prepared  with  lysates 
from  DH5a  carrying  fusions  IA,  I1W  and  11117.  Purified  recombinant  Toxin  A  was  included 
as  a  control.  Blots  were  probed  with  a  polyclonal  serum  against  Toxin  A.  The  data  are 
shown  in  Figure  3.46.  In  contrast  to  Figure  3.45,  single  bands  were  recognized  in  the  3 
lysates.  But  different  strengths  of  signal  compared  with  anti-MBP  were  seen.  Construct  IA 
was  recognised  strongly  by  the  anti-Toxin  A  serum  (lane  1).  Signal  from  the  IIIF  lysate 
was  weaker  (lane  3)  and  only  a  faint  band  could  be  developed  from  I1W`  (lane  2).  Purified 
recombinant  Toxin  A  was  used  as  a  positive  control  (lane  4)  and  reacted  strongly  on  blots. 
Given  that  the  three  proteins  were  recognised  at  equivalent  intensities  by  anti-MBP  serum 
in  Figure  3.45,  this  suggests  that  e.  to  es  in  the  C-terminal  domain  of  Toxin  A  are  not 
recognised  to  the  same  ext  nt  in  vivo. 
5 
These  experiments  confin-ned  successful  expression  of  the  three  MBP  fusion  proteins 
carrying  parts  of  the  toxin  C-terminal  domain  and  the  stability  of  the  recombinant  proteins. 
The  proteins  were  then  used  in  blots  with  scFv  D5  and  D4  to  attempt  to  locate  the  epitope 
recognised  by  these  antibodies.  Data  are  shown  in  Figure  3.47.  When  membrane  was 
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probed  with  scFv  D4,  faint  signal  was  seen  with  IA  (panel  B,  lane  1).  When  membrane 
was  probed  with  scFv  D5,  all  three  MBP  fusions  IA,  HW  and  IHF  (panel  A,  lanes  1,2  and 
3),  were  recognized.  Recognition  of  construct  IA  showed  more  prominent  signal  (panel  A 
and  B  lane  1).  Similar  analyses  were  carried  out  with  scFv  C5  and  D6.  This  revealed  that 
C5  recognised  Toxin  A  epitopes  present  in  MBP  fusion  IA,  whereas  scFv  D6  reacted  with 
IIW.  The  data  from  western  blotting  analysis  are  summarized  in  Table  3.3. 
Whilst  this  analysis  went  same  way  to  identifying  the  epitopes  recognised  by  scFvs 
from  phage  display,  one  observation  of  particular  interest  was  the  apparent  recognition  of 
all  three  MBP  fusion  proteins  by  scFv  D5.  One  feature  common  to  fusions  IA,  RW  and 
HIF  was  the  peptide  repeats  motifs  (Figure  3.47;  panel  A).  To  test  if  one  of  the  motifs 
might  explain  the  apparent  cross-reaction  shown  by  scFv  D5,  the  fusion  protein  RI  was 
generated  (Figure  3.44).  Bacterial  lysate  was  prepared  from  induced  culture  of  E  coli 
DH5a  carrying  a  fusion  R1  (Table  3.2)  and  analysed  by  SDS-PAGE  and  Western  blotting 
with  scFv  D5.  The  membrane  was  probed  with  scFv  anti-c-myc  reagents  and  a  light- 
emitting  substrate  before  exposure  to  an  X-ray  film  (Figure  3.48).  Two  bands  IA  and  RI  (= 
55  kDa)  were  seen  (lanes  I  and  3).  Negative  control  lysate  from  E.  coli  DH5a  carrying 
pCG806  failed  to  produce  any  signal  (lane  2  and  4). 
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Figure  3.45:  Recognition  of  maltose-binding  protein  in  Western  blotting  with 
anti-MBP  antiserum. 
Bacterial  lysates  from  induced  cultures  of  clones  IA  (lane  1),  IN  (lane  2),  IIIF  (lane 
3)  and  unmodified  pCG806  Vector  as  a  control  (lane  4)  were  separated  by  SDS- 
PAGE,  blotted  and  probed  with  anti-MBP  antiserum.  M:  Rainbow  protein  molecular 
weight  markers  (Amersham  Biosciences). 
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Figure  3.46:  Recognition  of  recombinant  Toxin  A  fragments  in  Western 
blotting  with  anti-Toxin  A  antiserum. 
Bacterial  lysate  from  induced  cultures  of  clones  A  (lane  1),  IN  (lane  2),  111F  (lane 
3)  and  purified  rTA  (lane  4)  were  separated  by  SDS-PAGE,  blotted  and  probed 
with  anti-Toxin  A  antiserum.  M:  Rainbow  protein  molecular  weight  markers 
(Amersham  Biosciences). 
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Figure  3.47:  Recognition  of  recombinant  Toxin  A  fragments  in  Western 
blotting  with  anti  Toxin  A  scFv. 
Bacterial  lysate  from  induced  cultures  of  clones  IA  (lane  1),  IN  (lane  2),  IIIF  (lane 
3)  were  separated  by  SDS-PAGE,  blotted  and  probed  with  anti-Toxin  A  scFv  D5 
(panel  A)  and  scFv  D4  (panel  B).  M:  Rainbow  protein  molecular  weight  markers 
(Amersharn  Biosciences). 
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Table  3.3:  List  of  scFvs  and  the  detected  fragments 
scFv  IA  llw  IIIF  Rl 
D4  x 
D5  x  xt  xt  xt 
C5  x 
D6  x 
weak  signal  in  Western  blotting 
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4  Discussion 
0  4.1  Purification  and  characterization  of  recombinant  C- 
terminal  domain  of  Toxin  A 
The  exotoxin  A  is  expressed  by  pathogenic  Clostridium  difficile  that  cause)  an 
0 
antibiotic  associated  diarrhea.  The  aims  of  this  part  of  the  project  were  to  express  the  C- 
terminal  domain  of  Toxin  A  as  a  recombinant  protein,  check  the  biological  activity  of  the 
purified  protein  and  use  it  as  a  target  for  isolation  of  antibodies  from  phage  display 
libraries. 
Initially,  the  presence  of  the  gene  encoding  the  recombinant  Toxin  A  in  a  T7 
expression  system  was  confirmed  by  DNA  sequencing.  The  insert  encodes  for  14  repetitive 
sequences  of  the  38  naturally  present  in  the  C-terminal  receptor  binding  domain  of  the 
toxin.  Other  groups  (Frey  &  Wilkins,  1992;  Frisch  et  al.,  2003;  Kink  &  Williams,  1998; 
Wren  et  al.,  1991)  have  reported  successful  cloning  and  expression  of  recombinant  Toxin 
A  or  Toxin  B  fragments  of  different  sizes  (3,5,6,9,19,  or  32  rcpeats),  derived  from  tile  C- 
terminal  domain,  in  E  coli  or  Salmonella  typhimurium  (Ward  et  al.,  1999b).  These 
fragments  were  expressed  as  fusion  proteins  or  independent  stable  proteins  (Demarest  et 
al.,  2005;  Mathieu  et  al.,  2003).  The  expressed  recombinant  fragments  were  used  as  active 
or  passive  vaccines  in  animal  trials.  These  recombinant  fragments  were  also  used  in  vitro 
to  study  the  binding  behavior  of  regions  of  the  Toxin  A  C-terminal  domain  to  its  receptor 
or  as  an  epitope  mapping  tool  for  localization  of  epitopes  recognizcd  by  monoclonal 
antibodies  raised  against  the  C-terminal  domain  of  the  toxin.  For  example,  to  localize 
epitopes  recognized  by  monoclonal  antibody  PCG4  which  inhibits  the  cytotoxicity 
vitro,  a  series  of  fragments  representing  different  parts  of  the  C-terminal  domain  of  Toxin 
A  were  successfully  sub-cloned,  expressed  and  tested  for  their  reactivity  with  monoclonal 
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PCG-4  antibody  (Frey  &  Wilkins,  1992).  The  results  of  this  study  showed  that  monoclonal 
PCG-4  antibody  recognised  epitopes  on  some  fragments  generated  by  sub-cloning  of 
repeating  units  of  Toxin  A.  Others  (Frisch  et  al.,  2003)  have  reported  successful  sub- 
cloning  and  expression  of  recombinant  proteins  from  different  parts  of  the  C-terminal 
domain  of  Toxin  A.  These  recombinant  proteins  were  expressed  as  GST-fusion  proteins 
and  used  as  ligands  to  bind  to  their  receptor  and  to  compete  with  the  native  Toxin  A  for  the 
receptor.  The  results  showed  that  the  complete  C-terminal  domain  could  compete  with 
native  Toxin  A,  when  present  in  100-fold  molar  excess  and  thereby  protect  cells  against 
rounding.  However,  if  the  fusion  contained  only  the  amino-terminal  half  of  the  receptor- 
binding  domain,  the  recombinant  protein  was  completely  incapable  of  competing  at  the 
toxin  receptor.  It  also  showed  that  the  addition  of  a  small  part  of  the  hydrophobic  domain 
to  the  C-terminal  recombinant  proteins  can  indirectly  improve  the  binding  efficiency  by 
maintaining  correct  folding  of  the  molecule. 
Protein  purification  using  affinity  chromatography  recovered  a  protein  of  37  kDa  as 
shown  by  SDS-PAGE  and  Western  blot.  This  corresponds  to  the  expected  size  of  the  target 
recombinant  protein.  Column  elution  by  imidazole-containing  buffer  showed  that  a  low 
degree  of  protein  precipitation  occurred  immediately  after  elution  but  precipitation 
increased  dramatically  over  time  in  storage.  Similar  effect  was  reported  when  recombinant 
proteins  were  expressed  with  a  his-tag  sequence  (Hamilton  et  al.,  2003).  To  overcome  this 
problem,  acidic  elution  of  protein  was  used  and  fractions  were  collected  into  2x 
concentrated  PBS  buffer  for  pH  neutralization.  The  activity  of  the  purified  recombinant 
protein  was  retained  after  acidic  elution  and  problems  of  precipitation  on  extended  storage 
were  eliminated.  This  indicates  that  this  is  an  effective  way  for  purification  of  acidic- 
tolerant  recombinant  proteins  that  carry  his-tags.  The  concentration  of  the  recombinant 
protein  (>  200  Aglml)  in  a  soluble  form  made  possible  comprehensive  characterization  and 
study  of  its  biological  activity. 
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Preliminary  identification  of  the  recombinant  protein  as  the  C-terminal  domain  of 
Toxin  A  was  made  by  Western  blotting  using  polyclonal  antibodies  raised  against  the 
native  toxin.  These  conclusions  were  supported  by  the  high  titer  of  the  goat  anti-Toxin  A 
or  anti-C  sordelii  toxin  in  ELISA  using  the  purified  recombinant  protein  as  target.  This 
possibly  reflected  correct  folding  of  the  purified  recombinant  protein  after  the  acidic 
elution.  The  data  also  suggest  that  the  presence  of  the  his-tag  has  no  substantial  effect  on 
the  confonnation  of  the  proteins,  exposure  of  the  epitopes  and  consequently  on  its 
reactivity  with  antibody raised  against  the  native  Toxin  A.  In  contrast,  the  presence  of 
TETC-tag  (nontoxic  binding  domain  from  tetanus  toxin)  was  shown  to  induce 
confonnational  changes  within  the  Toxin  A  repeats,  possibly  masking  or  destroying  toxin 
A  epitopes  (Ward  et  al.,  1999a).  These  results  encouraged  further  study  of  the  biological 
activity  of  the  purified  recombinant  protein. 
The  repeating  units  of  amino  acids  in  Toxin  A  are  thought  to  represent  the  binding 
domain  forming  a  multivalent  lectin  able  to  recognise  the  trisaccharide  Galal-Malpl- 
4GIcNAc.  This  carbohydrate  is  found  on  the  surface  of  rabbit  erythrocytes,  bovine 
thyroglobulin,  a  wide  variety  of  Ig  and  non-Ig  molecules  in  human  milk,  and  is  expressed 
on  brush  border  membranes  of  hamster  ileum  (Ho  et  al.,  2005;  Tucker  et  al.,  1990). 
Recently,  it  was  reported  that  Gala  1-3  Gal  0  1-4GIcNAc  may  not  be  the  only  receptor  for  the 
toxin  (Ho  et  al.,  2005).  It  has  been  widely  reported  that  the  C-terminal  part  of  the  toxin 
consists  of  short  and  long  repeats  of  a  series  of  peptide  sequences  (Florin  &  Thelestam, 
1983).  Each  repeat  consists  of  a  P-hairpin  and  a  loop  structure  as  shown  by  crystal 
structures  of  protein  derived  from  the  binding  site  of  the  toxin.  The  sequence  conservation 
in  the  short  and  long  repeats  are  thought  to  play  a  role  in  the  formation  of  kinks  in  the 
protein  structure.  It  has  been  speculated  that  this  conformation  interferes  with  receptor 
recognition  and  cell  entry.  It  was  found  that  some  repeats,  between  5  to  15  repeats,  form 
stable  secondary  structures  without  the  interference  with  other  structures.  The  folded 
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secondary  structures  may  augment  the  binding  affinity  of  this  domain  with  its  receptor 
(von  Eichel-Streiber  et  al.,  1992b;  Weis  &  Drickamer,  1996).  Recently,  it  was  reported  that 
adjacent  pairs  of  short  repeats  leads  to  a  rotation  of  120'  in  a  screw-axis  structure.  In 
contrast,  short  repeats  followed  long  repeats  leads  to  a  rotation  of  90'  in  the  screw-axis 
structure.  This  property  leads  to  the  formation  of  straight  segments  of  B-solenoid  structure 
comprising  short  repeats,  interrupted  by  kinks  (Ho  et  al.,  2005).  It  was  reported  that  a 
recombinant  fragment  of  the  binding  domain  of  Toxin  A  containing  11  repetitive 
sequences  was  able  to  bind  to  receptor  and  that  high  concentration  of  the  recombinant 
protein  was  also  able  to  inhibit  the  cytotoxicity  of  native  Toxin  A  (Frisch  et  al.,  2003; 
Sauerbom  et  al.,  1997).  Other  bacterial  proteins  which  havi;:  ýZplenoid-li 
ýstructu 
s  and 
which  contain  tandem  repeats  of  residues  (e.  g.  pneumococcal  virulence  factor  LytA)  are 
often  found  in  bacterial  surface  proteins.  This  feature  allows  the  interaction  with  proteins 
or  carbohydrates  (Femandez-Tomero  et  al.,  2001).  Non-bacterial  proteins  like  lectins  also 
share  the  similar  property  of  carbohydrate  recognition  (Ho  et  al.,  2005) 
Given  this  background  and  the  known  involvement  of  the  C-terminal  domain  in  receptor 
binding,  an  important  goal  was  to  determine  if  the  purified  recombinant  Toxin  A  retained 
the  ability  to  interact  with  receptor.  Recombinant  Toxin  A  was  not  as  effective  as  the 
native  toxin  in  agglutination  of  rabbit  erythrocytes  which  was  in  agreement  with  a  previous 
report  (Ward  et  al.,  1999a).  This  finding  suggests  that  firrn  binding  to  the  receptor  can 
occur  when  complete  the  binding  domain  of  the  toxin  is  used,  as  was  suggested  by  (Florin 
&  Thelestam,  1983)  in  studies  that  showed  that  50  %  of  the  receptor-binding  domain  of 
Toxin  A  failed  to  bind  firmly  and  compete  at  the  toxin  receptor  (Florin  &  Thelestam, 
1983).  Similar  effects  were  also  reported  by  others  (Frisch  et  al.,  2003;  Roberts  &  Shone, 
2001).  This  finding  was  also  substantiated  by  an  immunofluorescence  assay  for  capture  of 
the  toxin  on  its  receptor.  This  showed  a  weaker  immunofluorescence  signal  when 
recombinant  Toxin  A  was  used  compared  to  native  toxin.  Other  studies  (Genth  et  al., 
2000)  indicated  that  the  hydrophobic  control  domain  has  importance  in  the  binding  activity 
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which  suggests  that  the  complete  or  partial  absence  of  this  domain  could  reduce  the 
efficiency  of  binding  of  the  recombinant  protein  possibly  by  a  failure  to  maintain  the 
correct  three  dimensional  structure  of  the  receptor-binding  domain.  This  was  supported 
recently  (Frisch  et  al.,  2003)  in  studies  that  showed  that  the  addition  of  amino  acids  from 
the  hydrophobic  domain  to  the  recombinant  binding  domain  enhanced  the  blocking  of  the 
Toxin  A  from  binding  to  its  receptor.  This  shows  that  the  hydrophobic  domain  has  an 
importance  in  the  binding  activity.  Their  study  has  also  shown  that  complete  recombinant 
binding  domain  can  initiate  endocytosis  while  deletion  of  the  C-terminal  binding  domain 
prevented  the  binding  completely  (Frisch  et  al.,  2003).  However,  there  is  some 
inconsistency  here  with  earlier  reports  that  a  recombinant  fragment  of  the  binding  domain 
of  Toxin  A  containing  only  11  repetitive  sequences  was  able  to  bind  to  the  receptor  of  F9 
cells  in  high  concentrations  and  compete  with  native  toxin  (Sauerbom  et  al.,  1997). 
It  has  been  reported  that  the  antiserurn  raised  against  a  short  synthetic  peptide  from 
the  repetitive  domain  can  interfere  with  the  binding  activity  of  Toxin  A  and  can  inhibit  the 
haernagglutination  and  the  cytotoxic  activities  of  the  toxin  (Wren  et  al.,  1991). 
Haernagglutination  has  been  used  quite  widely  as  a  measure  of  binding  but  inconsistencies 
in  the  literature  hint  that  the  assay  might  only  measure  one  aspect  of  the  interaction 
between  Toxin  A  and  its  receptor  or  receptors.  It  is  possible,  for  example,  that  erythrocytes 
lack  glycoproteins  that  are  expressed  on  other  cell  types,  to  which  toxin  can  bind.  In  this 
thesis,  antiserum.  raised  against  native  Toxin  A  and  pre-incubated  with  Toxin  A  effectively 
neutralized  the  cytotoxicity  of  Toxin  A  in  cell  culture.  However,  pre-incubation  of 
antiserum  with  Toxin  A  failed  to  show  an  effective  inhibition  of  the  haernagglutination 
activity  of  the  toxin.  This  problem  was  not  solved  even  when  different  buffcr 
concentrations,  components,  pHs,  or  different  incubation  periods  were  used.  In  addition,  no 
haernagglutination  inhibition  was  observed  when  higher  concentrations  of  antiscrum  or 
lower  concentrations  of  rabbit  RBC  were  used.  Moreover,  in  some  instances,  higher 
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concentration  of  antiserum  caused  a  slight  augmentation  to  the  toxin  haernagglutination 
activity.  These  observations  could  be  explained  in  several  ways.  For  example,  antibodies 
might  bind  to  and  block  regions  of  the  toxin  that  are  not  linked  to  reccptor-binding,  but 
thereby  inhibit  cytotoxic  action  (e.  g.  the  N-terminal  enzyme  domain).  However,  cytometry 
data  in  the  thesis  clearly  showed  that  anti-Toxin  A  antibodies  reduced  protein  binding  to 
the  surface  of  nucleated  cells.  This  lends  support  to  a  more  complex  model  for  receptor 
interaction  than  is  observed  in  haemagglutination.  Data  from  wren's  paper  show  some 
features  in  common  with  work  presented  in  this  thesis.  For  example,  when  antiserum 
raised  against  Toxin  A  was  used  to  inhibit  the  haernagglutination  activity  of  Toxin  A  or 
recombinant  Toxin  A,  higher  serum  concentrations  approved  to  have  the  reverse  effect 
(Wren  et  al.,  1991).  When  anti-TIDGKKYYFN  polyclonal  antibody  was  pre-incubatcd 
with  native  or  recombinant  Toxin  A,  haernagglutination  activity  was  efficiently  inhibited. 
One  of  the  earlier  reports  of  a  monoclonal  reagent  against  Toxin  A  (Lyerly  et  al.,  1986) 
showed  that  the  antibody  (PCG-4)  also  recognised  peptide  repeat  motifs  at  the  C-tcrminal 
domain  (Frey  &  Wilkins,  1992).  The  monoclonal  antibody  failed  to  block  cytotoxicity  ill 
vitro,  yet  was  able  to  protect  hamsters  against  challenge  with  C.  difficile  (Frey  &  Wilkins, 
1992).  Taken  together,  studies  of  haemagglutination,  the  inhibition  of  haemagglutination 
and  cytotoxicity  experiments  reflect  continuing  uncertainty  about  the  identity  of  the  host 
receptor  for  Toxin  A  and  about  the  nature  of  the  toxin-receptor  interaction. 
Given  this  uncertainty,  one  important  goal  of  this  project  was  to  investigate  if  pre- 
incubation  of  Toxin  A  with  monovalent,  proteolytic  fragment  of  anti-Toxin  A  antibody 
could  inhibit  the  biological  activities  of  Toxin  A  in  vitro.  This  was  important  for  two 
reasons.  Firstly,  it  would  establish  if  the  neutralizing  effect  of  polyclonal  anti-toxin 
antibodies  could  be  attributed  to  cross-linking  and  agglutination  effects  made  possible 
because  of  the  bivalency  of  the  antibody  molecules.  Secondly,  the  overall  goal  of  the 
project  was  to  isolate  recombinant  antibodies  against  Toxin  A  and  to  test  their  biological 
activity.  The  recombinant  antibodies  would  be  monovalent  scFv  proteins.  If  the  protective Chapter  4,  Discussion 
effects  of  a  polyclonal  serum  could  be  retained  when  these  antibodies  were  converted  to 
smaller,  monovalent  derivatives,  it  would  demonstrate  that  recombinant  scFvs  might  be 
expected  to  possess  toxin  neutralizing  activity  if  they  were  directed  against  appropriate 
regions  of  Toxin  A. 
Hence,  an  anti-Toxin  A  antiserum  was  digested  with  papain  to  release  functional 
Fab  fragments  (Cresswell  et  al.,  2005).  Digestion  of  the  gamma-globulin  region  was 
shown  to  be  complete  by  SDS-PAGE  and  Western  blotting.  The  capacity  of  Fab  fragments 
to  bind  Toxin  A  was  confirmed  by  ELISA.  Given  the  nature  of  the  Fab  fragment,  this 
would  be  predicted,  but  in  support  of  this,  It  has  been  reported  (Aharonov  et  al.,  1974)  that 
Fab  fragments  generated  by  papain  digestion  were  still  functional  and  could  block  binding 
of  intact  antibodies  in  a  competitive  experiment.  When  Fab  fragments  were  tested  with 
active  Toxin  A  in  a  cell  culture  challenge  experiment,  cytotoxicity  was  inhibited 
effectively.  The  outcome  of  this  experiment  therefore  indicated  that  small  molecular 
weight  antibodies  can  retain  their  affinity  and  neutralizing  activity  against  a  complex 
target.  This  is  further  supported  by  competitive  ELSIA  experiments  between  scFv  and  the 
parent  antibody  (Deng  et  al.,  2003).  This  finding  gave  an  indication  that  monoclonal  scFv 
antibodies  isolated  against  Toxin  A  might  inhibit  the  biological  activities  of  the  toxin  in 
vitro. 
scFv  antibodies  with  the  ability  to  detect  and  neutralize  toxins  have  been  isolated 
by  other  investigators.  It  was  reported  that  scFvs  against  pertussis  toxin  were  able  to 
recognize  and  neutralize  the  toxin  in  cell  culture  using  CHO  cells  (Williamson  & 
Matthews,  1999).  Anti-pertussis  toxin  scFvs  were  generated  from  an  immune  pliage  library 
that  was  produced  from  the  peripheral  blood  lymphocyte  mRNA  of  patients  with  A 
pertussis  infection.  scFv  antibodies  inhibited  in  vitro  glucan  synthesis  catalyzed  by  P-1,3- 
glucan  synthase  of  S.  cerevisiae  as  well  as  that  of  C.  albicans.  These  scFvs  were  also  able 
to  inhibit  P-1,3-glucan  synthase  in  four  Candida  species  in  vitro  (Selvakumar  et  al.,  2006). 
It  was  reported  that  scFv  inhibited  the  potent  neurotoxins  Aahl  and  Aah1I  of  Androctonus 
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australis  scorpion  from  binding  to  their  receptor.  This  lead  to  protection  against  the  toxin 
in  animal  trials  (Juste  et  al.,  2007).  scFv  raised  against  the  protective  antigen  of  anthrax 
toxin  were  found  to  recognize  and  neutralize  the  cytotoxicity  of  the  lethal  toxin  in  cell 
culture  (Chen  et  al.,  2006).  There  are  some  instances  where  individual  scFv  proteins  failed 
to  neutralize  their  target  antigen  but  a  pool  of  several  monoclonal  scFvs  recognizing 
different  epitopes  showed  improved  potency  in  toxin  neutralization.  This  effect  was 
reported  by  Amersdorfer  and  colleages  (Amersdorfer  et  al.,  2002)  when  the  neutralization 
potency  of  single  monoclonal  scFvs  were  compared  to  a  combination  of  different 
monoclonal  scFvs  against  botulinum  type-A  toxin.  These  reports  highlight  the  potential  of 
recombinant  antibody  fragments  in  recognition  and  neutralization  of  different  toxin 
systems  from  different  origins.  This  strategy  against  Toxin  A  and  was  adopted  in  the 
present  work  and  has  recently  been  proposed  by  Babcock  (Babcock  et  al.,  2006). 
Overall,  the  initial  work  reported  in  this  thesis  fulfilled  the  aim  to  prepare  a  pure  and 
biologically  active  form  of  Toxin  A  for  the  isolation  of  recombinant  antibodies.  As  part  of 
this,  an  improved  method  for  the  purification  of  the  recombinant  Toxin  A  has  been  devised 
that  produces  concentrated  and  purified  protein  that  has  potential  in  several  applications.  It 
is  clear  from  the  literature  that  the  C-terminal  domain  of  Toxin  A  can  elicit  protective 
response  against  infection.  Studies  in  this  thesis  show  that  protective  antibodies  retain 
activity  as  monovalent  fragments.  The  next  phase  of  the  project  was  to  isolate  scFv  against 
Toxin  A  and  then  assess  the  biological  activity  of  these  recombinant  antibodies. 
4.2  Screening  of  the  Tomlinson  library 
The  Tomlinson  I  semi-synthetic  library  was  used  to  isolate  soluble  monoclonal  scFv 
antibodies  against  Toxin  A.  To  check  the  quality  of  this  library  before  and  after  the 
selection,  the  length  of  inserts  was  assessed  in  clones  from  the  library.  This  experiment 
confirmed  that  full-length  inserts  were  present  in  almost  all  clones  tested,  in  contrast  to 
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Griffin  I  library  that  showed  a  steady  decrease  of  insert  size  during  amplification  cycles  (de 
Bruin  et  al.,  1999).  This  finding  was  supported  by  the  expression  of  soluble  scFv  from 
Tomlinson  library  at  a  later  stage  and  comparison  to  positive  control  clones.  This  effect 
was  also  observed  by  a  previous  postgraduate  student  (Golchin,  2004).  The  expression  of 
recombinant  antibodies  by  bacteria  can  be  toxic  and  therefore  a  selective  pressure  can 
drive  the  progressive  deletion  of  sequence  from  scFvs  during  selection  and  amplification. 
One  strength  of  the  Tomlinson  system  is  its  use  of  antibody  framework  sequence  that  are 
well-tolerated  by  bacteria. 
The  outcome  of  selection  was  consistent  with  the  expected  enrichment  of  specific 
clones.  This  could  be  observed  from  the  number  of  phage  recovered  from  each  round  of 
selection.  The  increase  in  recovery  rate  at  round  2  was  shown  to  be  the  most  successful  and 
round  3  did  not  appear  to  increase  significantly  the  recovery  of  phage.  It  is  possible  that  a 
plateau  was  reached  in  enrichment  and  that  the  selection  system  had  simply  recovered  as 
many  binding  phage  as  was  possible.  Alternatively,  the  competition  between  specific  and 
non-specific  interactions  on  the  selecting  surface  may  have  reached  equilibrium.  Whatever 
the  reason,  an  increase  in  the  proportion  of  phage  recovered  during  panning  cycles  is  not 
always  constant  and  variations  have  been  reported  by  others  (de  Bruin  et  al.,  1999;  Li  el 
al.,  2003).  Increases  in  the  number  of  panning  cycles  from  3  to  5  have  been  reported  but 
this  does  not  necessarily  increase  the  specificity  of  the  screen  or  the  quality  of  the 
antibodies  that  emerge.  Whatever  the  bases  for  this  observation,  the  screen  provided  ample 
numbers  of  phage  for  analysis  and  characterization.  Clones  isolated  from  the  Tomlinson 
library  were  shown  to  be  specific  for  Toxin  A  in  polyclonal  phage  ELISA  and  rcaction 
with  the  skimmed  milk  blocking  reagent  was  not  seen.  Monoclonal  scFv  antibodies  picked 
from  each  round  of  selection  bound  to  Toxin  A  with  high  frequency  when  tested  in  phage 
ELISA,  but  the  frequency  was  lower  when  soluble  scFv  antibodies  were  tested.  This 
anomaly  may  be  due  to  the  multivalent  display  of  scFv  at  the  phage  surface.  Filamentous 
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phage  carry  three  copies  of  scFv  antibodies  which  increases  the  overall  avidity  of  each 
phage  antibody  for  its  target  (de  Wildt  et  al.,  2002).  This  might  result  in  the  binding  of 
phage  particles  in  ELISA  and  a  positive  signal  in  ELISA,  but  the  inability  of  the 
monovalent  scFv  protein  to  replicate  this  result.  It  is  also  perhaps  possible  that  nonspecific 
reactions  between  the  phage  particles  and  the  target  antigen  explain  the  observation. 
Similar  effect  has  been  reported  while  using  Tomlinson  I  and  J  libraries  (Wu  et  al.,  2007). 
To  overcome  this  problem,  some  modifications  were  introduced  to  the  panning  cycles  i.  e. 
the  use  of  immunotubes  with  two  kinds  of  surface  materials  (maxisorp  and  polysorp), 
alternation  of  two  different  blocking  reagents  between  panning  cycles  and  the  gradual 
increase  in  the  concentration  of  Tween-20  after  each  cycle  of  panning  to  enhance  the 
stringency  of  washing.  It  is  also  possible  that  scFvs  were  not  actually  expressed 
successfully  in  monoclonal  scFv  ELISA  experiment  or  that  some  scFv  proteins  could  not 
form  stable  structures  during  the  expression  process  (Lorimer  et  al.,  1996). 
The  diversity  of  Tomlinson  library  I  is  created  by  synthetic  variation  of  codons  at 
certain  positions  in  the  scFv  inserts.  Whatever  the  anomalies  in  screening,  phage  display 
with  this  resource  has  facilitated  the  isolation  and  the  expression  of  specific  monoclonal 
anti-Toxin  A  scFv  antibodies.  From  the  panel  of  antibodies  that  was  generated,  several 
scFv  antibodies  were  chosen  for  further  study  based  on  the  strength  of  reactivity  in  EUSA. 
Western  blot  showed  specific  binding  of  all  chosen  scFvs  to  rccombinant  Toxin  A  cxccpt 
for  one  scFv  which  reacted  with  the  toxin  in  ELISA  or  in  dot  blot  only.  This  suggested  that 
the  ma  ority  of  scFvs  could  react  with  linearized  peptide  sequences  while  one  scFv  rcactcd  i 
with  a  conformational  structure.  DNA  sequencing  of  the  clones  showcd  divcrsirtcd 
sequences  with  similarity  confined  to  the  light  chain.  VL  scqucnce  showcd  a  high 
frequency  of  serine  and  threonine  amino  acids.  This  could  indicate  a  bias  towards  tllcsc 
residues  in  the  light  chain  component  of  library.  Similar  observation  was  rcportcd  by 
others  (Carzaniga  et  al.,  2002).  The  result  might  also  have  arisen  because  of  selection 
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pressure  imposed  by  the  general  nature  of  the  target  protein  as  both  serine  and  threonine 
share  the  same  physical  and  chemical  properties  (neutral-polar/hydrophilic  amino  acids). 
The  diversity  evident  from  DNA  sequencing  also  suggests  that  the  chosen  scFvs  may 
recognize  different  epitopes  on  the  toxin.  This  was  supported  by  blocking  experiments  in 
which  phage  and  scFv  were  run  in  competition  ELISA.  These  data  showed  that  anti-Toxin 
A  monoclonal  scFv  antibodies  were  only  able  to  inhibit  the  binding  of  monoclonal  phage 
antibodies  of  the  same  clone  and  that  little  blocking  was  evident  between  different  clones 
(Boel  et  al.,  1998). 
The  Tomlinson  library  therefore  provided  a  convenient  source  of  recombinant 
antibodies  against  the  carboxy-terminal  region  of  Toxin  A.  The  convenience  of  phage 
display  as  a  method  provided  a  significant  advantage  over  conventional  hybrodoma 
mehtods  for  the  generation  of  these  monoclonal  reagents. 
4.3  Biological  activity  of  anti-Toxin  A  scFvs. 
The  next  series  of  objectives  were  to  assess  the  biological  activities  of  the  anti-Toxin 
A  scFvs.  One  test  that  was  used  was  to  assess  if  purified  anti-Toxin  A  scFv  could  inhibit 
the  haemagglutination  activity  of  recombinant  Toxin  A.  As  described  earlier 
haemagglutination  by  Toxin  A  has  been  described  as  a  model  for  receptor  binding  (Krivan 
et  al.,  1986;  Lyerly  et  al.,  1986).  There  are  uncertainties  about  its  relevance  but  it  remains 
widely  used  in  this  context.  One  issue  of  concern  was  the  failure  of  an  anti-Toxin  A 
antiserum  with  neutralizing  activity  activity  to  block  haernaggluti  nation  mcdiated  by  the 
recombinant  carboxy-terminal  protein.  Similar  unexpected  result  was  also  seen  when  anti- 
Toxin  A  monoclonal  scFv  were  used.  Furthermore,  some  anti-Toxin  A  scFv  antibodies 
selected  clones  in  this  study  were  shown  to  increase  the  haernagglutination  rcaction. 
Similar  unpredicted  phenomenon  was  reported  by  (Krivan  et  al.,  1986)  during  the 
evaluation  of  haernagglutination  assay.  In  this  assay,  when  anti-Toxin  A  antibody  was 
incorporated,  it  was  noticed  that  the  sensitivity  of  the  haernagglutination  was  incrcascd 
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from  0.8  jig/ml  of  Toxin  A  to  about  50  ng/ml.  As  an  attempt  to  overcome  this  problem,  a 
haemolysis  assay  was  set  up  with  surface-immobilized  Toxin  A  to  substitute  for  the 
haemagglutination  test.  This  technique  revealed  an  improved  result  with  polyclonal  anti- 
Toxin  A  antibody  but  not  with  anti-Toxin  A  monoclonal  scFv  antibodies.  Others  (Babcock 
et  al.,  2006;  Kamiya  et  al.,  1991)  have  reported  that  full-length  monoclonal  antibodies 
raised  against  Toxin  A  were  able  to  inhibit  cytotoxicity  but  not  haernagglutination  activity. 
Despite  these  inconsistent  findings  in  vitro,  some  of  these  antibodies  were  able  to  inhibit 
enterotoxicity  in  animal  trials.  This  highlights  the  lack  of  robust  in  vitro  tests  for 
assessment  of  the  properties  of  the  anti-Toxin  A  monoclonal  scFv  antibodies. 
Further  studies  examined  the  inhibition  activity  of  the  scFv  antibodies  for  toxin 
binding  to  F9  cells.  In  these  experiments,  when  Toxin  A  was  pre-incubated  with  polyclonal 
anti-Toxin  A,  no  sign  of  toxin  binding  to  the  cells  was  seen.  When  scFvs  were  pre- 
incubated  with  Toxin  A,  incomplete  inhibition  of  toxin  binding  was  evident.  These 
experiments  showed  that  the  anti-Toxin  A  monoclonal  scFv  antibodies  were  partially 
effective  in  blocking  the  binding  of  Toxin  A  to  its  receptor  on  F9  cells.  These  results  were 
gathered  using  immunofluorescence  microscopy.  To  validate  these  results,  a  quantitative 
assay  using  a  Facscan  flow-cytometer  was  employed.  Facscan  was  used  successfully  by 
Cirino  and  colleages  to  show  disruption  of  the  receptor-mediated  binding  of  PA  of  anthrax 
Toxin  with  scFv  (Cirino  et  al.,  1999).  In  the  research  reported  here,  results  were  consistent 
with  immunofluorescence  microscopy:  pre-incubation  of  Toxin  A  with  a  polyclonal  anti- 
toxin  antibody  appeared  to  completely  inhibit  cell  binding,  whereas  pre-incubation  with 
scFv  lead  to  incomplete  neutralization  of  interaction  of  the  toxin  with  rcccptor.  This 
suggested  that  anti-Toxin  A  monoclonal  scFv  antibodies  may  interfere  in  the  binding  of  the 
recombinant  protein  to  its  receptor  but  not  to  an  extent  to  cause  effective  inhibition  even 
when  high  concentrations  (100  tig/ml)  of  scFv  antibodies  were  used.  This  represents  an 
approximate  molar  ratio  of  100  scFv  to  1  Toxin  A  in  the  assay.  Increasing  tile  prc- Chapter  4,  Discussion 
incubation  period  of  recombinant  protein  with  scFvs  from  30  min  to  2  hrs  in  the  cold  may 
lead  to  more  convincing  results  as  has  been  the  case  in  other  studies  (Cirino  et  al.,  1999). 
To  corroborate  these  results,  cytotoxicity  assays  were  carried  out  with  F9  cells. 
These  possess  a  high  density  of  Toxin  A  cell  receptors  (Tucker  et  al.,  1990).  This 
experiment  revealed  that  anti-Toxin  A  scFv  antibodies  (100  jig/ml)  or  the  recombinant  C- 
terminal  domain  (100  Ag/ml)  were  unable  to  inhibit  Toxin  A  cytotoxicity.  However,  it  was 
observed  that  the  antibodies  caused  a  consistent  delay  of  about  25  min  in  the  activity  of 
Toxin  A.  If  this  is  the  case,  higher  concentration  of  monoclonal  scFvs  might  enhance  the 
inhibition  to  Toxin  A  in  cell  culture.  Surprisingly,  no  enhanced  effect  was  observed  when 
pools  of  two  or  three  different  monoclonal  scFvs  were  used  against  the  toxin  as  was 
reported  for  botulinum  toxin  (Amersdorfer  et  al.,  2002).  The  positive  control,  anti-Toxin  A 
antiserum,  showed  near  complete  inhibition  of  the  toxin  even  after  an  extended  period  of 
incubation.  The  data  suggest  that  binding  of  one  or  more  scFvs  to  the  toxin  impairs  the 
process  of  receptor-binding  or  entry  of  toxin  to  the  target  cell,  but  that  this  is  insufficient  to 
completely  block  toxin  action.  Given  that  the  scFvs  appear  to  recognised  different  epitopes 
in  the  carboxy-terminal  domain,  the  results  lend  weight  to  the  concept  that  receptor 
interaction  can  take  place  through  several  independent  processes:  inhibition  of  any  one,  or 
indeed  several,  serves  to  delay  but  not  prevent  toxin  action.  The  other  observation  of 
interest  is  that  conversion  of  the  polyclonal  antibody  to  Fab  fragments  did  not  result  in  loss 
of  toxin-neutralizing  activity.  This  suggests  that  an  appropriate  combination  of  monoclonal 
antibody  fragments  can,  at  least  in  principle,  succeed  in  this  assay.  The  specificity  of  these 
fragments  remains  undefined,  however. 
The  other  observation  of  importance  is  the  inability  of  the  recombinant  carboxy- 
terminal  protein  used  in  screening  to  block  cytotoxicity.  Recent  data  (Frisch  et  al.,  2003) 
have  suggested  that  residues  from  the  toxin  translocation  domain  -  may  influence  the 
conformation  of  the  carboxy-terminal  domain  and  its  repeats.  Recombinant  protein 
containing  only  the  carboxy-terminal  residues  failed  to  block  toxin  action,  but  better Chapter  4,  Discussion 
blocking  activity  was  achieved  if  part  of  the  translocation  domain  was  included  in  the 
construct.  Perhaps  some  epitopes  crucial  for  neutralization  are  only  formed  under  these 
circumstances. 
One  of  the  most  striking  features  of  the  receptor  binding  carboxy-terminal  region  of 
Toxin  A  is  the  presence  of  38  repeating  sequences  (Dove  et  al.,  1990).  it  is  possible  that 
the  multiple  repeats  help  to  amplify  binding  affinity  by  increasing  the  avidity.  This 
increased  avidity  effect  might  lead  to  quick  but  gradual  replacement  of  anti-Toxin  A  scFv 
(Ho  et  al.,  2005).  This  effect  is  also  seen  with  some  other  enzymes  and  receptors  (von 
Eichel-Streiber  et  al.,  1992b). 
Studies  on  animals  showed  that  death  due  to  Toxins  A  and  B  is  correlated  to  in  vitro 
neutralization  of  the  toxins  and  not  to  the  level  of  antibodies  measured  by  ELISA  (Corrado 
et  al.,  1990). 
i 
To  our  knowledge,  only  one  monoclonal  anti-Toxin  A  antibody  has  been  isolated 
that  has  an  inhibitory  effect  against  the  cytotoxic  activity,  haemagglutination  and  enteric 
toxicity  in  animals  (Babcock  et  al.,  2006).  In  this  study,  antibodies  were  produced  in  a 
transgenic  mouse  carrying  human  immunoglobulins  HuMAb  genes  by  immunization  with 
inactivated  Toxin  A  and  Toxin  B.  The  antibodies  were  then  tested  for  their  cytotoxic  and 
haernagglutination  activities.  Of  the  antibodies  isolated,  only  one  antibody  showed 
neutralization  activity  against  cytotoxicity,  haernagglutination  and  enterotoxicity.  This 
antibody  was  found  to  recognize  an  epitope  within  the  C-terminal  binding  domain.  This 
suggests  that  screening  for  scFv  antibodies  that  have  three  inhibitory  activities  against  the 
toxin  might  be  warranted. 
Screening  anti-Toxin  A  scFv  might  increase  the  chances  of  isolating  antibodies  that 
recognize  critical  epitopes  on  the  toxin  (Frey  &  Wilkins,  1992)  and  which  have  inhibitory 
effects,  but  the  complexity  of  this  process  needs  to  be  considered.  In  the  work  reported  in Chapter  4,  Discussion 
this  thesis,  a  modest  number  of  scFv  clones  that  were  reactive  with  Toxin  A  were  chosen 
for  closer  analysis.  They  were  chosen  largely  upon  the  basis  of  the  strength  of  reaction  in 
ELISA.  If  much  greater  numbers  of  clones  were  to  be  processed,  it  must  be  noted  that  scFv 
purification,  characterization  and  neutralization  experiments  are  time  consuming  and 
laborious  to  carry  out.  Therefore,  a  more  efficient  and  quicker  method  is  required  to  screen 
a  large  number  of  scFvs  needs  to  be  employed,  such  as  array  technology.  In  the  system 
described  by  antibodies  were  prepared  and  screened  in  an  array  system  in  which  antibodies 
showing  specificity  to  the  target  antigen were  selected  and  grown  for  further  analysis 
(Rubinstein  et  al.,  2003).  This  method  made  possible  a  selection  based  on  the  biological 
activity  of  the  recombinant  antibodies  and  not  on  a  random  basis,  using  immunoassay  data 
as  the  primary  feature. 
The  structural  differences  between  native  immunoglobulin  and  scFv  antibodies 
should  not  be  disregarded  when  seeking  to  improve  on  the  results  reported  in  this  thesis. 
An  important  difference  between  native  immunoglobulin  and  scFv  is  that  native 
immunoglobulin  has  a  multivalent  interaction  with  antigen  whereas  scFv  is  monovalent 
because  of  the  significant  difference  in  molecular  weight.  Stubbe  et  al.  reported  that 
polymeric  IgA  was  superior  to  monomeric  IgA  and  IgG  carrying  the  same  variable  domain 
in  neutralizing  Clostridium  difficile  Toxin  A  (Stubbe  et  al.,  2000).  Therefore,  divalent, 
trivalent  or  even  quadravalent  formats  for  scFv  expression  should  also  be  considered  to 
overcome  the  limitations  of  the  monovalency  of  the  scFv  antibody.  This  could  be  explored 
with  the  scFvs  reported  here  to  see  if  the  change  affects  their  capacity  to  block  the  action 
of  Toxin  A.  However,  it  is  worth  noting  that  inhibition  of  Toxin  A  cytotoxicity  using  Fab 
fragments  from  polyclonal  anti-toxin  showed  comparable  neutralizing  activity  to  the 
complete  anti-Toxin  A  antibodies.  This  suggested  that  there  are  some  sites  on  Toxin  A  that 
are  blocked  by  monovalent  antibody.  One  strategy  would  therefore  be  to  use  Fab  fragments 
from  a  polyclonal  serum  in  competitive  elution  of  phage  antibodies  from  a  Toxin  A  target. 
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This  could  be  used  to  isolate  scFvs  from  a  library  that  react  with  epitopes  recognised  by 
Fabs  with  neutralizing  activity.  This  form  of  competitive  elution  has  been  used  by  others 
(Meulemans  et  aL,  1994).  As  part  of  the  research  in  this  thesis,  the  molecular  weight  of 
anti-Toxin  A  scFv  fragments  was  increased  by  cross-linking  to  anti-c-myc  antibody  (Wang 
et  al.,  2004).  This  added  a  significant  mass  to  the  scFv  fragment  by  assembling  it  into  an 
immune  complex.  The  samples  were  used  in  cytotoxicity  tests  with  the  toxin  but  no 
inhibition  was  observed.  Although  the  peptide  tag  is  located  at  the  C-terminus  of  the  scFv, 
it  is  possible  that  anti-c-myc  antibody  might  interfere  with  the  scFv  function  or  more 
optimization  of  the  technique  is  required. 
4.4  Epitope  mapping  of  anti-Toxin  A  scFv 
It  was  discussed  previously  that  the  carboxy-terminal  part  of  Toxin  A  is  thought  to 
form  a  solenoid  like  structure  that  consists  of  short  and  long  repeats  (Florin  &  Thelestam, 
1983).  Each  repeat  consists  of  a  P-hairpin  and  a  loop  structure  and  at  least  some  of  these 
features  represent  the  receptor  binding  site  of  the  toxin  (Greco  et  al.,  2006).  The  sequence 
conservation  in  the  short  and  long  repeats  are  thought  to  play  a  role  in  the  formation  of 
kinks  which  is  speculated  to  interfere  with  receptor  recognition  and  cell  entry  (von  Eichel- 
Streiber  et  al.,  1992b;  Weis  &  Drickamer,  1996).  Because  of  this,  some  regions  in  the  C- 
terminal  binding  domain  of  the  toxin  might  have  more  importance  in  receptor  recognition 
than  other  regions.  This  was  supported  by  crystal  structure  analysis  (Ho  et  al.,  2005). 
Therefore,  an  important  goal  for  the  research  reported  in  this  thesis  was  to  identify  more 
precisely  the  regions  that  are  recognised  by  the  scFvs  on  the  C-terminal  binding  domain  of 
Toxin  A.  Potentially,  the  binding  characteristics  of  these  antibodies  might  explain  the 
outcome  of  the  in  vitro  inhibition  experiments. 
To  identify  the  regions  recognized  by  the  monoclonal  anti-Toxin  A  scFv 
antibodies,  partially  overlapping  fragments  of  the  C-terminal  domains  of  Toxin  A  were 
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isolated  by  PCR  for  sub-cloning.  To  facilitate  their  expression  and  to  assist  the  successful 
folding  of  these  small  proteins,  they  were  fused  with  maltose-binding  protein  and 
expressed  in  E.  coli  (di  Guan  C,  1988).  The  three  constructs  (IA,  IIW  and  RIF)  were 
predicted  to  have  molecular  weights  of  about  58,58  and  52  kDa  proteins  respectively.  The 
molecular  weight  of  the  maltose-binding  proteins  carriers  in  each  fusion  was  43  kDa. 
Monoclonal  anti-Toxin  A  scFv  antibodies  were  first  tested  in  Western  blots  against  the 
recombinant  C-terminal  domain.  This  and  other  experiments  showed  that  the  scFvs 
recognised  linearized  epitopes.  A  similar  approach  then  revealed  that  monoclonal  scFv 
antibodies  reacted  with  the  sub-cloned  fragments  from  the  carboxy-domain  of  Toxin  A. 
This  enabled  localization  of  epitopes  recognised  by  the  scFvs.  This  approach  was  recently 
used  by  Bacock  and  colleages  (Babcock  et  al.,  2006).  Interestingly,  the  reaction  of  scFv  D5 
with  all  three  MBP  fusions  enabled  further,  more  precise  epitope  mapping.  DNA 
sequencing  and  alignment  of  the  three  sub-cloned  fragments  highlighted  the  repetitive 
sequences  common  to  all  three  sub-clones.  The  hypothesis  that  D5  was  cross-reactive  with 
one  of  these  repetitive  sequences  was  tested  by  creation  of  another  MBP  fusion  containing 
one  of  these  sequences.  This  RI  protein  contained  only  3  kDa  of  Toxin  A  sequence  (20 
amino  acids)  comprising  SR3  short  repeat  motif  (Ho  et  al.,  2005).  This  approach  proved 
that  the  monoclonal  scFv  D5  antibody  recognized  a  short  linear  sequence  within  RI 
protein  and  which  might  exist  partially  or  completely  in  scattered  regions  throughout  the 
C-terminal  domain  of  Toxin  A.  Further  sub-cloning,  deletion  or  peptide  synthesis  could  be 
used  for  precise  definition  of  the  epitope  recognised  by  scFv  D5  antibody.  It  also  would  be 
valuable  to  sub-clone  short  sequences  from  RW  and  RIF  regions  for  epitope  mapping  of 
the  other  selected  anti-Toxin  A  scFvs. 
Wren  et  al.  reported  that  a  short  peptide  sequq/nýcý((TIDGKKYYFN)  fro  the  C- 
terminal  region  of  Toxin  A  induced  the  production  of  anti-Toxin  A  antibodies  when 
injected  into  rabbits  (Wren  et  al.,  1991).  The  antibodies  were  shown  to  neutralize  the 
haernagglutination  and  cytotoxicity  activity  of  Toxin  A.  It  would  be  valuable  to  isolate  a 
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monoclonal  scFv  antibody  against  this  peptide  sequence  and  test  if  similar  biological 
properties  were  evident.  This  short  peptide sequence  is  present  in  the  MBP  fusions  IIW 
and  IHF,  therefore,  selection  based  upon  panning  on  alternating  coated  surfaces  might 
generate  more  phage  antibodies  against  this  and  other  repeat  sequences. 
Another  observation  of  potential  relevance  to  the  outcome  of  this  project  was  the 
failure  of  the  recombinant  C-terminal  protein  to  compete  with,  and  inhibit  the  action  of 
Toxin  A,  in  vitro.  -The  protein  used  in  this  thesis  carried  14  of  the  38  peptide  repeats 
present  in  the  native  toxin.  This  was  sufficient  to  create  haernagglutination  and  the  cross- 
reaction  of  scFvs  with  native  toxin  confirmed  the  presence  of  relevant  epitopes.  Recent 
work  has  shown  that  the  complete  C-terminal  domain  can  inhibit  the  action  of  native  toxin, 
presumably  through  competition  for  receptor  binding  (Frisch  et  al.,  2003).  Interestingly, 
the  inhibition  effect  is  increased  when  parts  of  the  toxin  translocation  domain  are  also 
present.  Perhaps  this  improves  the  folding  of  the  receptor  binding  domain  or  creates  novel 
receptor  binding  interactions  that  are  different  to  those  in  haernagglutination.  Isolation  of 
antibodies  against  these  forms  of  the  toxin  might  produce  scFvs  with  more  effective 
biological  properties. 
4.5  Conclusion 
Overall,  the  use  of  the  Tomlinson  libraries  enabled  successful  isolation  of  anti-Toxin 
A  scFvs.  When  the  isolated  scFv  were  tested  against  Toxin  A,  none  were  able  to  neutralize 
the  toxin.  When  different  combinations  of  scFvs  were  used  to  neutralize  the  toxin  no 
improvement  was  achieved  even  with  high  concentrations  of  the  scFv  antibodies. 
However,  a  consistent  delay  of  toxin  action  was  observed.  This  effect  might  be  explained 
by  the  multivalent  binding  of  the  toxin  with  its  receptor.  The  experiments  used  a 
recombinant  form  of  the  C-terminal  domain  containing  14  of  the  peptide  repeats  present  in 
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this  part  of  the  toxin.  The  recombinant  protein  did  not  have  the  capacity  to  inhibit  the 
complete  Toxin  A  in  vitro. 
Although  isolated  anti-Toxin  A  scFv  antibodies  did  not  have  the  capacity  to  inhibit 
Toxin  A,  they  were  able  to  detect  the  toxin  with  high  specificity  and  sensitivity  compared 
to  a  commercial  monoclonal  antibody  (Fu  et  al.,  2004).  This  sensitivity  could  be  increased 
further  by  combining  phage  display  technology  and  PCR.  Simply,  phage  antibodies  which 
carry  scFv  antibodies  can  be  used  in  a  sandwich  assay  to  detect  a  captured  antigen  and  then 
DNA  from  the  phage  can  be  amplified  by  PCR  (Guo  et  al.,  2006).  This  can  increase 
detection  limit  of  an  immunoassay  to  10  pg/ml.  This  is  more  sensitive  than  other  ELISA 
formats. 
scFv  antibodies  have  many  other  advantages  over  conventional  monoclonal 
antibodies.  The  use  of  bacteria  for  scFv  production  eliminates  the  need  for  animals,  adds 
speed,  flexibility  and  removes  boundaries  on  yield.  Being  recombinant  proteins,  scFvs  can 
be  modified  and  expressed  with  reporters  such  as  fluorescent  molecules  possible  which  can 
make  one-step  detection  of  target  proteins. 
The  failure  of  scFvs  characterized  in  this  thesis  to  neutralize  Toxin  A  highlights  our 
continuing  ignorance  of  the  nature  of  interaction  between  Toxin  A  and  its  receptor.  The 
production  of  polyclonal  anti-Toxin  A  antibodies  which  have  inhibitory  effects  against  the 
toxin  was  definitely  a  major  step  towards  more  understanding  of  the  disease  caused  by  this 
toxin.  However,  it  remains  uncertain  if  the  benefits  of  recombinant  antibody  technology 
can  be  applied  to  the  production  of  therapeutic  proteins  for  C  difficile  infection. 
203 Chapter  5,  Appendices 
Appendices 
5.1  Luria-Bertani  (LB)  broth  or  agar 
Tryptone  (Duchefa  biocherni) 
Yeast  extract  (Duchefa  biocherni) 
NaCI  (Analar,  BDH) 
Distilled  water 
IO.  Og 
10.  Og 
10.  Og 
to  1  litre 
The  solutes  were  dissolved  in  distilled  water  by  shaking  and  the  pH  was  adjusted  to 
7.0  with  1M  NaOH.  For  solid  medium,  1.2  %  (w/v)  agar  was  added  before  autoclaving. 
5.2  Preparation  of  antibiotic  solutions 
Stock  solutions  of  antibiotics  (ampicillin  (1.0  mg/ml),  kanamycin  (0.5  mg/ml))  were 
dissolved  in  distilled  water  and  filter  sterilised  by  passing  to  solution  through  a  filter  of  0.2 
Itm  pore  size.  All  antibiotic  solutions  were  stored  at  -20'  C. 
5.3  SOC  medium 
A)  SOC  base 
Per  liter  of  dH20  Final  conc. 
Tryptone  20.0  g2%  (w/v) 
Yeast  extract  5.0  g  0.5  %  (w/v) 
NaCI  0.58  g  10  mm 
KCI  0.18  g  2.5  mM 
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The  solutes  were  dissolved  by  shaking  and  the  pH  was  adjusted  to  7.0  with  NaOH-  The 
broth  was  sterilised  by  autoclaving  and  stored  at  4'  C. 
B)  SOC  additive  (IOx  concentration): 
Per  100  ml  of  dH20  Final  conc. 
Glucose  2.0  g  20  mM 
M902  6H20  2.0  g  10  mm 
MgS04  7H20  2.46  g  10  mm 
The  solutes  were  dissolved  by  using  a  magnetic  stirrer,  filter  sterilised  and  stored  at 
40  C.  The  SOC  additive  was  added  to  SOC  base  in  a  ratio  of  1:  10  just  before  use. 
5.4  Citric  acid  phosphate  buffer 
To  prepare  citric  acid  phosphate  buffer  pH  values  of  3.4,5.0,  and  6.0,  citric  acid 
and  disodium  phosphate  were  mixed  as  shown  in  the  following  table.  After  mixing,  NaCl 
was  added  to  a  final  concentration  of  0.5  M  and  the  solutions  were  filtered  though  a  0.2 
jim  filter. 
Target  pH  0.1  M  citric  acid  0.2  M  disodium  phosphate 
3.5  65  ml  35  ml 
5  45  ml  55  ml 
6  33  ml  67  ml 
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